var title_f2_28_2496="Displaced PIP fx";
var content_f2_28_2496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Displaced Salter-Harris type II fracture of the proximal phalanx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 265px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Displaced S-H II fracture of the proximal phalanx that was irreducible. The distal fragment was herniated through a rent in the periosteum and extensor mechanism that prohibited reduction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kozin SH, Waters PM. Fractures and dislocations of the hand and carpus in children. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2496=[""].join("\n");
var outline_f2_28_2496=null;
var title_f2_28_2497="Botulinum toxin injection - glabellar rhytides";
var content_f2_28_2497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 605px\">",
"   <div class=\"ttl\">",
"    Botulinum toxin injection for glabellar rhytides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 585px; height: 155px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACbAkkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0vxT4gi8PW9nJLZ3d493cfZoorXZuLbHfJ3soA2xt39KxP+E+OR/xTOu8/wC1af8Ax+l+JZw/hjv/AMTU/wDpJc1lava+HvDXwV8D3eleCPDOreKtZtdPtbSO702KTz5pIlZ3c4BPGcksOWBJqG3eyLSildmsPHbEZHhjXcDn79p/8fpR46c9PC+un/gdp/8AH6zZbfwr4i+B2neKdN8LaBpmrNeWCTNZ2EcTwTC+hjkCkDcoPPGc7W70QqFZ+pJ5FZ1KkoOxrTpxmmaZ8cSA4PhfXR/wO0/+P0n/AAnL9P8AhF9d/wC+7T/4/VMt90bSSRg01gAWyp5wcms/rEjZYaLND/hNps4/4RbXv++7T/4/S/8ACaTZx/wi2u5/37P/AOSKrodrjeysccYqIMseTIxK54J7+1L6xIPq0PMu/wDCaTf9Ctrv/fdn/wDJFL/wmk2Af+EW13B6fPZ//JFRxsJW3EMRtJGO1SMmWB6tnAGOoo+sSD6tDuxf+EyuMZ/4RXXcf9dLP/5IoHjK4IOPCuu/992f/wAkUSRKwyrZRm4wOcehp0jqMZ2/K3ze/wD9an7eYfVod2M/4TOfv4V13/vuz/8AkilHjG4JYDwrrpK4yN9n/wDJFMCBGJeUkK2OBnI9qlXG4yRsGkHI747E01WkH1aHdiDxhct08Ka9/wB92f8A8kUf8Jhc4JHhXXSBzxJZ/wDyRVxo3EM0pPHA3jpzwP61GqHGN0e1iAe2Me9NVpE/V4dyt/wmVxjP/CK67/33Z/8AyRS/8Jjc7gv/AAimu5Of47Pt1/5eKVlMsswX72dwCnA//VUzxsse0um5ZAxJ9+v4Ue2l2B4eHciXxZdsEK+FNcO9yi4lsuWHb/j4pw8VXhQMPCmuYPAzLZD2/wCfirdoVh+yXIQYE7Yy33iMDHsec1JEH3N55CmFpdpPqBgZ/E0/ash0Y3M8eK7suVHhTXMhiv8ArbLGR7/aKT/hLbrfs/4RTXc52j95Z8nr/wA/FXbeNhJF5rgmcklccgDv9etNVfJNs6LkFstk549Me9T7aW5SoR7lVfFl2xUDwprnzZx+9su3/bxTP+EwuSMjwpruMZ/1ln/8kVbKkTiaPk84DDOPwqGMfMwYgMyNgMP5Uvby8hrDxIf+ExuMZ/4RXXeRkfPZ/wDyRTm8XXQRWPhTXcMSB+8s+cdf+XipWWINJscvGAMN6AY/+vUsqqzRhHkCAsy8duMEfWrVWQ/q0CkPGc56eFtd/wC/ln/8kUHxnOGC/wDCK69k8gb7Pn/yYp0apGu6Rl2sgPJxg5P+FR6iZIfPDMd6RAKRwTnsPpS9tK1w+rQb0uKvjSZl3L4W10jp9+z/APkil/4TSfdt/wCEV17OM432fT/wIqraKphQK3zhcL/n9akjjLliMdxkVPt5FfVYdyX/AITWbAP/AAi2u4P+3Z//ACRTv+EynwD/AMIrrvPT95Z//JFVgzCPOBz0IH86mGSoDEtgcZ7VKxEmJ4WK6gfG0o6+Ftd/77s//kij/hN5ckf8ItruR/t2f/x+mSo2Nuwe59qr7QrABjzycUfWJ9h/VYW3Zb/4TaXI/wCKW13n/bs//j9Nfxy6fe8L66P+B2f/AMfqjLKqkgHb65qKWQFBnGO3vT+sSD6rHuzRPj0jr4Y13j/btP8A4/Wpa+KrS48H3XiM213Fa2sdxJLA4TzR5DOrjAYqTmNsfNjpzXKzHeSBzUdr/wAkN8Tf9cdZ/wDR1xWtGq5tpmFaiqaTR1v9v6n/ANChrv8A3+sv/kilGu6oeng/Xf8Av9Zf/JFc74li0jTPB/xK8U3HhzQNX1Ww1OFYX1SxS4G02tkNpJw2BvY4BHJq38L7bw94i8W6rouseC/B5W3soLyCVPDv2CWQP979xNucqCcbxgH8acHUlFSutfL/AIJnJQi2rP7/APgGude1QDnwfr3/AH+sv/kikXX9Tbp4P17/AL+2X/yRU3w4YH4c+Fxg8aVaj/yCtb+BgEkZ61wyxtRO1l/XzOuOGg1fU5r/AISDU8/8ihrvr/rbL/5IpRr2qH/mT9d/7/WP/wAkVvq+9zhTnGckU4OAcsRgml9eqdkV9Uh3Zzv9vamP+ZQ13/v9Y/8AyRR/b+p8/wDFH67/AN/rL/5Iro0VlDbcjuPelLYGTyR1p/XqnZC+qQ7s5o+INSH/ADKGu+n+usv/AJIoHiHUj08Ia9/39sv/AJIrpGPJOB7D3pvYdQfpmksdU7IPqkO7Oe/t/U/+hQ13/v8AWX/yRR/b+p8/8Uhrv/f6y/8Akiui3fNk8NjOfamI6sM5yCScVX12p2Q/qkO7Of8A+Eh1LcB/wiGu5PP+tsv/AJIoHiDUiMjwhruP+u1l/wDJFdDu/dgspDN8uPSmqSsbIwIGcfU+tNYyp2QfU4d2YB8QakBn/hENdx/12sv/AJIoPiHUhn/ikNd4GeJbL/5IroEYBVcnBTv79OlRmQq2FHyjIP0prFz7IPqkO7MEeJNQOMeEddyRkfvbL/5IpT4i1EZ/4pDXeOv72y/+SK2znzMEYwR83tVgcYVwQ2OW7Gn9bn2QvqsO7OebX9TAyfCGu4/67WX/AMkU7+3dUyR/wh+u5H/Tax/+SK6Ib92CAygjnrxUhBPJXJXpz1FS8ZNdEL6rDuzmP7d1T/oT9d/7/WP/AMkU1fEOpMu4eENdK/8AXay/+SK6ck7cj5ipxjpUTkgKVUYJ6+h9Kn67U7IawkO7OcHiLUWYqPCGukjqPNsv/kinHX9TABPhDXQD/wBNrL/5IroHGJBIpzznAFOBBGScjPSj67U7IHhId2c4fEOpA4PhDXf+/wBZf/JFH/CQ6lgn/hENewP+mtl/8kV0TtzjAORwScVAyMd+GP0o+u1OyGsHB9WYJ8S6gBk+Eddx/wBdbL/5IpP+Envsgf8ACJa7k9P3tl/8kVutHuSRWJ/wqEKV8vBBBFH12fZFfU6fdmR/wk9/z/xSWvcdf3tl/wDJFN/4Sm9JA/4RLXc/9dLL/wCSK13ZipBGAB6dTVZ1IwUbLDj60njqnZf18wWCp92UT4pvR18J67/39sv/AJIpreLLtTg+E9dH/bSz/wDkitDc5VsrtIxiq1wQW+XJPrSWOqdl/XzH9Sh3ZVbxlcIMt4V10D/fs/8A5Ipv/Cazc/8AFLa7/wB92f8A8kVI4Dk854qA4yTjOTzT+u1Oy/r5j+o0+7/r5Gn4b8Sx65e3tp/Z1/YXFrHFKyXXlHcshcKQY3cdY2647Vv1xHg458a69gYH9n2P/o27rt69GlNzgpM86rBQm4o4v4l53eGMHB/tQ/8ApJc1n6RP4B1XRPAUni/+2ri78PaTFanTJtEupbXzTCqOXX7OQ5BUYIbHyg81f+JvXwzzj/iaHn/t0uaywjNyzHb061FSo4SNKdL2kRNTn8GaX4Q1nR/Bc+tudV1m0vxZS6XcRQW5F1C8nlkwqqIETOGPAUYqcqFJCneq4yRx1qPAXGQcLx/hT49rkABvQ1zVKjm9TppU+RFpU5IBX5cnr0oDnePbPalt4/3Z2gDb6+9RSK5lYseRjJJ/CpNI7jst8pC47dOlMuUO7KygMBnnn8PrVmFSZXQEhipGD9OakijbzYnVFZ+V46E9R+lJxuik7MhtQ6xSK6sBjPBwfTOKtjh4SrOMHHTpxzR5YMEAPJ2ls9CT3H6VYVdwjWMA5P8AEfeqUegua5XYhHQl9qZ+YmrcLDYGON2CGXjODyDz1qM2IlnYBl2Ek8tkd/T3FSzBo1VcfK68ZxnHb+tWkJ22Qjw5AIO5g3zdhjk8nsaijBilZ1QFmAOD0IP9KkkKxWr+aWEfyhlTgnPQY70wHe0Ilbco4k3nAA7Ci3USuTlkCRKS4jdAxHUBvQUl5saFmJZS7ZMZ5AA9T/Kq7XDK6+bIY9pwuwY2j2qRj5rnad6vHjHoaLi5epC2yG4iDKwVG2t6c+n4etaAgK3QAWN3CyAK38WPm2n8KyrguUy7M0rA7ix6ke/etCeWSe0F+0I3QSKX6bScbSAB7YNODV7BJOwnliZ/LLPExumwFAwP3eRj3zxT2cH7axOY2VuM5ALMoJJ9fbtTINkV0snKn7SZY92TjCEg+nP51YcwiIxxsqhEy+ByTw+Afcn9KpK+pDCRgskrTK4iYvKHA+YjheBSrJEP9YWeRNwCjhcY4x75qN1jW0kKuTIRHC2GzuLEsQPwFLbzbBK8fXaTtZdwA7ZPao66gkQSIT5Zd2+T5Ao6DPJwaVyscsMgLbQv3iN2RkjGKe+wiQ7WXZEARnC7zzUk4YJFbtGFIjUsW4OwjOAPWhIq5XYh9uFZQ8R3bQCCe59qjid/lyWICshHTA7H2zWlcxbLmWTCRoMsmzq2cBcjtyKpQqbbUpjvJAjZeB1JHBp2aBNNFLCxw/6QoV9g2qRnJ5Gfp71FfIzQOZG3sSh9OMYyPXninfIImZPmYbELkHBGDuHPfNLLcRhrYTksAf3TY3ZIycfnU36Fq4txCluFwS0isEAHPbPHrSRBSMOwQZwzBc4z7VOrmRgZHkLDfk4ycnsPfNRWq7oc73ReWIC7ug/QUmuw7kW93woBDcrx2FIW5C7uM49KspBhcBRwpc5OP8ikkRNoKsSCu7GOQf8ACp1DmRUIZgw35PTApOrgA8Djj2p4fyjwpIxjI9aHkwRtXI288Y59KLdyrlK5jLKykA85yaqg/Ii4PBwAauMS27napP3arzFdmG/1h7Z4xQ11HfSxGTkk4zggcUlv/wAkP8T/APXHWf8A0dcVNCqu+SdoByATmoYf+SI+KP8ArlrP/o64rfDXuzjxWyN24GiXukeOfDPilNet7XVtRimWXT9LuZ90YtbQblkSF0+/EwI68GtHwze+D9E8RSa9Nf8Ai/VdWNmunpcX2g3X7q3U7vLVYrVFAzySQT79a6BRkc59qaQc452+uK5Y4yUYqKWw5YZSbdzC8BQz2ngfw1b3MLw3EWm20ckUilWRliUEMDyCPQ1vnkdcL3xTGDbhjpigA9jj1xXI9W2dUVZDwNpO4575FMb5QuBuOelNIyxOe1OZ1UKduT04NDLJBn5gM8c80x1BOR16HJ4pjSAnAJBA5oLD5lPb1ot0BJoJSfL3LywPHtSRZ5OS3fmkDsY8tgZp+FLqcdaq2oDGdjuHVenFOjYYwSMg9R0NMXcNuRhWPI9KFAUEohbB3cU0htkk7DYAMnB4IPeopXO5kyf7rYHAqWJNpkbq3XbUZ+WVXOOnzDPBJ9aGJMby0IQNtZuA1PAVYsvkfwsT6f40IxCkEYVVBB96lGGiOACu3Iz3NWtBXK7DD9GKEAYH86ahaRiCCMH65FSRMJEAwQ6dvUd6cpBKuCCTkHHWkK5YQ7Rn+HpT8hUIJJI/OoYiApVgGyfWpWzvBIz2JHSpdxDgysCUPyN396jzuBGOOn1NMaMEMnODyF9DT0AO0En1Hpn3pJMCIp5e1cYXGDk0iYyNvKsfXpUofcpPXbk5FVyyDkEkM2Bt7UWGg3cbW56lT/SkQ5cFzgFcA+n1pXTd688jn0pYymz5ejc9OlFrlX7DZMx5XIx3+tQNtwhX7gyOKfcTY3DPTGM1WLq0KkYCN1HpzSLS0HycAg9WzTMZEeeMd+nNEhDZ55Tg4PtTZlymOcZzQwGNwXUMSeM+gNVZsBjk9hjFTzAqJNucZ6VVLbSWOCG5qdRogfbgnB+XFRTck7c49KWXJKlGA/lUigCAE/f7n3p+TK2Kng0f8Vrr+e+n2P8A6Mu67euK8IZ/4TbXs9f7Osf/AEbd12te1h/4cTxMR/FkcX8Sxl/DA/6ijf8ApJc1lgEoc9PQVq/En/WeF/8AsKn/ANJLmqJYKf3mCG7Djisq/wARvhvhEMSbOWDYAJ4OB7U4EF2KSBRjOMdTTkJEgyApIxzz+NPMRdWMeTwSAB+dYpG6FgG9Qxwcn5hnGM8Y/OrCQmR41AUu4IAAyHYH1qKNAtur7tyg8p7HuD6cVKZHwQCcLIDkDBORg8fkaqKE3cQlXmRixBdSdxPQj0/lUySKq2oKlUVtxI+91/U46U1/3Ms0ciquxldR1AwQT+ByanljYwqvmIXjuXRVcYGGBzx9aq24XWhPKmYp1UxRnaXzjBxu+6PenzOqeYdhZcBQp5H0/wDr0kyJLBG0ahGmtd24dCwwDj6/41YW3O9EAfy3TcTxwM9c/UYptEqWhGI1AiiYjIVguAQB7Ej+tVU8wW8RTc3mxtGCTyAD6elaXlhIYGkKKDKQSpz/ABcH6D265qnNtU7CwAjYjBGWBzxk/Sm00EZJi21u7xSxqd0exM8cew/P0qG1tZQhZhGQYvM299xzhf8A9dWoyIrh5LeTzGjjYFDwrDvn3pyuLBLfy2wM5I2/fPXJPtnH40KKe4+Z20IvscN1cmMTF1+8Qi9sD/2Y9KqGPy3kjBZzG+FI7Y7VbhjeCDeseS25SmcbRu+Yg/hUXnG12PID5O4bgRk4IwfxqWl0HFvYazCW1eUyL5kfzLER3PHJ/wA9KhjR2niiIbbdhWAQ56ZI49asM/lbtmDII8puUEMh6/jg1Qtt6zWRtjtkSXK+uQeOtJtIa1uTSXUiaWUmPmCJ1cDuAyEdfXtVyQi0t4QuA80X7znPIYYyP6VkXzv9jYdSkxiODwx7YrR8q4mu2Vm80LJ5bOAB8x5K/pScuiJ5dNRXm3yw7wnLmUkLj5m61O5cNGrKPmQ71T+Lqc/59Kq3BaKUxIyOIQURwOv/ANcZp9tuRJMMglkITO4hsn09qm+upVrIkjC28McMqyq7N5m4n5cY7juasRbJJoHVWdCwXc5ywG0569cYoy7LlwqSRPhkxuATpnJ702zb7NZxS7vNaF8PEOdpLEfe7cc/hWkexDZYhTeTJhhgRrnBzwCfm9sVn3BbMrMQoO3gcnFPhlnmWRBIxjXnf3cb8VFqnFy4t3LQkbmyOp9DVSatcIx1syl55dI02krvMihT1PAGajCv9niWUcKGIHTIJqPldmzGQwoVz5Y8w7goKgn0zWHMbNdTQuC6W6hFC5kfPrjAGcdutNKyRyb2fESfKmFwWwPSklkDm4kTc/nDBY8Ee/6VcVDPIsbqNyBVBPQE9TxV7k3stStJGHLszfNgdetMjUKCAoznqT1GOlXWRDLIUQqpyAM7ufrUE8OHywG3dhXz1oasCZA/L7dv3sDiopSDuKkYHGc1ekh2MVkVd2FLc9TjNULoBYX42sFwQ3Hf/wCtRYVyLy2JIVdz4JIPQYHWqjjYgO0bfXH97oPyqwsjtGqgGJthLN9f6YqKYiTE0gLBQ0jdsAcJ+dTbQbuQA7CWRdyqe/c/WobfP/Cj/E+evlazn/v9cVoNENsY8ry2iRUcE8tIed35VRiBX4JeKARgiLWhj/tvcV0UFZs5cQ7pHpbPhQFpS5ZD655pCBgHjrTJMhRk815CR2Jjg2cfNwe+aeo3HnGar4AHHTJGKkG4FB0qrFEUp3OSOOOKaSsa8AkYzmgY3Bx0z0pHKhSDyWGP19aOUu45hlmZTkEUqsCQpGcYJz3qvEXC8DOR8wp5kO1QDgiqsMl+9nIwuM80RShXGwHco+bNR+ZmMrgcgDJodQh6cNz702hFlCNqEEMdtCAllwTsJ5H8qZGSuTuwwT6dO1ODOVQABSnf1yM1ViAwBuA9M+2aguWOCr4I4xx1qVD5oB3YBUYx0OOc1Wu8g8fKGxg56e9S0NblqTmMKpAJxk44qNnKTI+7erfdA6UrnKMrgsNobAHXtilVCGBXPyrjaf50AhVIkIkHB6bsU7CqSORkdVPQ0sKYiHfjkeopjRpsAUMARj2+lJi6kiEiYq56cBvWhJnMZZhjJwR6VGF35iYkgjp6fSlQAIWVT/dbPcikPQlSTIZeSM8nvikRAA0YPygg+9RK5Lyck59scUyRxGI5FJ+Q84PUehoRI6VjGyNtOVPI9M96N2eNoxuyBjqKrXGXmXyn7cZ7j0/pUobDIR8wGSFPb2/nVJFLYsgEkhsBl+ZCT19RUO7bGHKYUA/Uj1poIa3DLlSj9D7/AOf0pr4lZtnygq23J688kVVrCW4yRVKr86njnPpVYqoQgjOwjAHQip5irNuOCcbcAdTVN2YW6MDgY5H40uXqzVFhG3hwAOTgmoZpCckjvjj+dKjEI4VgGDA4PXGOlRcB48EgFtx/pUtaB1C4cDnOeoI96r43ocjkHofT1qR9iqcjk8ioLmVgpEfUHnipaGiAjL4GMDtU8hXPGdrLnNNt9pk3Z6r6d6kfG1eMY4NJDk9bFPwoMeN9d/7B1j/6Mu67OuO8LknxzruSCRp1iOP+ut3XY17ND+Gjxa/8RnGfEnPmeGMcn+1G6/8AXpc1mxI8mW6474/StL4kqXk8MKOp1Q/+klzVfG4qwYLnAIAxg9qzr/Eb4Z2gJGoYLnABPHt71MGKSLwd4ypCnqO/TtTFYBSCvzqMipACTuiJ+XkHuaxsbsfCn7qaIIu2JSVBPOz+77+uafbjbIIleQyqGXj/AJaLt3A89sbhSx5jMc6sPMTagXqT7flx+NOlZoZVeDIa3b5S653A5ZB+PK/WtIrqZyBpBd3NrLK37mePY5XjAI2n2+9j86sCQzJIRkzSBcq5AJfGxj+ajii0g88w2ikYYtAmF4AYbh9OdtSRzxK8N0q/vQ7CTKbhuZA3P/AwatLzJ5ujI9zLDYMoZYXEqDjgNnGMdqswJtlghMP8ORJGSMLyOn60QwPFb2rkHZHctlkHL9D9euRV6GNBcW7jcDJO6DYM7BkkZHejluHNbcgj+eEyhoyzKuM8byHO7Hvin3vkbZCvlsYpRIhHXpuxx3x1qK3CMNPmaPgO7be+0tgnHbFJOQzOIkOTmIMB2C9fc8c0At9CJsSTxqm6O6kGxUBxhXzkZqaUI7WgIZW2mRQxwSF7MfwqMtFGIZJPmRoiySEcLtPIx78e/GamuJZGZpHWMoA8gbIyPkyRj8alPcrmILuSPyAkscn7zEirycZGWA9vepri3LBYWKnnYjP3JGc/gMUtkgmEKtukijtg2E6gsdvHvin3iL5VyYnL7pXkiTcNwK4XH65ppX1FzW0KM04NyRMyLsjdAQcb8c4J7k1j3QBi3s4JUq24dQCP6VsXVvFiWMthLePcGC5zkdT75rJuIv3zRxYZ3Vh8owCAP8Kymmb07Fe7x9ncxPkeYCB06AHI/Wr22SO1EzEkBwwjLdWYen071Qv8LGyco4G0qRgsMjjFaVmizz+beSYWMKWDDBI6YX8KmOr0Ke1xsO8MqM+QuWC44z3/ADp65Milzg5xn0NPYAtlIwjkO8mGBKL1UY9ulRbibVysPIG8S/3fSpasyS3m5mXYSQEQRuijBHXG7361UtJXtppJI2OFK/JjIbtj9aLO8njdvLlAaVcM7HJ+v6062Cqbx5drTqV3RnoQGA7deufwq171rCfu3uWJ40jTT1OI1JbzOMlcNzk/iOKNQCPvZFKoy7tx7gn9ajlL/b1SWPazhs9gfc+h4qeQFrXeFAExHfkLj7uPT6VejJRkzqq/e3AgAgqKrRD/AEbODzye/wBa0JEJlVS/VOC3GCKrwAeVJnLbNxO3rWNjVS0LltGHjbb83lxngnB57/SppQwiEkcjKSwXcW64HT3qGw86K6S5iQbm/dEnOCGXlavRCOW0g8sgAEJgrtOcf55rSK0M27MbAVfYgzGrLnnnmrkG/wD0ZDGjnLEEjcOnAx2pJlikPmK/Ag4wMDaDyOO9TRiJCTM6KEADlUJDHHBPbvW0Y2M3JPUoSMvlblKnczH5VyMAY/PNYV/KZEZn37w4bcRkcdjWtfy+TCyqyKQrSKANpbceM/4VjMj3U8Ns7Km5TlmPplmz78VE+xcNNRuySWe2VnIklUvICOg5wCD2wM1G4NxOS4byhglgvOxRgYHvx+dVzcNObmQ/MzxBQRkFc4G0evHH41o6WBbxP56BvLIbbu++4PCA+xwT9BSSvoEm9yaUhDGoZvMiTdMSAS0h7fQcD8KyI8/8KT8U5xny9azjp/r7mt24jeO3jAQfLvkMm7/WMerk46L09Kw4xj4KeKf+uetf+j7mt6e7OWtsj0ZHYAAgEeuaWRQxpPl24wGIpHTKkqO3Q1467HeKxwyggj3zSfxtGuSc9+1MYhDznsef6UquC5f+LGCMYyKoENPyocfeOOnTPpUcmWBGAAMMO3fmpQCzvuIxjNQTHz0OHGWXaB6c1RVyHzAsskeQcdxULS/MPUjoaqyNIs534JU4I9aHlCnccbs1CNLFoyEsCW44H1qRXZ2BbO1e+eM1RZvlzweMdacjYUKeBnNWtAsaUcu4ZPQjBz2qeOUGMSFQCQ3y9uf8ms+Nsjbn5gckf0qzExMbg49PpTTIkidmZMKhwgIXPXjFQsN7x7hhUbaMd+OtL5hYttOHfaR2wBSylRja2Qpzj3oEiwFG84JJ28UpIA2Z3MRsBz370yPLuSCFYAZXPb3p0aBYVJXAHJAHIJqWL1LNuo8obhgoODULnY4GcsBjnoc0STKAAzL5YXBHt60yT5QuDu9m4wKn1CKuwZhGADlRngmpPNTzmXcCowDx396h3hlCnPHOWpsu5GZzEARgfL3oWpTQ6Q5Y7hklcAg4qnJOWkDNn73zE96fNIJAwiYsT8vPUVRmcq2zAP8AFn2qgUSd2dvLOCGzUsTFsluxyD6+tZzTHc3OcHcDU8UzGEg9A3GKE9RtF15gke3Iw3LZHBqCOUBcLyduAeo5qrPLkkEDj0qNJAqHAHToOgFVuCiXLltpUpg4GRmq0k3yxqSDkc46VXmmHQNkk4IqJZORnpjAxRsWo6F57kBiMH8B7U1mLSgjBVYywz2aq6PkfKeMEZ9zT2JEblcAYIH8qW4tgb7+N3IQBie/NJKTmTockn9KazkI3rgDI60K2QHbHzk49hUiHEjauASM9RS5BYnr6D0pyEBA3A9B+NMIAOcDIHJ/GlbUZB4Y/wCR41wnqdNsSfr5t3XYVx/hnH/Cd6/jp/Z1j/6Nu67CvXw/8NHjV/4jON+JG4SeGCgJI1Rjx/153NMCP5akoDvAKjrVnx6qPfeE1ldkjOrEMy9QPslzVYHFqQS4TcS3YZXJAz6ipqr3rm1B+7YazFZGwHwu1XbbjDHsaswJ+++UmVY2KlegcYzj1FVVjknxIhyGCBlB6c9a1oEtYpWa4Z5IceXtjT5nJ5yPX/AVmlrqbt2GwRl/saqh83zN6kcbUU53ZHOD6+1PvApgvJh5o+0jzlyPubZPr6mr8luVu7/z2MUhtVAWM/KF7Lx2weTWbcMbqyZ0BjjkeO3UEY3ljk4HoABWyVjByu7jIIp0mnjOY7pRGQqdN6yDBB7AZNRpdhLm+jTfhp0KBuQAHOc/mai80yapALcOC7mRRnhhuOCD6HFRIrb7aFVG64COXJ+7lifyxUuTS0K5bu7NhisVvd3CucfbUcYOSYyCcj64/Cp7D7RHH+6KoVSeVnxgo3BAz9DVGJQbTy1XDOHlTPBHIVc47kE1dEmLjU5SrFzKkKRgcBGPI+oxT8yX5D5I8WTw+aS8MCKSq4xv557kmp47YOyQReZIckjnmMbcZI9MjtUUWXu59j4jVxESefuJxyKrvI1k8UsbM8kylcgYIxyQfzqXvcqzegzV5AluzojwgDYU2gA5HQfXHWrLokcdwSsPnRo2WPUkbeD/AHvlycUswt5HWELnzF890/iBAxjnt35qOXHkSIGd2kDPGVwA24fMM9umBRs7sbu42QtjJFG6Nn5zGCEPYhsrjHUc8ipbJUaGcXR24ilfdnG07hzntz0rOimIvoplAjUgPGccbQMEVo2kMk1h9kmctC8hEiA8EsRtOfwpQlfQJxsrkeowlt8u4tmFMspGCT2P4VhXIaG5iYgSoG3KjcA54ro2iDG+nAWJC3kI2cbiehHboMH1zWNqEjC++0BFDROhIAGG98GonHqa0ncyrs482NmBLSJhj1PJ5yelaNszSSL5g85txbY33WwMckenSsvVnzqO0bAskm/avPTPQ/jWlbObeDZDKge4GzkA8Z5B9KlLU0ewgDyhywSNGYlsL8oYfwg1ILbyyr3bOsbZX5QTg+4pbSVrWXEbJIINzMjcruPBI9e1WWnt7ws10qrOy7RsOC7ep9hSsmtxNtPTYpFjaTKhRWVwR84xkHgGqkpljt1cFRHv2MFOdrjoT9RVm7865hIaZpkhPdcH/wCvjiqsjSMbsB1jPlhjGoyJShHb+9g5pWvogv1Zpyif7dZ+bsmEu5htOQ4PX9ecVajZ7a7uUnZJRAqou7GD0A+h7Vn3MwW2DWiRvFBcjyZVPHIDEfTOa0F2XMixvKDP8zOSmM87jn3H5YrRGfTyIdQh2ywGVPlzs4/h+tVHhUW07xDKebszt5IK/wCIrZKPPZI0oxcK2CAOGi6dO/OBx2rOkkzLfjZ5fmwkxMBtXchBwQegNOUFuyVUdrdhNPMcUEbzK4khmUNwcMu3jP41sxKhtJ/LRlWFCxLY3ANyGP1z27VmylGvruzUFo7y0WaFVypDbQVGPQYOK1ElW5a7hQlt8TwNuGM7cbc+nXA96uEbaEzlfVDUhJ01kgZd3kHCpzxnn6/zqaYNHBcQxwo2+LdC7nGOcbMnoe9Ps5Ldrf7RB8ktrmHavTb6+vPpUd3efuY5WiV98fmMD3y3Q+x9K1irK5k227HPay0qtdCRkGwR/KADjI4yfXNYF+ywzyFeUjbywJCCc49K1vEU/lTz/aWjmuy0bfIOBgZz/IVzOoS/aJHmcfPI5JOe/c1zVGrnXTTsrl7TVYxqkSM8hPAHI3E4TP4mtyKARjyFeNzEcuzchQP9a+fdsKPpWVoMsst6sYJKJ/pGOu0IpO79a19IiL3UKTocG33CMNguc5QHHvzVwSsZTvcuNtuXaN0iQmREWIs3+qQZ8s/oWPWuXGf+FLeK8jB2a1x6fv7muo04M9vDhj9qnuDEmR/Axyzg/UYz7Vzdwu34PeMF3F8DWxuPf/SLnmtodznq7WO/QbRwOfSo5XZeudx70rsEPIJFRMzFVzxknivHR6SQK5dCDjnkA0wuqsGIyTwTnpTZFwuRjBHH1qqWZsHkKeSPSjVFWLjTlM4xwO1U1lLHcQQ27mhZMqQSGxwB61Dv46YGMD296dmxpEV1JtPzdc5zVYy53jsOlJeSsBu7DFVDNGqqQ+Sev0oNFsaEbHBLeuMU8NllPPHfrVOGYY608SgMcmnsFzRR9hY5UVKkoYbUz7VnO6lcdj1qSKQgEnjngCkS1fU0wcZYsegH0pgcbjs3ZZs496gEoWIjPXBai3YzXe4YCLwvvRuTbqa0BOFywwTz9O/FSLKSrIhOCCct6Z4qnvEbbSoYnoO1WIhuAV/ukcnPQegpkvYsqscm4lB0+Y4/Ko3Ebrs+YEkAZ/SpvusNpyV6jHamOJDI5VUV8Ag9c1IRIPmKMy8kAghhjkelQu5bBUEKV7H+KnXMuwM28gqQcEdKqXBMWAMrGxzntnrxUvQvfUj84LMpUMA3IPpVaQrg5OQMnIp0smGBPC459jVN5OxPAPWqWxVhrzAEDcBxtY471Ishi2q/BxnmqEr5yOMg5+tS+YrBXY54xn0oaGyxNOUJfOQ3Ydqha8Xbg9TVaWRWAxjOarvggE5HrVRi7FRLQfDMzHJPQVKJeiE5z1PSsxZNo+g9acku0gkgf1qrA0afmqBz0BzxTHuGKKpJJwQPcmqPncHH3cU4SfOuBnjBOelKxNi/vOBvI4Xt6+9WN+BGFXbhQp9s1RjGx8k5z0FWJHwGyMqAOffFO1yWTKpMDsWJG/H4U/Yu2UDu23jtTYG/dDoVC5yPX/8AXT3BWF8jkkHipasBX8LDHjjXR/1DbD/0Zd12Vcf4a48d6+PTTrEf+Rbuuwr1aH8NHj1/4jOP+ITKl14VZyQq6sScHBx9kuaikkHzQAOHJdMMxH3uSfwGM+tL8S22t4YOCf8AiaHgf9elzVFL6LAd3XzBub3YmpquzNKK900DvMzsHBiCCFSnylQRzx+JrRM0cUt40Sh44YlVDn+XvWDG4Ma5bcEfaQTkMeuAa0I2URKpVQiN502WPzHsD6DtgVkpGjRovOzozzI3n3eESEDhVA+UHHQe3tmqss8BDNb4Y28Rt0Yg4muH+UkD0UZwagS7ZYkuWhkKqSI4921jnJwCOTnPPsBVSyeWaViNscahgoD52ZBLMPVsDHoM1fOiVTZJqCmR5ZIX3RRoIIMfxKuFDce+Tn61M5hkli2FklWJlYE5K4wAoHY4BJPvUBgK20ZaJhKUEiqrfxP8sSKO4UAkkd81NaqyOxAQiMmJip5IzyR64xz9aT3LWxrpGlzI0wwLeWbenH3VBHTvzjpS2dyZZN6tg3U5ARQOOcdO2AOtRWZ/e5CnZHIZVXOcjHC/UZH5GjyVht8LIqsUaRGIwQSMdR+NO/VE+pdtJkLfvowIYpzM2wYAUA4+pPH51BKkotRI8Z82dmBwv8TED8Pr9aSK4gjeNB8vKGV+gO0cY7f40iXR/dyOwCSq4Bxkjn72O9PmWzBRa1RDdbQ77GSYqiW5ZP4+B0/Hmk1IlZ/JRWBhCK+eGBwck1DDPJJC8q2+EJCRchduPvHH0qV490Eqs5Dzuo4AJkA5BJ7Afrmsm+Y1+HcrQ5W4VpFy/O4E8Edce2RWrpkoN8yx/cbIJDYCrjHf8s1lyJhzKHLlix+UdMcdKfZvHG0iSNsDgoSwzjuCRURbixyimmbUM8VtaWwDPJdPcEr6KAMAAdx2rI1aJV1DzVQKVZCUzjvkjHoOmau2dxCs9o0yBvs2543PA3Zzk+1UNbjZYo3YFLgqSy9hznI9uelbyd4kQi1KxgayUGuDyiDHvLLznjNXoj5e2TaHbdlSenvmseUl9Wx1ES8Ed8961wyqyqwHQHHrWC3bOp6JF1FiX76At99mweM+gqeJ1uIspaxCLoc5+U46E+hPPP0qJRIiedI+ImIHTPHpV/zofPkXEUYYZLyAhHUdiB1/mKuKuzGT7FW9VWt0t54PJgcjy5d24KT6kf5FZULm31G3SXarRsYWcn5WxkA57HHf6VtXSpGlxbWySJ8nmLCTuDA9ceo6EGuavpnmRWkbPO4ZHfoR+lKorBTbZpaEBLp13b4LbpMpnG4NjK4+uORWtZxLO1rdPJk3CFGIfkNjv+YrB8OrJKGSAhZ0uFmXLYDgcYHuK6Cw/e6fe25fy455PMjMYGcZPGPwx+VOmr2uTU0bsW9SSJbJmRl80QFJUXJK++fqKyiW2wxhY90lhIWJGTuA5X9ODTtZnWSL9wDGZAQQef8AJyKzZLjc6zjCj5QAOuMYb8DVzmrk04PlNaObebW5cKWkszGG/iwAAOfXPpUmmN+7FvMjxyiTzXw2G2cZB/AZ5rDiAFvGwk2Esyg916YwK1IbgJFIJ8ON5ETKoyf949Rn0pKfvXFKmkjQjuC4McGY5SrSLg43ZPH/AOqqmsGUtqKxgKqyxRIF4B6cj0+lWbSRbWSOOUI3lr/DncxPOCx6AYHT0rDvLlnwm4vufzCC2ctnvVynZChF82hT19jNdyl1Gd5z7YAGM/0rBvCpkhjOcbm8zIwQCela+oyFmwnPO44HcmsS/j2u5cDOckE1zyetzoResi80rgyKpeFYwQcDBYLjPpg101tE0l0pZHijU3EUZA3ElFxgevT9a5iYKtraIpKv5LK65xsJbgEdc5rbF0Uaa7jjkkEXz7HPGGAVh7YIzkVtEwlqW7K6bCXGFjSGH91HGSoDlfvVz8II+CPigMckRaznn/pvcVr2paO0u0IXcz7SB1VcZU/SsiL/AJIl4oyMHytZ4/7b3Fa03cwrKx6Ay5LfnUUjfdUDgc9asyKTnGSD39aiaParADnqc8V5C8j0rlK5djGSGJCHoBQnzpmVcBhg4qSfHyiPqwBBHvVcMfnxgqeFPvQ9xoqz5UISSOM9Kr3VwFyRk+oq3JGWkBySUHP4VQvIhzkY5plpogumLwkknJxwO1ZEm4OpHPIBrQuLnETReWu4nO/vj2rNmdlQn3FUtS0Xkcj5c++askgjOcgckCsqOXLqCcYq0smeASATyapoWxehk8w5c7cdKtK43AN07Vn8rgqOelS+YRyOv9Kh6A9S4SGLc8/SrFjKQxIHAHWs0O3l5HU8mrmntmEMw6nJ+lK2gmaLMVIf+MjrT7QsWCkEBvXmoUyVDMPoKsxuoUZcjPp1qfUnoXpJWihBZDLjjI7mmSHzJAUIR8cAfxY7VAk+yM+XvJ6YqOWZk3jYxC9CRg4qhJBd7n3BRz1XJ79waz7meRiikkgDODzgjrVhrn5A20qn3go4IPrVWZ/MYsADk81MtS1oQSODkFgTkE/SqU8vzZAODwfanyMBKR0BPBNRSOrRbWX5RmhPQtlaVwThDnsakRwYgpPBOQKrlwG47Ukbnyjxzk1aE0TSAFuD/wDXqu74OzPI606R95J6Cq8h3HK9D3qlcIiBuvcU8MSB6dsVCMbeOvtSs5CLt4x1x3q7Fak6nPGeBVmFAeScKOSTVOJwx29/WrKMGUrkgKfzpWsJstI4ZwSNwqQ5aRFdiQxLMAO2KrwEb1AGPSrmTI0rjBc4UAds9aRLLdqpWIBipBOdv+z2pfmcrsJyAG6980m7YkucBiuCc5x6CpFi+RlYY+VR+P8A+qlIkreFyD4510Ag7dOsRkf9dbuuxrj/AAyCPG+t5x/yDLHp/wBdbuuwr06P8NHj1/4jOJ+JxZR4a2IXY6owAHqbS5FY0XzCJSoTnaQSM+3+Na/xTiknTwzFDv3vqu35OvNrcZrn4EuYcXKu8eDtjLIGJ+vYcVFVXZdGVom5DIiiBY2EgilxCpHyl+5yOo6U6NEkdlO4pHvdy/SRgOT9AegrMSSaGJDcXUcUSkO6jBbP8PHT3p32m0Nvcf664uFQKisSxYlsnA6D3z71DTZXMbXnulvCkHmKV+Z36FFPO4k/xdh/9eoS/nyTRRCC1gwA7HnZGMfKpPUk8k9SeOlVLYuVZpU2gISiFs5c/wARPqO1JIkSWklqsmZJJVY9CNoHf8TQhKyLqzK0azPKwO87XAAIXHzMAOhwAPzq3I7tK05VVSQvLtjIwBgYH+e9Zc89jaTIPOSQ7BEVWP5jznIx3Jxx6VE+oRy6eWXzFkaQZJTnAyeg6Cm79S4tPU6KSUxzqV2ACNcspI3Ajn8qpzNKVQbf3YAVyG4Y9f8AIqjLfszksrAiMKNx655z9Knmk2Of3p8tVDFiPlz6A1D1NI6GjCiLbPu+8SzJEwyGGMc+/p6VDcRva2+VLPIpA+zqMhFPfP8ASopLhDbSPHJ5bHDDDZGe/Hoahiu7wyM80ecdHRvlCgY3EdhQ0rIE3csm4QneG85YRjYg4YnqT7dqWO9CmK4byjsGUjHY9s1QlmR/mRfLLDapA+99fXNOsLhBcMWWJyMAKwyTg+9ZNl2RLDIUBeJmLPnOR71YWBXmARmLZyuR1/yagYEOZG27ixIx2HoaT7STklTtQZGO/wBKSauO76GkMW89yzsZZVIMexeGPfPsKbrG+YRz3Dl5HQggNnBPJH9apxOwdXyzEevJqzqarJbLELhXCjeUAwc9hj+taxlo0S1aSOWZCb2ZuSIwN3Hqf881pQpu+7kemayrkbNS3MTljyAMAVpQTfMoLcN6dqzjY6GbFnmaeO1JIQsDkdCavX20RwC4VgsTEbAvyzJ2z3De9RaQysswQxCQJmNnHAPXk9qdqQu2RpGdpZtql48ZC/Q9/WuhL3bnK379itqsxt76Py/miMeIm+6VBHH5VzN4w3HdkeprSu5PtWQWK4wNo6YFYt9JsHzkjGc1jKRvCNizorytcPEjKPmDKWOAD9e1dBBOfIT51XyVO0Y5bmuS0h5GuJEQ4RlBPGR14J9K6hpoGQI0SLIo+V14wfelC9hVErkc0u6NUQMHA6kevrVOc7BKq5wCOvbin7mGx9+8c7ifWqs2cnd0boPpUtjSL9gd10H2ApENwyBxxxkfWnwy+WwTBJcbuv3u2P8A69QWksjHbFGXdpAdoxkkD/DtU32kmCSTy93loDvIzsIPT6c0J2Ik9S35/mefNPJkRR4RV7knHP0rIkbG/H3sgZPSi4u1MRZY8MTk8HLGqckzyLtWMjJwS/Ax9Kpu5K0RJc/61flZVyF+U1mzx7mdQ2Tk/eq3cF2UneQ56ZxgCq06PhssCCQACvX8qH2BSsWnjm1G4hGFMzIA+Bk7o15b8gKuwGZrMzZbyYvmkGMAluqg98gZH0pl3K8TxxyII3Rkd3A+4QNpUEdsVNpsGy9SD7RsjlDocNhM4OwseRjnvWqvcycizL9ydSu2KNFilGMDGMxufTPtWYrB/gr4qYdDHrRH/f8AuavW9zL9jRru3jngWBoZVU4JQH5G9wCMA1nW+P8AhR/ifClR5Os4B7fvrit6ZhVdz02RRtGVyM5B7VBLGSzbiMFeuevtTDdDOWHXj6+9Ma4zxlMY/wD1V5CO9bkTxB5s4ClRx9KrOG2yMeEY8ewqyJyFC8sxGG49aYCA5UgbccMaGNT6FHDxliOX7c9BVG5bCuM5I7Gr9zKuGKnJ6Zx3rPuMAY6Y6mizNIu5lXKbgR7YGKoykjPPIxV+QsMgjr0x2rPmwz8AEkfjWkVqapkIcb2yfarUJJTrzmqSnD49TxUyOTKT2FaNC3NES8AA8ZqZSG9T3NZ8DsGOQDk8AVbRsjJ7/rUOIXJgxwcnB6DNalr/AKlAB8q8n3PpWWmGTtgn9K145FRgoyVA/WoeiE2XEkHPB3fpTVVQfnYBj2pIcYDNwAM4BzSy7XBydvGeKm1xIkSSXaQAWdQBtB6ikOwRgSO0cgJGHyRn+tLEyLEN0hUj2zxTbqRZlCtNuAHAZeKuw93YpyymLepO8A8YFVvMIkbIOQOT60XOYULNGMk4+U5zVZnyGT+HGMelQ0jWwXJzuwQQaqSyny2wMDOOaVpdmAx+lQSyK64JwKLWBogkk6NnGTzSoxUbTznvVGUtGSCd3ORVlWDqjdD1rRK4mSMePSmj7gPTAwKRpPmTHNMDqVI9DVJCuAOQMcDOacAd/wAx7cVGFxg5BBNTg9D7/lTHcdEgxkDk/pVhhtwqkH1OKgiK7j1PFWowoPJyQOlMlsmi6E5JbHGB0q7HHgLwTtG4k1WiwuTnJ459B6VYEoWMEkZPGM9KViGyU7mAYjrjgdhnvV7ep3qM9Rnj2rPjmDXAiHGCDz3p0dwgdgzHO45GfvUraCJPDzFvHWuE8j+zbHH0827rra4vwnJ5njbXSeo06xGPT97d8V2lelS+BHkV/wCIzz/4x3DWun+HpkkEbLqn3iM4za3A/rXAwX/2khDdSJJtZ285ggCj+7nluB7V2vx0LDQ9C2Ehv7UAGOv/AB7XFePvb2z53RbpCAMGQjHuKJ7hT2OzGq2KKBFGrTOv+ulkLs3uVHT/AApDNfXGZYZ5RluFEYRf/r1yUMgsVc29yvmKclETDfmetOluWkWP7Xd3Z3/OmzkL+HaosXsde+qgSeVdTMsgUZR5MAj8OtWo78rGAksUaHkKnLN/WvP7W6hjLrdWbSlG7g5Iz1A6GrUupbpi0VrcwEfKSgxxStqNqx3S695Em1bZvM7uQMD8BzUtpriXT7EnO/7pBTZ+OT0rjhf3MykRXnXqrgIT+HU1NFfyOyreoT3Eko+X8sc07CudPcaq0dyM27RrLlEleTCNnqp9GqtPqc0NxGjtLLIpykKjCOg9uhYfrWUGjSWR5bWO7t3GcBSu33APBH+RUN5aL9iSTTLhHGd0EDSlih/2W6/gaHEpTOrsr+XUI8X0itbhcqsRwrD0J6/hVrTLqbFzY/aNlwgwpPPmxdVOPpwa4nSpZ3Q3dqxaIEtLBMQDvHBAPY/XrWqNXtpLqJd4gI6T4w0JPQYPYng1k13NL9jtLbzJBuEaHeMqj8bPYfSriqrR/vMZQZwvO4jtmsSPUxEkUbARTyuFJJJQn2+vpWvbuPMZcbRjPB/PNZOI+YejRlAQg35zkdqjBwN4BC9centSyzLt/dg4bpxiqvmFXwW5649qmxtEvodku/IAxwBVvz1eLb5Qw5CgKPmkbtnPQe3c1lpINhaQbieMCnpcNC5eLaSBgDd2ppikZGpI32hNzAHJ+Udj7mrdpghAynNVtSkWa7RVPmMrZc9Bn2FXbZlXlvwFTomaJ+6bGnRRiVtxZEkUo5wCME4/P0q7qNolvp+Gd2giYqkyqQzk9j2IHrVG3Ja1Xyzujk4IjySMeoqe8lQ2xtoEMAkUMcyFkfH1+6a6ItJGEruRhTugVsMdx5FYWqFQm4Ebup561r3MSoTgEheRnvXP6iM7iydOma535nSldljw7cO2oxyCQRFhje3SuhZxIHlfcZCecnvXMeH5l81oCypIehIyADXRRMwkyWUvngg+lNbClbmJJMBC2c8DiqpZzKy8DIOdw6VLJK24MNvvmoMbwTkFep570mmK5P5gCoQpzkMWXufWoZpYFDeb5agE5G75j+Hr7U1J2Nuu7P7pv4e4qhqV1BbSm7mMUJP3IoxuYn+efpVqLMHLoNuJ1itzM+Ux0TcePQfU96zZ9VZoUCyhUII3OuMDuRWVe6lc3dw2+Bl2/wCrWRgoX1Le9Z89xZQN593fRyzDAYt8wX2VRWsY3IlOyOhS/wBy+a8m2KP7isOT7/8A1qtwaufvxNIGHKK6dhznPYD1riUvrrUZC0Nupx/q2ZvLWMep9T3pl1PCjtHcazLNcAfOIRhPpkdR7VajYycrnbTavcXkwuLpTszv8sNjzD3Y/wBB0FStq8E422yCOWQDdv6Yzkc+grgRexovlCcbycuWXOwAdCR0+gqOK5Wd1SCKVHGWMhYgDA5OWxinyO5Nz0ptStXmKJFFHJEhWR0kBUqe+D3Bq7YMX+BHiNmOS0GsEn1/fXFeWvq2bRYkC7gcM+3Jc9sH6V6VoGf+Gedaz1+x6t7/APLW4rWKs9SJu5qzeJ40kW2hd7q9IJEMQxt/2mY8KPr+VRQ66WBlnYSyKcCKJsRIfdj1P+QK8vttVkjimgS3Cq/O1CQre7H7zH6kCj7eMo7yMSo4L9B7BVwF/OvN5Ej07nrTeIlQKhkBY8u54Uew7mpX1+32DazCRuigHdj1IHT8a8kbU1a2VhcXHzEg7VEYPsO5qtealcRJGgllUAbigwCc/wCeppOC6iPWxqschUjKwjhSxwXPfAoku1l3MrrtBwSOn0ryjT9TdMmS33seDIZd2B6Yqzc+KZ0YCDZhSBjZ09wOn51Sgirnoc0o2fMdpJxVQ9SwJ3HgA9hXFx+KrbzCWa6efOAZEA59gOBWjba4JWCFZC/QKccn3NPlsVzWNuT5Tu6kdKIGO7eR+FUHnJkB3KARU0Ll1YqSR2p2KUjShO5s55zVsOM4Bz7VRiACAgZIqWF23cDqcVDRVzSiO7Yg6Z5rRt3wQMHJPGazrPaMu/QHArQhO8Z6k9MdaxktQL6vhMAhQedxpSMoMn8SaqSqxTdkcDtT4i0ijauT2J9akpJE/wB5wEk2djuXtUTRQpMzm4GT7ZB/CnADDPIdy9COozTYbeKORizFsjO3HA+lXEexnSsDKwQ8Dk5qswIkPJD+lXLx8uducHq3r+VZtw+DlhjkUWLWqI7hgVIJ/wATVNiQAMblPGallkWbcVOD2zUQbKY6N3FNrQZBMV3MD+tM80bcD6ilmcZ4+8O1VFfEmDzVRIZZVmYbgcVKhwo4571XLqAB6dKbJcBHCnOSM4HertYgs7yFwvc8e1P8zae/HrVNpAq72JCDrVObVCJDFDA7SA/MWPyr/wDX9qpK5PMdBExByO/PPapUkVSCTyBk471ykmtOhUS5UZJzHyB9e9U5/EKhWYjgD/WI20j8DT5SHI7ptRTZww5OPxqpNqKBiJv3ZHRWPDfQ159J4iSV2MUe9V/5aEkfjSNr9yVGYmmi/wCm6YX8+poshX00PQ5dRQrgsSnXd0ZT6ZqOTUZGU74xPGRwV4ZfrXmq64mSIVklf+JekQ/H0+nNXLfVpIoXcXMySe+NmfbPQUWQlI9R+GEiSeKfELR+Zj7FY8Oc4O+6r0ivI/gjcS3WveJZJ8lvs9kAxGNw3XHIr1yu6n8KPMrO82cL8VrZryHw3AknlM+qHD4zj/RLk1y7eC9MlleTUfNlmXAy7khvbjpXZ/EEgXPhYsdo/tRsn/tzuaoSlRG21i4J4OORUVNzSirxOKv/AAbayTYtCbYYOCGyawb3wrfwjDXBk7Z2ZbFekykNw5CjoGH3qbNGygbhyPu7ucioua8h49c6LPG+BOI5B0bBQj8+Kglj1K2YeXOz7RjdwQfqK9Tu7eG4BDKDg/nWTdaTbsuAMMPwzSu0Vyo82nupWUPNHIkwz84/h+hp8Os3a7UI82NRgLIN34nFdPqGixKN0BwxOSjHKn8KwL21eP5PJXg5wo/woU+5m4Fu0vXkVBNKIyfmJRS34AZ/SrMKeTMrW8k1pLJ3fjePpXOs2yUtEskbDup28VfhkLkBy4GMFn+ZyPaq5kLkNBfPtNTkkDfupzkkn5S3Qmt+Rj5CTuIjIrDaJACGU8HP17VkQ+Q8aBxIAh+TcdzDt0rTsQqp5ZIWPGC5549qTsxWaOjtQmx1MBkhdRtSZsGI/j2/lWvYsUHlRjIGAPf865CG5lNxCZXYGIeQ25fvnPBH4VvQ3eMgMD2wOgrGbNYxZtCVhGSThj2NVpJNjIIzwuQfrVI3mMhicDvWbc3sss2IBliMbj0FZs2jF3Na51FYm8stn6dagNzePlggRDwM9abZ26RR72G5zyS/Jq9bLu+dhk9ADU6suyG2cO37xznvjvWlCArKpfBXsadHCNnRee2elPjRlIKqGwOeMgU7WC9y/ZQO8gWJ3QIcl4xweM5xV66mEsJiQXErKu4+YuABjrjtVfRbcTl2V5MEc7OHQn09venXrOzGBluPMiG6VnlxvTsPrW0dI3MXrKxh3CkgheVJzk1i6gvD/Nk9q27ogrvVWwOo9ax79lYHI2g9x2rJmyfU5+WQwNFKPvg8jPOK37HUPMiRtwIIyD04/wAaxNQi5J56ce1ZcE01tM+3JQnJHpSKdmjuzKr9PmYDjJ61FIcZICovcA8A+lZNtqH7sDOQfTpVhroYyCAGPUDOa0ST1MGOuZ1WMKzOE9UOBj3rn55reFmkKSzE8iUNkmruoMtzGC7bAP4s4xXOXP8Ao0ziHO7vzwK0irGMiW8vpGjKx2Nuuf45X4z64rE8opI1xPcCS5bADCIBQPbsBUd1dSO5I2yOv94jH5VQmeaVWUzSSkjlFXgfj2rS5m0W77UGBMdxLbtx94jjPphetZz6sTGgDRRgclUXBb6k1Yi03zk3Su0cx/iVc/TtVq38OmWJjGzPn7xkTafw70+ZMXKzMN/9pGJnLKjZEK8Ae3/16soktxIJJwMDiOIdAPT2+vU1s2PhuJGUGJWbJBBJXPvWvb+Ft4AMjInXAbdxTv2Gqd9zkkF1Ew+1Cx3HO1CeMe2K9e8Nkn9nTVyQATY6rkA9P3k9ZWl+HLOPa4VA6HIynJ9810NqNvwN8Sj0h1kf+RrirgTVjyo8ju/taKPOgeWFPm2qAoz2O3P6ms6S4csI3ieEHk7skL78V6rdWkT7VdFwOnHf6VRm0yJ1ChQF74HX61wqKPQaPN5ZcAqsiSL6qnzH8TzUgnhRiq22wgcuxINdlP4ds8EGIqT1ZWwT+NZknhxYmP2eaRF5OHO5SfXFVy2Cxy8khU77ZsE9FznJqKd52I3s0cg+8CP6108Wi3ELNtZjkZyuOR7g1O+mrKmyYqko6ADj/wCuaORgcT9pmVgHwpB+UsOtW1vDCFDSOVbkA8DNac9iIyUcBuc7OxH07VVktRBIEIMtqT8qPwAT2B7UrdANiw1EJhg/JO0rLlvyPaur0273x5woXtg5Arz6OIW0wGPMtnOME4Kn0zXTaZ5se1oifLGPvHIHtmmxXsdrAx8v+dWI22npnHU56VQs5mMID4BPQA5rQt1+6uCT1NZS0NU7os25J2Lnk81rw4A2oeccms2MfvM+lXoiAuB1PUisZFl4NlQAu8D9Kfv+TEYLe4/pTbceYAArbQORV2NQozx7AVmF+hB5YlASSEn0+fFNkieKJlihdc9CCDuNaGWxh4wQ3GC1R3swiRmESKvUkj/OatOyBMwLkPGQrqSQOT0rOuAAMkknP5VszXEUgPO4471lSxqGLLjB5I65pXN09DNbBjOSCM9utU5tysCT+VX5kBZmTC+o9azrjaxIAIIrRbBcjkPJOeagAw+fepAecMeRzTghcc9Qaa3M2M3BSzH7qjOcVTursQwnyYi8p69lUnsW7/Qc1d8tgArNkBsjP9ay76bEMHlsomK7h3ESZ5bHcnt69q1WphJlAyTvK/mSSs0Yy7fdCewHRf1aqzXBEZUzSLEwOAmVVfqepNQ3uxERJ3MaLlgJWIAHrgcu5/ToKypmacZiE3kqMB3G3P0GeKpaEPUluZ4I4/MaFgh48x5Cob6AcmsdomuXa4bEFr0AP8XsB3qSSBSWaQPPKp2iNOcHspboP545qzY6Jczybpjk5wWB4X/ZT1P8qpdxbkCTK5/dx4A6BI8hPoOgp0kEjIftMk0EX3iJD8ze57AV08Ph+dQhXbDGDuCIScfUnqav22g24cm4VpnLbiZTuGf5U+ULXOHSFJSxt4pWz8okZicfQV0Gl6NO4QCIjjJeQ7mP+FdfBZww4EUaKCeTjrV1EVSMAkHqaLIpRND4N2bWXiDxFGwwTaWTdc/x3P8AhXqledfDb/kbPEOBjFlYj/yJdV6LXXD4UeZW/iM5Xx/aX9wmh3GmWEt+9nfmeSGJ41bYbeaPI8xlU/NIvGaxfM1qRybjwfqhBHKrNZgfX/j4FeiUUOKe5MajjojzaUa0Nwi8Jar/ALJM1mv6eearyxeIZAFPhfVivf8Af2Y/9r16jRU+ziV7aR5BNp/iQkeT4W1IfW4tP/j9UrjR/FjsRF4a1Aqe73Npn/0dXtlFHsolfWJnhEvh3xa/H/CNX23/AK+bX/49UL+E/E7gBvDN/wC5+0Wn/wAer32ij2cRe3mfPh8E+IGJ3eF9QJx/z9Wv/wAepV8Ea+Dn/hGNRz/182n/AMer6Cop+ziL20zwCTwb4iLEp4Z1Jecr/pNocf8Akal/4RTxWAVXw5flPe5tB/7Wr36ij2cQ9tI8Ig8O+LEcNJ4YvnI6H7Va/wDx6riaP4pQYHha/wD/AAJtP/j1e10VPsYjWImjxNtF8Uv9/wANaiB7XNp/8eqxb6R4ihUD/hFdROOn+kWn/wAfr2Sij2MR/WJnk6WniEfe8K6n9fPs/wD4/VmGLXUPzeFNV/Cez/8Aj9en0UvYQD6zM87WTXAoDeFdYJ/67Wf/AMfqRJ9ZWRT/AMIjrBUdQZ7Pn/yPXoFFHsIC+sTOJgvNTgG5PCetlyfuNJZbMY/6+Mmqtzc67LINvhHU1jB4AlswQP8AwIr0Ciq9lHYFXnueayLrjEkeFNX57Gezx/6PqlPZ6/J93wrqoH/XxZ//AB+vV6Kn2EB/WJni8ujeJHyB4X1Lb6G5tP8A49VNvDvijzdy+F78j3ubT/49XulFHsIj+szPCE8O+K42ynhi+CnqPtVr/wDHqnXRfFoznwxe+3+k2v8A8er3Cin7GJPt5nhUugeLJFI/4Ri9x6G5tf8A49WVdeDvGMrEL4audnYNdWvH/kWvoqimqUUJ1pM+bJPAni9l48MT59DdWuP/AEbUkHgTxXFyPDl6pJyVW5tdufp51fR9FPkQvayPCLXw34piYNJ4Yvmf1+02v/x6r6aL4kRcDwvqBPfM9pz/AORq9oooVNIPayPHE0vxIo/5FXUP/Ai0/wDj1WINO16M7m8K6qzd83Fnj8vPr1uijkQ/bSPMVTXgQR4S1NQBjas1nj/0fWlZ6JqbfCXWdKksnh1O7h1Ly7Z5ELZmkmaNSwYrkh1/iwM9a7yiqUUiZVHLc8j+weIio3eFtTLY6+fZ/wDx+mHTfEW4Y8LamAOn+kWn/wAfr1+is/YxNfrVQ8ek0vxE4/5FbUhxj/j4tP8A4/VdtF8Rkf8AIraj/wCBFp/8er2min7KIfWqh4mNC8R7st4X1E/W5tP/AI9Tn0LxA4AbwpqJA7G4tPz/ANdXtVFHsoh9ZmeEXnhbxHMcp4Wv1ORz9otPy/11Uj4N8TrM5j8L3nksP9W1zakA9/8AltX0JRR7KIvrEz57fwV4leIxnwzfkZ4/0m06e/76n2fhLxVBMN3he8eEdvtVrn/0dX0DRS9jEPrEzxm10jxJb7h/wjGplc8D7RacD/v9WjFbeIEHPhXVfTH2iz4H/f8Ar1Wik6EGP61UPMPK17jPhXVvwuLP/wCP1at31uMgt4U1f6Cez/8Aj9ei0VP1WmV9bqHDi/1nOP8AhE9ZVfaez/8AkipX1DVmVV/4RPXQB1xPZf8AyRXZ0UvqlMX1uocZ/aOrZH/FI60QB1M1kT/6UVK+ras0ZH/CJ65nGADLZEf+lFddRQsLTQ/rdQ8+mm1pydvhPWFJ5yJrP/4/VVhrjfe8Kasc9/Pswf8A0fXpdFH1SmP69VPKri015xhPC2rfjPZ//H6pvpniJlOPC2pbs8f6Raf/AB+vYaKf1aAfXap4ydI8SH/mVtR65P8ApFp/8eqRNL8RJgjwtqWf+vi0/wDj9exUU/q0BfXKp4zqGleKJoCtt4Z1GOTHDGe07/8AbaqsHh3xDZ22y08J35l4AaS6tT0HUnzsk/54r3CimqEES8VUZ88XPgvxXK/m/wDCO37XL8PK1xaZRc9EHnYHHemS+CfFTQiKDwxd26DgbLm1LAfUzdfevoqin7GIvrMz560zwV4ltSkknhi93rkIiXFoViH+zmbknux5Nb0Wi+IUAH/CK6iMDHFxaf8Ax6vZ6Kfsoh9YmeOPpXiJj/yKuokehuLT/wCPUp0vxFtIHhXUvb/SbT/49XsVFHsoj+szPGn0nxKwP/FL6j7f6Tacf+RqE0vxMFA/4RfUv/Am0/8Aj1ey0UvZRH9bqHA/DbS9Vs9Z1m71XTZ7COe3tYohNLE5co05b/Vu2B+8XrjrXfUUVolZWMJScndn/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images of glabellar rhytides prior to botulinum toxin injection (A) and after injection (B) are shown. The patient is attempting a strong frown in both images.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2497=[""].join("\n");
var outline_f2_28_2497=null;
var title_f2_28_2498="Congenital toxoplasmosis generalized manifestations";
var content_f2_28_2498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Generalized clinical manifestations of congenital toxoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical manifestations of congenital toxoplasmosis in this infant include hepatosplenomegaly, jaundice, and thrombocytopenic purpura.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sweet RL, Gibbs RS. Atlas of Infectious Diseases of the Female Genital Tract. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2498=[""].join("\n");
var outline_f2_28_2498=null;
var title_f2_28_2499="Hepatic hemangioma US";
var content_f2_28_2499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatic hemangioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 282px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEaAWsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACilooASilAz9aMUAJRS0oGTzQAlFOA6HIpAM5yRQAlKBx0p+0EdsY9f8A69GwZAFADdpI45FPC/OBg5Ip20FsfpjpXV+BPCb+ItQYSyNDp8AzcTAAkZ6KAcZJ6e1AF34d+F4dWma/1RiumWrK2zbzctnhF9uOa+p/Ad9Cti0UdkhLEIAQiRIgHy8YzgdMjpXEXNhbW+mwwabbPIhgUCCMLH5RB/hA6k9Sc+ta1tI1te26ndHaSRhXkVvnjHdQynjn1FAHsmnIk9uXujbwyCUFQkpcoMepyCfTHataDTI41Asi9mM7mMaLuc+pJB/KuE0vxLHp8Fj5NjLcQRnyhNK6qVz2UZLMfwP1rrLLxHp1xahnnJkmbCxZO5j6DIFAGhKksLtNLeALGpyXHGPUgYx7U2eW1ghMl3dkRFgUYgAKwP8ACcE5P1PtTo7+2H7mHzZnzlgp+ZAe7MxHT65qCTUrCZrZEkdZHfCOI92GHAzwfwJ/OgC7JeWolVZJYQ3DkO+NvBxgHvxUaajEYmljXzFJ48khtw9c9P1rMuX0d5pjPqEIkSQRv52Bjj7pzg8885qtHpmhWNuscU+YTwGXMh65wGHQe1AHQm7P2VJhBKNx+67KpH15xWFqOr3U0bpYmOWXf5eyGZdqk44ZiD83XgYpZdQ0F4RCbNrxZM5U2xlBx2JIwD7E59qhtPEltGRa6bpM8TMnmJEERcYwMbVPH40ARDQL69uI/tF1e/ZSnziebkN3G0dqedKsdBspI7crPeMh2xSDcoHfK+mPU4q5qV7rH2SM2SwJKRvkDYJQemSQoPuSa5+41TT7eaZtQuY5bpB88AYrGHP9+THJ9hmgDlNTXUtUZL2XUDDp+/Y1xdKYdqj+GJOjDivK/iFoWi6s0psp2jvEVpY7iSAIbjudwUYPbBFd/ql+b24nuXjgk06MbUjm3FJB02DICj8ATXMzQM29NYCWlvaxFoEtzkbD0znnPtQB873Vu0UmGRs45BBGKpFSpwATg9u1fTWj6T8MtQ0C+/4SC3X+2HMkdnLLFNtAKDYw2fLjJ5zXgWvab9gvJLdkXzYhtcjkZ9Qe4NAHOuMrxzxxSshBwwx0PX8atMu0fdx9BUJUjGSMYx6mgCEgk9cfhQAxbIUdMc9qeVAJLfdOPrQBhiOpB/u8mgBqrlTz0PXFKFPPzceoqTAJyT+tJjcM/MOO1ACgcfP1HJ70pU5454yaACCDyBxxinBgvUkfhQAijap7+/NRn5m4xj3705jnJ6UwEgZ24UHtg5oAcpUk7ue/IoRc5bICketOwSNw9M4x/SmqBt6Z5oATjseQMHjpQuAMEDPuaU4yTjPHTNHHfOaAMuiiigApcUlKaADFGKM4p2PbNACY9qXBJGRml+7kUqqDx0oAYBknANOxk5A/CnADdkdPalIGcYGPrQAwduOlSDgnkD+lIQOgx144peMZ7/rQAuD26nuDTowx6gEUqDnHPqDnkVb0uze/vI7eEFnc8jrgDkmgC14d0S61q/8AslsBhR5kjMwUIgPPJr1zSY10exgtYreKONCd+G3F/f8Au59c1zOmG00SAwLFH5oVjI5T5nXtnB4z6c1r6DqUz3sMtszizYFf3xBUn+6w7fjQB1ljqElzoouIxCxfeDKzjbEQSAGB+6TW/wCHdWmjtooobDenKO8MZfJx97OBk/SuJnuYJbx5ba3SyUjEixo20A/ewvofaiDUmY+VHlYkjby1UFNq/wB8MfT+7QB3Np4hnjuyIILyIBQRJKoODnnK4yw+uK66bUFmhgmmS2t72V9qB7cAlj34+6D2FeZ6LqIgEjPL9vtSqsPLkHmoenQ8kd617u6vm3x2jEkkbnnAZSeo3Y7+maAPRL97KaNLu/lu7ouFgEIYS7XHbZxj6n8q2NNeO4m8xrpdLgkXhXhClscYc5249OleO6Rf6zNqjNJcWYCDLQ7ljEje4xkH6VLJYXEMTyPJeGVOTC6mXcc5ADEHBGeuKAPXLq00QzF1vRPJu5miWIkHHQlj8x+nT2pmmvoNlKqRLLHuyEM7pvYdSVCqc/zryWCW5ljdVKSoDvEp8iJlwOQRgce3erWlajH5z/ZYbJZ/KAUyXOxQPUKp2/hzQB6Pc+OtHZ/IurTP2eRlWW8OdhA4bYBzn0HNV7X4gfabcppVlDDIyEozJI29/wC8BgBR35PFcZ5wtISZLq8nhWNlckDyRnrkjkADpwDXPS3dtKkdrY3N59jSPLyxBipGfubmxigDuB4s1HVYjBdRzXbySGGXydybT3KnoV9cVmXWsafaXUP9qW0U1tbqy20DSNK249Wbrj2Fc7PJBFbRBL66jSFC6tIQIzk/dG0ZLds81itdPcSzGZliKcSeWgycdF3MDnpnOM5oA7eaO0uBPeXdxJFBNEALVcIyJ33E8AH6ZrmZrjTQFg+ZgUKxeerPsj/vZJGM+uM0ltY3C27TF2trSdd43SMvy+rZG7d+GBVX7JA7zSNM0jqSsUESbpZD1ycnJPfOcUAO0rSXkea3RrmQ+WFtmI3Q7yRyw/hGO3tV7XPCehT6VJpsu2fVmO9Lq2kVhG/dQM/MO5ArZVnGnHTtJhnSeQr/AKS0A3I5HIX6ZwSc1H4X0u6n1KXStDgVY3P+l3ki+WqRj7wHHrj/AAoA+ete0WbSL97e5RQyH+Ho3uD3FYsqYIzjJHY9a+19a03whZ6CNFv9HfVb+dHWK4Onh5Fcg7WDH7nbHPavljxr4butC1J7a4hGGUFGUjDDHU+h9qAOKdeBxzQEUYzkepHWrMqHlcfMOc8flTGDFsBRmgCEgLwpOD6U8Dk44GePXHvTwCWGF5Hamso3N39qAG7MAnoR8319aYQCdpIPsKlIOe2O/NJx/TpQBGAu3BX8MUjKM/NzmpSgB+9x7UzAGcnoetACEAEkHIOOen4UwcgEDuTzzmpGABPJIqPgk9gwx06UAISBg+v5U1s54wffH/16cSOMdPUcU0jJ6/rQBnUUUUAL9KKSloAAOKcDxxxTT15pR3HrQA8n86ARnLZzTFJByAPxpwGe/SgCRSCMHk9BzQMAdjz600ZHQfkKXp9KAFOeh7DvTsZOQMA8cU3tx1p6Asc4OT0x70APRSzbVA3HpXR6fJFpyKkau87N8zqCpHuDjpntWNbkwFQM7iMAmraz73QTtuK5GR1AoA2kuIJwzX7PFKW+8CScZ9OhrodOa2uNNkSJEidF8symQDeB0JBIHPqa5ITpJFGjs0gPyjJGPYgip7R3gLMyyqCNhKLwR0oA6ieS7TTzbAyCQYmkJJIwDgMOM1dhmwYZJIVVFGcmTcgk4IA46nnjrWJZXs9nCzQhdxURqmwkMvXH1Peuu0PUYnhWSa4tNrkRmEFcfTB6N70AQ2lrcxzTXVrKlluIMgETAxD/AGht4z2xXR3t9LcRwRTXeZQBI8ablUgd+OQfemyaPBd6gZYrkxhkO6OZl+f0Tdkg+vc1nyab/Zd80zuGfyMMjEbE/wCBDofYUAaFv9h+1NetZtcXUfzfvpWlG3/ZCt+p59qt3E09/cS7by1hACjzJ42RUHXpzgj8qwnuZ7pre0khiit1XMccshQkY6jOMnPPXinXMepJYx20sunC4IyjwtJKyEnq38sGgDZm1S1tpI7eK1g1F2kyXgRZZFP+8eD68AAUxNaszt0+eG4meR8sHYSszdgVQ4XHoTWQgurLT457qewfO4s0M3lOpHRTnqfYVb0m5Syng86KCKW4cMGu2KvkjjhRk/WgC+z/AG/aAqLA0mZIlkUN8vTDEgZ9qjmuIxbtEBdLC7Fd5JViB1UtyPxFS3OnW0l050+8thI0u6do49x9SAc8flzWhBqNvG0kzWU5iWQKrhAoPvtPFAE+lyQ36pKN1tbW+EZroZjC442kjn13dapaoLWOzdrMvdI5cGUEIT3ypJ6fUc03Urm6u7sLe3MlxdmQeVhUMe3sQo/Ko9W06+uorddUuLa0mlO+GFVT7QcdFCHlAaAIbfURfBftc8c14LfbEvlebgdCX2g4PtmpYbVLSdpp1m+ziMsVjiaN5DjgKxGQv4ZrWOkjQrYG4mMOotEpjRmXC88mTHfnoTVWJrGcS3En2iWGSQNJI2FQMPTjr7A0AUdAlu9WvEhBmtYUcA4m2mBMnI5JGT6nvXe69rNr4c0cW1k7x6gwYqnmBymBkZH8bH+8eKytJ1tdCg8vwxYpdaley+aJLwhfLUfxHj5D2GeawtU1NLO6vH1CcyahMzGRIcERsRwVcgFj7GgBdF8SarPp0s++7nuJMskkwG9j/wBM0XnA9Tiue8SzpeQz2Nzp0YklQNMfMzK784JwMj3FXm1S4nIkJkCEbT5KBVOP77H9BnmqEkYtI7i7vGubWVztjDRBWUk9fqfzoA8z1fw1qVr+9Nu7wFS3mohZOOucDj8awZIipO4Nxjkjqfzr6v8ABuq6zd+D28Nx6fbTWkpljuJppHZgj9BwOGOepOBXm3xN+F+reCJE1JTZ3+nzxtF5rRlxCxXGCPb+F/XtQB4ngKTkHuOlNCBSM7gpBxjj+f4ZrRltmQ7SrLt6kjFVWi+YHcO5znjrQBCwBycZ4Axn/wCvTU4BO7kkkZP8qmcd15wOoGaTadrYXgdzQBEQwJyDnHQVGRjBJ46kZqRl5B689cUNjbgNkdevegCI89cn6n9aYQDznI6cH/61S7Qzn07j1pp2gkj6UAQkMeMj8c80cDgnn6GnvjPQg9803cB0Jx9DQBmUUUUAFFFLQAU5fXrj9Kb3pc4z0oAcBnkninge+Tiox04qTHB2/nQAEg4OMUo+7ggUgHYjn2pRkqMDgdhQA4YIBwB7VNGo2gknPWiFQoBJ7elTH/Y4J4wOaAHl5JW3eZ8y/QcVPbvMpkaMNgEE4JqFMbdpUc9cdqt2p3bWh3FlUjHPP04oAFyzZZGCH75A5z6VrwRoIoSk7eXz93kfQ+h5qrsaK3CTpJGrMCwK4yM9RxV+wjRZmuLeGTy04ZJB8rL3I5oAtO9jdtEqpPHIoKsFkOfqRj+VCtFbhjcQF88Dc33x6jHNX7LTrHUJpntTcIcYWNhub1GGBJ/GnSaOoWRVaRJk5cib5W/PJDe1AFm01eKC8aG1hnlcYEZL7M5ABCkdvY9a3v7SlieO1E77zhmhiCKBkdFP/wBasK20c2ojubXUWkgKeai8A/TcVwDUry38rpbrpv2iVDvEhi2Mqnrlh/OgDYkcTRtDanehJM5lHmSAj1PYD64pZbeySySaVrK4nQ7laS7AZVz1Cp97txk1jWyS3IEV1HNvhbJjQ8hT0xyMr+tbsVtdyqrQRiOE4KCRYQCfXAO4D65oAt/aoDNNBexWG+SMeXdPJ5YA7BU7D61e0vR7a6mN8tx9kuFOPMlRyTx2BZjj3Arkr6Z7u7VV3LKy7mYgDcB2BwRyRwa0oZrgSxtFcJa+Zy0Mjh2k47nt+JFAGrPM9mZ5je2iWED+XmM/NOT3GR97Pfk/Sla+snjSK7jljtJv3hlcktFn0LDlj3G6s651e9SHzpPsi+XlQ9tbeYY26DknBPTpn60kd1qdw6zXlyl3IFbbE2EZj6eXhsfpQB6X4Q8Q6bFpyQ2unXckuTn5o4iwHG7Kg7ePemTeKrexuLxdIj+y38rhFmjiNwSO4aSQscY7gj6V5tPqN7NbRWrPFbq33HXAUt2BIAIH1q/ohFjJOUiS8mKl2BcGFCOrsD06/jQBp3ukarqt39pnjuJ1yzKZgFVie/yjAUdeatQXE1pZfZoQ8pGFDRMuw88sp2g5+n51m6r4j1O8Fqsmr2yxKzbolysRX0BwMmnXUb3USS2epwSyIBt2yiMjvz79qANTWrm6MUbxSiG2AwbZDh7h8cbiOcfUiuWtrG7vCj6vc2NmM5UMTvI/2AM8n1PNS28t496un+Zbyz3CMZXTJWP0XdjGfUCum0LwnqmrGGTUMGODLfZbWIl8gfKhIXjOeTkUAZurXtm+n21lZtDf3Cv8qBvMEfoqLj9T3ruvAvgU6yhu9Ut9lszhCqSAn5eo449ckc1f8F+A4U1aPVLlIYZjMUSNN64wMnAIHT1PWvQru+t9Dtbp5UEcK5YyqmxQPTexOT9KAH6ikGg6UxsBFZx8KZGOVjHrgnk15h4o8T6aYLmzubu4uE2f6TLIoYlSeFHUKT7YxWL4+8eXGp2qx+UYJAuF3kfNk8FQOTx1rzy61X/RCl7dPNamQsykkmTbxt/E9ulAGB4o8G6i8V1qulaRfPoseX+0eXmNBnpu/iA9ea4KaB1bDqwK4B5/SvXofihr0PhhtBthZDTPnjdfKBl2sSeSTjv6Zrg9U0fUZzNcwQyyRgbz8nOO7EcnFAHLFOSMFcDrjqKYyZbOABxk4HYVcaNkPIxkDmq7ocZwpbsD3oAgYBT0bOAQMCm5wemR3qV0b5mUjGcY9/8AJqM57DHsM8UAMxgnOPTJ7Ux0wckkDNPKkqSwwuM9KTC4BxlcY696AIip7846dxTWA3H5Qfxp/LN2znNNOfb8RmgDIooooAKKKKAFpeo6UlLkmgBQMAHv6U8DnJ4xUeeeakBwCcDH8qAHDrnAPfmrVpC7FGVQzNkY4qGLCnOffHIrW0m6t0ugl1AZIGGCVO1l9wc0ANi0/wA5X28TINxjPXHtUUSPGwYr0bk4PA/Gunv7aEQq4xJCRviuIjg/7re/HWoLWOJgTIsTwNjdLnBQnv8A/r4NAGtcaSLvT4LhooeAP9JjY4I9Gx398VLFZmCwJkga5iCknGBgD0bsfr1prwSW2nzSWdyAHO2RImURyL/eH90+oq9pWlquku1pqO2SQZZCwdJB9P6UAV9DXzElgeb/AEUncPNUN5ZPQsvUD3Ga6CWy+x2Mn9owwMA3CK4KMOgaM9Rn0NV7RYtFtUllle5tpMLG8ZVjGfcHoR+tbukyWZuY3lgt7l0Ut5hTePyOSn1GRQBkaPoFhLd7pbhoCoDRtK3lt9CAcce1amt2F3CrTrqRmXepxvWRGU8ZwBz/ADrYjnuL+TyoLOAozjygkCb4+5wSPmB61am0+2tCJ2s7zznGGaHyo2GOuVPU/TrQBxt7osd9C6CS0hnADIVmG6X1BAPP86rWJjsZfsU08gRvl2u2xU9hnBP51qeILe6Mw1DT7ZL9JGG8TQbGX8j+orG1HUZLeGSR4o4opT5ZiVApzjsSOcd6ANWWDT0Z5YzceYBkqXztOfvckgj2pLe2tZYnlDi3kkBRWDbC+O+F6D61zkFzdX4gEQllZTtVSSqKB0IbnI9qm1Kfy0hZfJcCTL7yRk/3ckcfSgDWv7a7QQEaq0y7RGv2f94qnPTjkt+GKh1dEcD7VJMzK20JKixE+5Y/41U02+gtZzLa2cMTsCWwrSAMcYAJIx+FRjxBqa3259/mM2DGw/dr+ANAGtGblbSKG2EUFqnCxLGXLkf7Qx+JHFMtbuORIorqCSQFyryxFQOuTgk5z9KhtZ7W+B+02NnBDnM0jBixOemew57V0ENs9rbC2sDpdsZTgOIldyh/hG4e9AFRYfMxa2Znt48FTHPcIVxjjcpbn1zio7aKaeONLuSGVVf5UikQFwO/+FaWn6dc2N9Or3kDwqoGLnDtnHZAuAfSllknS5mtmE5WIgtF5MalhjgnGPyoAakVveqI4dMjPJ2/aXZnyOmSP5YpItDvZ1RYdNjkuY5gEUxGMe4JYc1BBLNpt4qwARCaQBtg2Oo+o3fL7fpXXaR45k0qRobpEafcQzxLlwPT5hiMfTk0AbQ8OXFnaQxaneW0c7EOLFTsOT0QKuTg8da9V8KeH4tNsYmubRLdmH/HvGSyoT1zx+prF8B67pusTn7DviMIHmyEEbyf4d2QT0zk8dua7DWdUttLj3yAs0nJRF3MRjrj0HrQBV1vxLpmkx5up1/hKoAR9OeleV/ELxDb38tyr2sMMcUfmSS4LvI2D8oPTAHc8elYfj7xY9zeXTWlvM6zn97LcQlVVR0CAnP868s1e8kllMcrzKgKmQIDtA9z3xQA+4vHx5hZ2cdcLkKD6k9D9M1R/tG0WFjFb5KLs82U5OPRewouppb+3W2sbWcWqtgDJ+fp8xz9fap7Kxa4u4Yb4RHnBSP+AfTPJNADdDf7dd28NvCSiNvkbuxHoD2H869W8OeHjJZeWgubi6uGLurvlUT1cgZBPQKOa5nTtEuWtBblFjgYnc25vujnbn0H6mvQtAtr610+NbWB47md8QGzgHmqgHbd0Y92PQUAch44+B2pDTZtY0pbUFFaSWyQENwTnaOnv1rwy9sJIJWjYrhc8dD7n8OlfZWp6VeaToyrqOpTsjDeYTcO3lgDoMDn6nvXh3jbwpNq0kt9Y2bwSOC2x25mHXPu1AHi8ifMACAOODn8aiubeSJ9rrhtoYYYEbSMjkZ/Lr61o3ds8bFZFKsh5DDBrOePAJGR7KvNAEBHDdA3ao8D7wPOO3ap5FMbd844NRtlicrkEd+lAERUE4PUA5PrUWNmACDx34rW0y0gkiu7u9D/AGS12eYsTAMd2Qo9TkjoMfUdaX7faR/KloqKOii3QgfiWJ/U0AcjRRRQAUUUtAAKB1openpQADjk1JGOAT0z3xTVAPX9KlH3epDenNAEoXkkjOefSpoIZGBk2FkH6VFEnmMASB2J9K07axuYZEkiUcjKlfut7f8A66AEtluIX8mIOUIyQuSGHr710mkRJHdoVj86Cb5XTjafUgA/pUlhLbmNWltntieQ6/dDcdPT6GtKG3W7nV7B7SK4f/XRo+3B7MvbJ7igB4t5tDklWHDxynf5asuCOx2n73/1qS3dbwI7wQRvGcgQg7lb6Dtirtlp0uoW1zbxTb3icuIJwdyHvt/2fpVCzhe0ucSQTW9zv2lSm+Mn2bqP5UAdLClveItxbRG4dB5ThRh19QRjBpIra6gvUkEc1g7vmO4gC4b6jo3Q8ZB9qsRanbwxICr73bYwEYEit/tjuKk+1iOUyCylWTO1gFPzKT1wpBFAF77HPJqL31lNcT3K/LKyHylcd2x1UjvitIwpIkJubxGaU7wzZcv2wOSAfwz9KrWc5laWW3n1KFn2ophHIYeue34VT8QW6reQvqFhctuJUukwWJm9WBHyk+tAFx7nTbRzJaXutSO37pfsZXAYdi2CT+eKZfR3t3AztpyTSspYxXjASbcfeAJwfepNJmAvHhhtLW1cgF0kL4f3Jx8351e1Qfa45XeKy1CZVKMscCg4A4U9gfqaAOLvrTTbeNJWhFrcIMN5Ssin1wEJANY11fzXTGFZolSXACT/AHpQOxP/AOqtPWNDih0/7Xc21vE7DaqQzouPUOR3/WsW01KWB3ttQuZpYdo8vZMrMMdBjB/SgCV7Rkuo28ieBVG4eVEH2D16dKDc3cskKcskp4MUYSQn/aPSrVpq8cFybizMMk6rk+dHufHpgnk/SrVzq+ozRIJrmG3spRuKiJYYj7E8nPsKACCSCePypnubiZSWFvubaMd8Yxu981Tv5phe24tYbl7xX3PFKCT7cgD8hmtK2bUJbD90Ehtpfl8+0bCAdie5NOvLR7OyjAa8eYj/AFwUhl98sck0AXrC/wBQuYZRJG9rGOSPsznBHcEZP5D8ahhQwzTuTdeYfnDzoUEnrndk5q1o93FcGG2uGvUjAyTd3OWY+uBwPx61sy+GjcThdPu7iSbYXKRphY8j7z46dsE80AcjcKZpvtF3qMojxyUJ5X0ztyBVrSbDzrr/AIlsrJauRgttjU88gMxy2f1rq9P+F+q6vDHvtrqTJHmTtMm0AH1br74ya9b8J+BtI8NWH2y4mhvL1FCrNIvmpAAOijpn3oA5vw5f6vaB3gjiubWMgTT/ACtFDx1C5HTHQd6mv/EySf8AHxqStd3BKrLBbAS4HT5ckn+VTeLPFV/LZTxwXLxW0ZI3oAXPHGQMY9gP1rydtYe6nXYbi+1A5VMNwoIx83bPegCXxLqV2ySQlZpQwON7ANL/ALxIyB7DH41xYgF4kUMLMit9+UMSW9lQfzro9P8ADuo6rqKqtqscuThnkAAT1Zj/AA/X8K9h8I+EhBZxwRxx+a3yTTCUSvMBzsUYwif5NAHjmj6HqNxFFcWmnsIWJRftFxjeo4yR2ANdTpHhKG2Ki6NlcaiAXmcsRFbx+uccmvaNS0trHT932e2iUYLSyuznHQKFA5I6gdK5WTTpXsGXULqOy09v3kkSDDv7yP3J7L2oAp6RpFqtmrBbucFgFlhhOT7Irgce/T3zXR6JqKWkaR2lv5eoS7jKzKSUAPRQSMD1Y4+h4rnn8Wm2it7GyuZTbJnzJyuJH6/LubhUHtWJ4h1Ke50qWG3RvJkwTHG5Alye5HJoA6fXvEcl1evG7QiCNcNECpaYjgM7Hov+yOTXKtFd6gbzUpZ8W8eTsVQFBx0B5/lVbRfCzfZnvNTtkt7RyAqFiw9yOeTx16Cl1u//ALSaLToXi07QbXKlIiMynP3i+PvcdKAKfjj4ZtqHgkeK2voorkxq/wBn+z4+TOArPu5I65wK8E1CzSGVF3q+AQ+1udwJ49MdPavXvFWkRXM32qOOFYUT5UkAG1R3471yF7ogvraFkjRZXB8sRL0XPVieufagDz4p8xAxzwMkYHP1qGOJWkVXfYhbBcc4z3FbWr6VeaZdtBeQPHIvGG6H3H51kyxlu2fT/CgAvHVWFvFDJDHGxJR5Fcl/72QADxwO1VACAM8e3H+NSEBR29SOmKj2ueVbA9KAMGiiigApc+/5UUUALnigH1NAFSL0I/KgBExuxzipgMHmmKp45IqQfMADjIHBNAFizh8ydUIUep5/wrpbCC6tjhAZI8AFd3Kg85x3+tc9YLucAbWPXaTjNdVDHvs1ktXkRkILo55i+h/pQAlleSaRfl5WaW1Y5dAoP5ds+9dFa3kDXCTWlwHgdgfIuFG0fj1U/SuNnW5ZlMYLgMdsicgjvmrlm11bRrFd20TRbsbpBkZ9Ny9KAPV5bdtRdbi2Vrad12EuoIGP4gw6/Q1AfD+syyMsOq273Yj3G0dB5c474B4z7frXKaVe6lYrts4lNux4heXcoP8Ast171041sfYki8RBrWRX3QXEbjMf1PHHbOMe9AGHNp999ugSQ28d5AMtbpmNyuf4T1OO3Wulg1u7uP8ARhENRgRd4MoHmRHvxjP45qxDaW2r+TO2qK4UGWOcjYMj+FZFJCsehDBfrWjYjTQFjk1PzpyPm3qfMiXPQFDyPfNAFSz1kraFo9OujKPl4jJbk987gQfQmiBoNYndJRHBeJEf3E8e75exwrbce1aMltYedcvAtzvKny2a9LJIMc554psI1S3tIoYbnSba3ds7rja5QegcUAVrHwvfW8ayRzaSm0580mMMnoqgZ/nViHVJ7EE3hm3JlQtrEGVwO7Ede/pVqcwvcQCa6t3dRzNDaJOU49A/NW/Kt4rea1N99kAHyzXVrJCJFI/hxn/vk8UAeW+JrmC+u5Xjs5LVH6+bGwD++ATXFykPdHa8W9ecqcY9wMCu38U2dhBMDb6rY3K7i6iCJ5Dn3zjB9q5qdbbakUiXMCMckG2CEj1BPSgCG2FpGQXkcM5BzsO/8TtxXUaK0c5ZFut0ZB+byxIxI7YbB/pVJdDgvFSWDVDIy4+S5kHH0wR7VUGjXmmak7XlvLDECT5phLKSffnNAHRX9lqhe3je3SYk/u5JpggYevlA8fhzV06ULSEmQTm5Y/LG0mRGeOfb8TWb/aeq3zwra2zME+USJaszAevC/LXceGfDEt68aNZzpI48xZDLCwOe+xyCv5E+9AGPpmh/2hqMN01vcTwRjyzLcTRxoG9RnP54NekadqVvoc0IWWxgDPtdYLwvub+HB2Lk+/IFaVj4O8PeHoTc61cRXt46YaGBSwHuQWI6duKjt28LSuLLTvOlvB1EKADn+EBSTx6BTQB01rq7XemO0EG9TkGJQxDEHsScH8cCsDW/Gv2JLeBdPa4mdv8AltceYyDowCjCgD64470t9q0mlWv2aC+W3CqQ0Els4Yem0sPvd8Yrin1Jmu53a8iIBLu1woDMR14Kg/rigD09Na0a501BNbRK0mQSYQFYnqVAGWx6nA9K5+81Pw3pVk1rpljawxk4yxVFDddzAYdvpwK4uHxTpL7fPtroXEZwEAZkT/bJ7jp2/KtJ3XUbJjoWn+VPJ8v2mZF3MOu5myPLX9fagB+pavbSy7pLh5pplyA8YRAM8EqOcegJrsfC3iGG2dEiPmB48ecARHGv91UUeo6kj2zXlN7b25zJqmsRzrFjctthVLd1DHqKj07Ud91KU1SKxkGPLER3kHtgcAGgD3q/lfUoISLudAxyYgh3uMd06qPrjOOlcTqfhq4v7wxR3TWirl7mR5fMZV9PmOBntjge5pul6nHLZIkOsAovyz3M6jfJ68A7mP1wKbq8VlZiExXUsCBurzbmm4/iUHn6UAUZrPSrExIJZUEeAr3DkBh3ZjwSfQVt3MejWumi4uGcwFg/mSl5JZ+eB8w+RSeyjpWCtyNPJubtpniaTILqCRkdNu3r7Vr6fLa3GpR3t7DH5uwyRxuxdhxxlyuB9MUAYusQzXDy3bTRwyFNiLuwsUf8KkdgPQCuJugLmb97di7liPWKMoifQYx+Oc16ZrmmW7abc3d5JPtcNtht15Y92dv4evevIrieREmttJRsKcGWVwoQZ4PXr296ANuyJmOL4mRmlyidvZid1LcanZ6RIhgjtt8asBLIchfXA7fWue0tbmEtbxPJczyHG8cKCewPU/QV3nhDwRYS2ssurXD3UrMRKVbnPdT6H260AQ+LPB/hzUvA0XiO91+eS8mgRo7dDGu0seFC43YFeC6/pMun3PlSoylhuUkD5h6jivffF9jp1vew+WILJYVASGNQJSAO5OMe5Nc/eQaRrGj3UEqJCSMreyYJU9sevPoQKAPCJRt5JGB6VF8x55/StzXdLk0y8eCbZvGCNpyGHr15rHKqSScA/XFAHMUUUtAAKBSjk805QPrQADAOMsfpTlPGSDx7UbTgE4A96d5bKemARnNAD0QnkZIHbOKnt4GkYIoTJGRk4zVcEgfKRn0FXbOVg6mPaCOcOvynFAGza6JNLErRsfMBHBzz7VoQaXeKnnKsjyIdk0TqSHHscdParel/aWiTyFzJjAV+dx9Awxj8a6iyv7cwiK5jCTqP+WmN2R/OgDC0TTpcyi0KngN5DqQVB7gn6dea27zTbKfNzFfGxugNrLOvysvqwHU+4/KtO211I4U3rFd2atkyxYR4/fjlfT3rNu5Fv3N7bRs8WSX2ttYknqQDgnpyMUAUtK0Q3E2yO9i8sgl1hbJHoUPb6VsahaalbW/kXDQ3lqNp81AJCo/utGepq3ZS2l1AJNLultbmI5eCdNqyew56+9bVvqTZaW40VbqVgsavCQ2wDqFfBOP97P1oAzrCCS0QyWktskbcNa3MPlCTvhT0J9qguYzd2rm1GnKoBUJNtVoWzyAcAc+tdNHN4entyuqQSbWbcFGUZCO23/2YEZ9Kp6ve6cirbaPDf+ZImQSdoA9Tkcj9aAL/AIViuGhRJrNZYwMMXuApOOuyQZB/TFdp4f0aCSzYi3t5VJZmZ0WbB92RefqcGuF0uCe3tY5NQZbqKYbVSF3VAenIVuPc4xW/Z2N/NctdaJaXUOCNqyThY1Ydg3DEe2PzoAdb6LqUmoM1n9ntrPGYIyzBZfVhnGD+Bp2tG9SKWCXeG2874XBPH8LDIP44q5pl5IJrxruKcXofy5LhJTKoPuJhwPpTr+2uLeNpE0q0YFSftUFwIlY+rBRtb60AeK+IhazX4nt5ntbtCeZTwx+mK5K8Mksh+0XEcrqcu+/r7A4GT7V1nii2uL6aSS3iJuBIRIXu8n/gIOOPeuX8oW120d7AUZhgbgzt+W8CgDSsL/S4DGYZrmGRz+8cuRx6A8kV1H/Cb6ZDatZx21wWVCVuDcu7t9S1cYNPtm3bbqY7eShtmH68jv610+jeAF16SOGG5D3bjkB0RAOvJ5oALPx1FFbbBbSW6KeClzIRkjklM4Jrn9R8Q3j332iO7aRiCGO3H0r1Of4C3NjYLcNqliZxyqNzkfoPxrjr/wAB6hau9xcW1skSkhluL1YzLgdVAORQBz9t4rvIjJJMUuJduF8w4Qe+wHk+9WNK8bazp0kh0+8ngWRi7JCuMn1zgkdaxL5LZpXjgt7WBlI+XzHdjjrySRVZC0hVEzzkkJ3Pv/Ien4mgD0yw+KGpSxrHcBhITkzBA7fmegrIm1oX13NOskSKwOXlT539RuPSpNB0+8vtLW3ttPmKrgyeVF87Ae+Dj8cVJf6G9vJG8lvcuEIYidwVPt+HrQBThuTczyMykp8mw27bRKAOckcnt0rTvdZ1AWUSam0y2p4jso5DDHgdnHcfWnw2rS3CNb20UYBBMqx+a3/Ad3f9KztY06VbktOtzIig5aeTA/4Ef6CgDK1G7NxGS5xGhx5cX3UB/h9afpl/BFHMEtYomk+QMx+7689cn0FZt15UjlIYkWJemOST7cZNQFZYsvIu0g42sOh9ODQB06arNazLJAI4m6fu+MAddoHFdt4X167vIJbyRWd13HcOTj0Ld/8AdHWvNNJuSABcCWRiPuoOAB6nPA9hXWaHvvI4ow1uLctuEbybiPqo6fUk0AehaYb7VdQt3nhgdWT70p5yP4QxyM/7A6V119p1toyRXOqsI5pEykG/5Ix6sx4B9+tcDaeMtD8PNm2xfajwI51QKsPrtOOB9Bk+tcl4r8QXGrFnmvJZlDElSRhT1ycADPHvQBseOfEv9rslvZ3bx20Q2KolyG9Tn7x/GuNiSS5eOFZg6RHOyXKg+/uap2FreXSSSIJShOWPADfn1rtPCXhO91K7tYZC0ayMCY4ivA684/nzigDe8B+Hwtw99ebJZGTZBEIjM6t67f4B6c5r02KOPQ9NN1eaeIURd1rawR7XJxzI/ZSTmun8PaImjaeLe0t4YTnLSoQdg7nJBy34Vzfi3WLW0HkWtuu6QszS3B+8B1Oc8fiBQB5zr2syz28k89mbZZkwIEO8uT3b1/HpXCatdNpaGCDyjO5DyO7Z2fUdK6/xDdLqEzNZFWmX5laGUqqKcZJb19q4O+isPKcKz3Eu8s9wQ3Tv/EaAOt8T6j8O7/wSEhtzc+J2jjE1wiykK4I3fOx2468CvFprQNK5SM7cnGRg4+ldFc3duI28gGRwDlh8vNZQhikAaQjdgA7IRj+VAHmlGD+NFOA47UAKBgAnNOGD2+hpuMdwR607Jz6DGR9KAF/h68j9KkHI5HP+feoxnGQfyNPGc5PORjpQA/BK8nGe9W7aB25XOPwOKrxruGOc89sAVoWCNu2MroOgYDJH4UAdV4fuLiyjUxQOYifmWUDafox4/Dg10UrzanDE8cdvJt6oWwVHtzkGsLRpbmJQJ3UITtWaMfL9CP6EVtTRXMEj+TamKUgEsmXWQf7v8Jz3HFAFSOKSG4khnspoJnGVmjwRIP8AaGeR79famaTMkD3KSrDuUgvECVDDOMjjg47Vbto9ajt2lhljuYm+Yxk/MD6EHv71WQS6lfRSTRMjK3zqqDcDnrkdPrzQB2WjNpnkbEvdsca4WG5Qfu/o+Mg+mfypttJZtfOjxzWzyyhYrrTplXe2OsiHGelQxwiArcabcW884YZS6iDFh6Bh2+vNdv4bksJAlvdW8FhNNzhAzRyH2JPH4EUAYuvXk8OLW+tbDWDtyJW2wMAB0OTn6kcVT0LZb3qxLZrDK6eZ9jYtIg91ZQ2B9eK6LVLPWLSWUSnT7rT8/u5JGZto7gkDIH6VJaWZbS2uP7LsJ4IctvsLncYx3OPUemKANfT9K/tG0aTTobWYkHKRybpI8dcf44xTLa+1yJPLtWabBKDybVwI16fOBt/PvXJ2F+kQEmlmS4hdiT9nmIkRjzuJI/ME11mmanc3dviayuzeyqdol1FFLD1UnJJ/2RQBantLk2Ie5gvbVif9ciF2PP3hkYb6c4rL12K502x3x31veu4OVmto8Nn1Ifd+AUV1ujXs1jp5C3N4lyqeY9tNAY+oB+U568965Hxdd39zZtdCeNDKP9VISkjn/eQ9aAPMtf0C+uE+1SaRIsbncZbUMFGf9lvmx+Vc/wDYbe0hxdXEjM33VLDK++3rj8a29Ue6dxBPcyHJLMWu3kKD1xkH8qxRDv3sL03ES5Gz7OZAp9OQaAJNHkhhlYtqCylQdqsBsYfQlT/Oug0+/eF4mWKXbJn91Z7QD7/WucGo2UO5JmuFkcdYovs+f++Rk/jWhb6tbWdvDc295ciPvEZTub9cigDrbnV4bbylsxrMt3j/AI9g6O34gMSB74FUb+fUpVjN/ZX8Nuwy8E2Nn1ZuW/xqnH4jsr2QW/2H7ZM5+UlyyIPUnZkkfWtK4mW108G5udzA5WG2BiUf99tg/lQBpaZPo8mmot5a2N4kZGY7ePyNwz90nG4j3OK9AtPiB4X0DTlXTfD+nWcxUAbI9iZ+uzLD3rxKXUpp4GEkrxQMuwxxgFSPcjrUFqNNmQJpjzNcAYzvwox6jjI/OgDs/HXxNvL5FW1Npbgsfls4yqn23EgsfeuKuL65lQtqMY25LAElQuf+Ak4rP1S0uYZWmKNFEoHzRyZz9PSqCytICqvFbgtgea7MGPr9aAOog1CKOTdapOkoX/Wbyixj13Hk4rKu547qRlja5l3n95JNk9OpHWo47XTFgP2m8eZQMHySdqkfUYH61NpgtZD5eyR4SDkCTbuHTnAyfoTj2oAdZWNxcwmW1bbADhTtCF+3B7/p9ahgs/nZNqyzKSrMcBUGeo9frVh50jvVW/V44V4igTJyPTrx+NX47w34jtNF08W6sQGYtjPszY/lQBlW0kkN41u92EhPDbVzkfT3q1qd/bq4jsoFBQ53+uR0x3rrbfQtD0GBbnxNdJPeMMrZwSHj6nvXH6/qaXjoLS1hs7dM7Yozg+hJ/wAKAKSz3c5At42BwQWC4Cjr1PerdrlEMTf6VIx+VAT5a/1JqhbA3brAMiPqdgJz+vFdfpOkCSJY7Qbp84+VQ7KPQseAaAG2tn9tuooFjnuNmN8ScDj1PoPr9a9Q8A20kOqTXHlb7ZdoD43Z4+6pOM+hxmqnhPwytvbtNdMTbBtpES5WVuMLu7ge3Fej6JD9mjBvXiWQDEdpC/3c9sfxn6UAauta5Pb2BZIZPK2dDGclumzOAuB7E14F4w8QX9xqssskb4XgAPuz64A4/SvQ/iLq8FlEdOgsIYZmUjKOCw7nOB8p9gfwrx66EXmBnkM0znKwQtuIx344FAGvpd4i2IjW1iR2JBVckMf7xJOTj8K5fVw7FzO5Cjn5Wwqj16c/Sup0SO7udNmuBE65+QyhBgew7kj3rBvrm3t/MJWaRzkJ5438jvz15oA5G60x2UTiFljZsLkkg5/X+lRDSrphkQkA/wB47T+VbyeXPfebehbmRhv8sHCLj36Cq93rEn2h9kduVzxtOBQB42o5x3NKQVGCMGk46jirMCrKyo/XoGz3oAhUsfUjPrS4OBnBP1qy9lJHn7rL6AVDt9T9BQA0YzhgM+/alPUYBPH40KOCcd6eOMDBHcUAOhLCQFQQSe/9a0FljZRJzEwOcgE/iOKpwKrYR9pY9Nx/zmtC2t/nCMyxsehA4/DNAHaeHNWlVlS6zGkgCpdxRhlH++pIyP1rq5g8aGEcENlUb7pz3TJ7+ma8+0fS9R+14gdF3jlSx2yfTjFds+l6jBBtljDQDGbeQ5X6gnv+IoAQ6ZLeus9jdlbgDLW7Y555AOM49jWKkolvHS5sZPMjyqy25CTA+h5w4+uD9a0tO09Humk0yUJMDkwtLkE+o3dDXQ67p94sLfaQttMUHzOgOW9TkZzigDjZIb+zcSwi4kgJ5EkeGUepHQiu20idZ4Io3EzQZBdkXdE3HRh/Cfaue0qc2s+5tQdHTgiUlF/BhlTn0OBXRzBmljlsrhYJMZwmY2yeTyODn1oA6mC1iigD2twQFXA2SAY56DjGPY1VsLC9OqtO7WMU2f8AXRAxSFf7rY+Vj7kCsRdUa3H+l21zMD+7beFbcewzj171Lb6iszIEu5bNGACBpQORxxJyo+lAHoOn+HrwMZraDTbu1kb52eYhF9tyEgkVrf2RpUMRENvpFtMw3B2leQbvY8cfjmuLX7JYRbr2e6liznG1EA9+AMn8q1dKvNPuUaO/ubgwHhXmuAJAPUquQAPbn3oA6551jt4Y9RbTGMYIjZg3H+6HRxj/AIEK838cSabqTNEsl0sqtgx42xt/wLcT+prZ1+bVbS2mW3uLHU9OXlFmvww2Y6ldm8fQk15Re+I7gXsk1ra6eBzujModT77Tj+VAGddJNYXbm/tUggA4cDc35rz+eazoTq5DyabeSywg5PkMw+nBwf0q1Nqt7eSuYooEc9UjUoM/Qkis65An3SXMtjFNHwdkwUNj9TQBVdZ7icveXMYkPP8ApBbB7dAD/Ota3sZLRvPS9sYVcdfs8jZ/QisqGAPEWe+YIDlUjJcjH4GljmMeTLtnTP3Z3C4+o4oA6G31O5tpBDZEXQf5mNnaKqt9Sw/wqazjmaczskEboTJ88+78GUZz9BVDSfEcseYzqUllb4wIo4VcfXk/zrTk1zTpovJuL/UNQY8mJZFhUfgF6fSgCRtcS+iC6h5AhUkK0cJix+ucU9prOCGMNeTvvwEjg3oDn13S5K/QCqC3mlQSCRNEvXlkGI2aY7QPUbgKvaRdNeXZWRWWHd822IuR1wA4yR+VAGXfRIZfNa6tEUNgAZbb9M5/LJqlK9okyhJ3nJHzyNHwSPRR29s10mu6VIFY2VgkaEcsyM0reuCw47VylxFPGrRFmhIHKquMfXJ5P0oAkENu8g+0xT5JACu4SMnsOxP5VLevb29uIbeC381zgJHGZDn3bOCfwpdIlt7d0Mtol6+AFEi5Xg9xngVvy67PvRXf7NGQVWK1tgx+gPQfUUAcO0UsDsbuKVOMbSMZPpWvoj6vPMw09MylfmYfKFX0z2FXZItPtpZZjFLLKT966cfIfp3P4V3/AIIt4P7Pea5mitLdvmLGMJv9OOtAHnk9jNFchNUaR1yTuiGAWxwqk9ecZOPpVe50+5knUvEI0A4GQM/gOlerazpNpKkc8cs6ryN5G+aU+gXoFrnP7Ihe6bfatHGg3g3E43E+4H9aAOTtbF0KJcReWvVQxJz7gDgfjW/obqJnSLdMWIYgHOR78YHvU+sCyhtzHBBHlRkySZP5L3P40ukoz2Jbd8uSjSyjCqQucYA6emaAOiivLueW2R5UupfuxWalSv8AugY+7+H1Nek2+pxaBpQNxGrXmAZpZMIFY/wrt/L5RXldpMNKsDdxSRq0oy8u/Bcem48446KM1TGrX1x++knM5flE6IgPHAHX1yfyoAveItee41FoUt5Iw75fIOdvvyMfWs7R455tZZAjGFcAhHJ2j+6c9KgsNIvtaujvjMcW7a027bk+gzgnPpivWdH8JW2g6Qj38hR26RlmBVf9rAJZvYUAZtrAsNoPtG2a4JIjtoYwAi/XHA9WPNcpqvhXUbszXs7C0tkBJlZtqhR2UY5/KvVoo4gqBrO5lyOIvL+aY+pUKDj0BNP8R2Ek1p5msySWlupBjtUCgY/2+Tn6UAeEQWkTwTW1krwxA7pJpBgkdRgHoPbNZVzoMTzu0MT+WTxlsV2mr6qkbmaOc/YwxjhhTbx6kgj8q5C41ee6maa3neGJj8sZOSvb0oA8J6kdSe+TTh1GPp+FDEc7SOaUIQqnAx2xQBZS7cKFLFQPunninSSLMxE2RJjIfsR71UBAHAP5VIpJwoA5/E0AH3SMYoUE+/c8VNAqGQeY3ykY5XNa83h67WzW5gVZrcruLJzj685oAyFUsSEySfw+taNuZlj2ABwvO0jkGmW+l3MrFIF3vjOyPJbj0rQ0+1Esggu/NTnG5BtZfrmgDV0y5ZIQrSmEHnY3zx//AFq6jS/FOoaefKn2vYlcIwO7b+Pcex5rlLrQ7iHAjX7RG44cEZ/+tTtOspzcoltM1hO38M5wrH0560AdtbXkVzeSXAtYoWVtvmrEWRgcH5h1H/1xW22oXMJEFncqokwBbzzZt+euwn5h9OlYllaatYo017aG0BUAXVgA6MOPvocj+VXNR0uXWLZGiubIqOd0eEY/QHhT7HigCPUrbS1nV768utNuiMsixh9wOM+zD9a1LDS7a+h8vS9VidEwWyNgA7ZVhxn1qvfh7Gxig/tjckYzsvLUSeXj+JSP6Z+lamlyzT2qNH9mnbZkSRME3D3DcH1659qANKLTvLjWDWdL2Q4/4+bS4MZA74wSMfhit7S9CtPsiNpniUraEbvLvIY7pduPuiTsPqK57RpZYNREc1u4tj85Rn3hB/sHkDPupPpWj4itNAniZo72K0nYHBMRUqT0wVOaAOx02wNigMd5pckRGdsEfyj8Cx4/CsLxD4lvNNv9lrq1r5ePn/0SN3Q/jxt/WuStdNhSMqdb0jGMPK0c5Y/WMHDfjWXqsFhAshN1pl6jnBa1hO4YHcnn9DQAnizxVqt5KwjvgI+jgKkXXrt4/rXGRLDdzNJJelXHBL/OQfc559K0GuNIlSQXdi9wpY4ka4MZPsAw/lVZLa0SbelhIIWI2tFc+ZIvvgjigDPujBbs0sCxM4/vTMQPp6VGmrrcSiG+jBGR8yS5wfq2c/hXSPp2j3sIElvqPmAdWKcnuThefzpIvCdhcjyEfT7Z8Z3T3BTA9htJzQBzuoabpyRedbX7EnBMckgHX/dpLVQGR7cSI/X/AFmVUdsDBNb8vw4lhKtbatpkspGdsUyBgPq2M0TeFry0PmreoigfMXm6/wDfAP8AOgCncw+ZAxFxufqMW8h/DdtGal8OQXyI6rPd2pHRlVxgHrxkD86u6Zqdnp85iQahJMzZfyJ9qZPUknditiQ2V9DIbu3Mqn7qx3EhP/AicfyoAwtQsSwYXD39xKQR5zJu5PYZY8V0GjfaNI09VjvHjbAJJiQMn1YnP5Cmm7u4rJobWRLO1TJ8uISyfrnH5iqujX90WDJBbSQRnDO0ZDN7gnofwoAYbrWL0zA3s0kTZC+XKFMnqNoXPQZ49K4zVLt5ZTFEpRlbBbcS2c45JrupPEcFzFc2kOm21uZV8oARh5uuSwdztUHA5x0H4Vzmp6ck8Dyl0W5Em75AzuFxjaWwFAHU4oAybYzAktJcOV6mPPXHAqe6iuY2+0STXC5xyz4z145FWNPS0QkSXDHnb5mSpJ/2V/xqdNON1OBEDIu4K0p7nPUDHX3FAEelyOpQ2sJZwCS6MjP+Z4FbX9qOFYTwzSSId21pTIMnsPT1JqsLDy5QkF3DAwO1hG2/6lsVs6RpGLmGNVF0XfJeVTtHvgnLfTFAGtpct/qdkBbQyIpXa0gOBjvhvb2qjDZx6eXMYhjhGSXw0hY98k134so7OzVXikurlwCqM5CEjoSvp+nrXP6xp6XKlNRvY1lfrFbrwv1Kj9KAPO9XEc9yZ4kJQ8qo/wCWh+g6D9atW2r/AGd1Fyw8xBhQY/3cfsF6E1vDTbS3YTT3AEa5CJIxznuCB0H41zGtSCSQbJTsz0WPaF9gM5/OgCSW4+23izTvJczqfkRmyQffngelb0VxMVW0Te0rEFyvAGegHvXMWatbyh4t7sVztZvuj1OOPwrqvD8NxbK17dJhycwqMAvkdVB5A98UAdp4YsrjTmjkkVDOxCJ5knKjPX5jy1et2Ntp+l2skghSS+ODJJMwLZPqTwo+lea6E1yBvkmMd2w+5G3zqD3Z8cKfbmtO6sreW7t4VZ3Qn51Vd7yE9FVfT3bmgDabUYIroz2Vv9ruyGLOflhUj3wM/XpXIeK7m7uLT7Kvly3M7eZKRK7D6dsAewre13RLxbMSXcp09V5iiR1ZyfcA4/niuD1hYpbdtzBnjBzJIhJHv16f5FAHKeIdKa8MBlkkCBfvDBH/AAH3qrbaFmBCgiRSOBIilvxNaN5HC1gzeXH5TKMMGYIB7MV4+lU0uJSgMVnlMcEzqP6UAfPe0jjPBHU0m0jIBI7YzTyAPfI5GelHB5IGc8ZoATZ0780AAH0xwakx82c+/FTABouMAgc5NAEcW0bNoPT867DwlfT2l6jadOsW7aNk5ypOeRXIoMDJBC9wSa0bdyrRne6MBlTtGR9D6UAe/wCn+HtD8VW6tqUJsrw4PmxNtBb1BH9ah1r4e32mQGUQjUIFU4uYD85H+0ASSOOtcb4D8UtY3USy3CsrYEkdwNySDHv0I96+jdAgtNa04vol6be4xk27kFD+Gf1H5UAfNd3qotYJIyJWUkbvlAwe5GO34VmzXMsy75IBcryBj5jjPHqR9K9S8f8Ah3UIb9jfaUqzEndJafxj8TyfY5NedS2ItZGJE8XqzJh0PtkdaALWi+JZ7LECGeFyPlKZIIx6Y5rf0/UtLu5AmpLbCfqSq+VuPuM1zsFtdT71R7a8hXkncElHTqDzntVqWHztkc3yyKPkedACo9M4Kt+NAHaWun6A1m0Vv5iIxPyf62ME9yp5H1FYMtmNFuzNpglEJOWWP99E/wCGdy56VlJdXVn+8iVxt4Eto5WQe4xwf84FXLTUtRu1kRNR2OSBulVVYj1ZSRnp15z6UAWL7XLnUY0t4dLuLWbr5ZXdvHoARn8q2NP1ZDGseraLl+BieQrnHfOCKxrXUtU08yR3ciSsPvwPCHXb2KjqufbitFVl1KAyRNKkbAhkA+XPsDn8hQB1mjPbpITFpmniNuqT3cZLDngf5FVPFFzpc0axWuipFKfk/dMTj8V6YrkbENbyxRiCVkIIbzLeRBx6HP8ATFP1TVYIrlWaPzCOFLhy49hkHAoAt/ZQRifSLq7AHEkdxKw+u3HX3BrCGgWxnleJdQhJOfLMBIX1GeajvvEkkpaO30iydpDxJGSHfA7lQM/nVXT1le4E0Wn3EU2ASPtGAGzxjuPpQA26truO2mVoZnjUnY01sqcH/aOD+lV9K01rtWdftT7ediKhUn03ZP61Z1x5m2EhluR2WUlvzIz+tT6WZLWMSwPdecy79scuEOOudooAz47aKO8f+0jLaSg/KF+8fxArReWZiEsb+8uNvHl7XYgfU8CrB1HUriIh3SKUHjIJ49wcmlbTL69twbieZsfxBWQH69qALWmI0Csby5tVlP3jL16+5AFa9pZ2DJ5jx6bcktl3WeORvyUHFc1a6HdrcxiO2IwMb1jdyfqRjNa2oabfxrF9otJXXqMh14/3cj9TQB0+l2Ph+4t5RBbxK2TvlZTg59S2B+VZWvW0yyhLNVa1/jKXKQoB2yf8M1izSzFxAqwBVwcXBK4HsFJ5+tDt9o+VX05iuBvuJuFP+6AP1oA0dJmWz3CzksS5Ocwwvcuxzx8zDHHtVDXmvroSNqMt9Mmc4mfy1A/3R3/Gs+YwG6/0nVoJQpGVgVtn054NaU2m6TNaedPNJIqdnfyU9jgc/hxQBgrbQW0DGGa3jcjgbllkH5HAqTT7wu2yWe52nJwFXnjqSePwq7NpOlCHz7iSCGIHIighO9v+BMf/AK1M+2W0gCQWkqquNgluSCeOSRwKAOhsjpwhVpYZGQDBZ/lVfQ7QMmu20bV9I0exMtpNDaTCMiVmTMhY85LEEspA6DmvHDeTXMyRm4LID/DKV3e5xnP1GK0kEEYWeeOJygPkxJGOeepAHJ9+tAHo8dx/aVwZ7i9nNlJ8zMWKM57Y4HH0A96ra/qNjbRM0fyRkYWKJeT7nua4u1kCXiTEyKGxkyvggY6Bev5VBrVzLehILdZ2GctI7bFX6jt/wIn8KAK7XV5fSO8MckUQO3ecEbfTPrVMoiyhXWQ45JAwCexBz79ulX49yQr9rmnMIXjYzKD9D3+lNg1CCDc1pbKegZyvJHbnsPfrQBa0u1RrxVmiEIBVn8xCxPPGQ3J+orsbzULPRQZY4wLmQ/ef5nYj0GPlrhLaNXvUEAR7yQ7VihiHy89OnP1NekeH/CFvDi81uU3t5jP2diDGg7bh60AQ+CzqGtapHysFozF3uXYAJjqST0OO1eqWmq6F4etJI9KmiubxR+8u7hhtU+7ensK801m4uJ5FiFxbpBlQILaEEkDsd2VA9qh1O+itoIYLiJREG4WAKpDeu0AfnigDZ8UeKbK7Ek/2uO7mlGFnKvtX2jQf41xQu2nQyxysiFSry7vnc56Ec7aq3+oCecLJt8lAMqxyEXvnnrXPXt5G7ubN9pT+IgZHrgD+oNAFrVprjzQGlTrkBlBc/Ukc/SqaX0pUeTa3Tp2bBGfwxUdtDDOUikk3TSfMkO0M5989q1kj06FRH5kXy8H92p5/HmgDwMZ4Hb/PtQVJB659+lLgYzyT7DinINu0AH5eTmgAA6YHX+VWFyoCuvHqo/nUWSWIYYHc9atRgtgDHPcHBFAFvS5It4SeMvnow6/pW9YWFtNtEMquAc+RJEASD6HOeK52AmP/AFiAH+8eD+Fati8M0i+Y4iOR8xxg/l0oA6C20a2Zw1uZIiCcg4DD3APUflXoPg3+0rDC6ffRzvjckSt5Un4Bjg/UEVx+m2rvLGoMU8jdFRwN4HYNnH1r1bwlolvNGgmti5b5gkiHcGHUr6Aei0AWr/xZLfwtpfiTSZpyRhJY/lmQ/Xpx65rg79Z0Z4vOM8IJVHuY8rj69cj64r6Et/Dtvq+kGFwt3GEx5UsgMkfpiThlP+ycj3rzTxl4FfTWMlm7MIzlors7Xx6ZHDDPoaAPKP7Kklu/OS8jUq2NoGCo64GSQSfrVi5ubhYFEiwXGAV2PwWB9icfjWy2iWcxkR4ZIpQxA8qXkH12nhvwzXPvDbaZetHNheAGcxFgR2Dp1B+lAGZNdDzj5Wn29t6sCdp9OnT6Afia1PD8NlfShb68jNwGyocZ2+ynHI+pqxqsGmS258qEJcBSQ1sS2c99vWsTSVluGKbQixr99oAzD/H9TQB1N/brp7CRykka8hcDgeqsMH862dH8RWyiOVLae4UdjB19Pm3D+lcxHbeTLCdQuopXUgiNQyg/UHr+FdLp9/opCi1W9S47JFGSzfTg5oAuX3iiHV7eTTtQ0YoxOYz9oRWb2CncfyrCa8sdOwLndGTkFLhX3Y9MKMH6kCpb/VpJZnh1CCSGBDnfd6aXIHu2AR+FVY9GOpI0MSRzBvmVlScKy+xIx+tAFTfZ3UxTSrtbVj82fsxIJx7kZHuAKs2Vjc3M/lXkcN2CQu9YgW/MsDUMvhN7C2aRrVgy4z5kZZTz6HmsKSFhJKjiGGbpkyOuCO+M8flQB1eseGFRDLHDHNJj/VOUjH1JYnFYreGtVSGZo7ACMgZMMmR9Rt4/Co7BXiUPqFzZT4AIZ5N+z8xW7HbT6ixaG6kkQgZFvbyMvp0Xg0Ac5pmlz+fvCyyTqcZlaPj67s/lXRRXGrKphFwEVgBhIrVuPTPB/SsHVNINlcs9z5iknLCazdAfwqs2npeFJLWeJcH7/lbMfXGTQB1EN7qdnvi08XLyMcFzbqkZ9twY/nipDa3V2xbUFnhZuPMN8iZ+g7CqNnNrFvEzQatbGNRjZBFh+nv3rX8P3l+SWlhT0MlxHI5J/wB2NTQBLBYwwQkW9q7qRjc1+hOO5JHP4ZrKvrO0ttRXbZm6mf5xFIysg9zgDP1Oa0PEV1qbswubKMW2PnnNrKmPcAkVmeHhpsUhA1pXLclRZsSc9sscYHagC/PrOqWcUUENlp8cTHlYSnAPbHy1WvbpZoy095aLchchVGWHuRnH5Zrfur20ijKpcM4cfKskscZPrhV5z+NYos7idQ9rBawK+ArBxcSAk4G7AOPzoA5SV0JKi3SacA/vXckD8x+lUs28UhW5hW5mYYDCTaMemQP84q7qUV2l6yLPLLIDktIm0DtkggEfTFLFDdrC7W9rvZB8zMFK+/Pb86ANLT2htcmIWlvJnOcGaUe2QB+Vak14uRv1COMA5I2Bm9sLwR+J/A1y0FxOj7HiUMAOY8DJ9zW1pzw25ISMF1GCwHC+3zdT70ARXMVw7mU/6PERhX6uw7AemfYVDLqCg8F3A6b8AE/j/Kn3LvdXLyPOzFcBnILKMe+SPxNdDpPgo6i0byFzF/ekbbvHsMfy496AMSC8v79V8hFbII+7gD0wev8AStC18K6teyRvdk+SrfvFU7UUf73Qn6V7B4Z8OaTpCoblgWAziJQzH0OCMKPzNWPFniHSrC2+W0tVYqVU3J3N07L3HT0oA4myt9H0S2zHAZJMYAD7eOnJPU564yavyXbNaOIkSI4wQrkY9snGBj2Nc/cy/wBoyi4lY+QwODgRjPoAQOP1qxa3MXl71lhygO1y26OMdOASPfg8CgBk15JZRgGxdix+XacB+5+Y8H3rmNXvPNBcWjDK43Oeq9wMnd7Dmtu+1LTpA5e6jnYcF2kB3egwO2egFcpeXU1/cARSxhVb7wyCPpwKAMy+kcTbkSQIDhBKQxQDpxwM+/epbR/Kh8y52RgtwTgkHPUDB/KtOXTy1qWidI4hyTtByB15IzmsiWKCUBfMAiBzuIO4/QdPwoAqLM0ZdkJQSE5O3PGeuTjbWjFDOY1KQzIpHCjDY/HvUVvfQRtstohJt+VXMYXf9fUexqrLc3jyMw1BIwT91cgD8KAPMRjjAI4/OnbTgdsUJgjGQcccGpFOGHB59ev9KAFhC568AH3yfSrKBUKgqQCOCOgP0qNSDg4DH69PyFXLZCWxExR9uAMHHToDjrQBYsSpZV8r7QTwAW5/StS3tAjkRBs/whmyPoOcVjhZY2DsPKOMdOB/UVv2V1dtCqyRw3MIGcoNzAfTtQBqWtvIz7Y53s2Oeg+RyOmeefxB9q9r+Hl5cWsCQzXamM4/18e+FmJ7MvK/l9a8ZgmiaAR3EcZtwR95XjZM9xwcmuo8P3eo2DK+i6hBLEPvW8h6r3GQOcnjJxQB9LW+oeVEsxgNsQMh4EE8TduoAI/E1R1HVBrSSWLG3YkHbIrnIPupxj6iuC0DxPdahb5iJtbpGwwR8qW+gJGBXRnbq1iVv50N1GN0d1HGeDngkKQfx/nQBwHiXwbqVuoaUyKpBP7iUkE598/zFcXqGlanHbM0sNxPCODtdWGfZh37k8V7DfR6rbL5Ul5FexSDCm3JLDHUk4wfyFcI9tp8MkrtqMsMrgKyyp5YyP8Adxk+9AHnv9kWk0nmGGSNQSCrjdg/VeVP86lgsrSFQ6JKzB8BxINy8fUH8RiulvtCS7le4N+I5FyFUZO8fQf0zXPQRS280jQkrtJ3xzxbwx9R3/TNAEE+qPDI0d0l1cQnqspEgHuF5x+BrQsn028iHlahNZA5BjiLKAf9pQKjt/Je686zlFuxGGAjk+b/AL5DD8q6W21qCBhEvzswGXW3dgffO0bjQBZh0i8XTUNvrN5cADIjSUMCPbPP5Vg3ivaJkQtb3W4kSy2Q6/72SSfyqK8uB5zLJLKyO29UjbyHGfZwO+eAPxpLLxLJbEjTlviv3cSTow/U/wAqAK76nqkkZWS6ntowSA/mOq4/M5H1qs1rPGDcLLYSK/3pDKdp98Hr+XetfU9c1rVWjthZXJUjBaQIMemG21FDJqkEix3FvchgOXjKvke/y4/AUAR6PZ/2mgdRpsjxkjzFi27fqeP1BrRns/EtoJIkDTxqCpDojKcE9CDmoriTy/3lxb20j4+UnAYj9B+FUpxqE6iQWk6R4DbsMQR26GgDIvLDULiYtd2Eltk5KxQnBPr1qW20m4umRPtkNpbD7xuGA46fdByarXLalmZGspVTOd2HBJz7mrelaZGxH2s3EblshVjlbP8A44f50Adbp/gaO2gW5t9bWe5I3bY7ZMZ+jZrRe/1LSbMpd6lqahAQAjRxrj6LWbo8+g6c8eIbUzDhWltWyfUksozW/N4ljlgKsqRwbcA21qnzfQkAUAcFqmqXWsTFLcTTEEAvM/mED/gfH6U22sHsnL3S3EjH743Ag+3pXXnxbpenQPJZ6Rm8K7QZ9ru2eB0O3H0rr/DetxX9vG1xpFtc3DKAQIHlQE/7K/KB/vYoA8/h8Q2y2r/YrAeaB80iRc8dgScVVlmuNTw99dyKM5EFuxdvxyePpXsHimFDp7LqJ0e0tSBiBIYk498sST9K86v5tJWLy9OtUjJOASuUYfRec+lAHGagPNOzTLIAjJZ5phIwPfAAHPuc0qXkVnaMLtomlCnbGoUYOPXGcn1ro20fUGQi3sbQW7AAlAYwR6Etn9CKxr3w28Z3x31oZXIQqACoGfX+tAGIt6rzIRc+WcH5FUAj2ya1tPdLmSL7VP5wQY/fPnA7YH/1q7HRfBtxc6Zst4Ue4HVhBuB4/iLfe47Ctu28MNpkBLNLGpRcExBSR9ACfy6UAcvaafBqR8mKBpFDbmVUw5I7l+oH0rat11OymNvZzCNA53SFy0h9+QcVUu443uEhWe7AY58uFQVc/QDP/Aj+NQaqbi5ltrSxV/MPIZjucjGOcDNAGvPNJbxkahePI7HKorYb8QOn4mpLDTbO2K3V9bRiZ8lIGwSeOOOgz69axU8P3mnSRNn5mfM0jyAMB9dvT6c0/V9aisLN7azDBpBktHuZz75Pb3JoApXzzazqPlSu67eAUh+WMZ+6cn734VO2m6Rodqsuovc3RIyqTEKo/wB1R15//VWCb+RAGmu/Iz/yzh53+5Oeax5p/NvE8yQgk5Lyyjd16jPT6UAb2q6taTRs1tZwwZBwWHzMp46en+cVhtewPFLHHDFDOrKsSIGZCmMN5jN1bI3BvcjoBhLy3gkQyyu8UIyTtG4/TAHBNZU7W+BHbxyLBkZLHJfHtj+VAElzdPKViM5kQHBLdFHpnvTjHEYnRXIQgBdnJLD2OMDryO+KkitRMB5qSrATtHmuowffAyfpirEkNlCB53nOoGAhXHPoDnI69aAM9raMW6yTTRRO7YAx8/HTtUZt4l4YS5HXn/69aV1dLu+e1KzbflDcAAe/eueuWEs7vNMRIxyQR/8AXoA4eLnaCFI9zT8bgQpBz781XBPB49qmjm5xtXcSDv5yOMcc4x+FAEirl+ABnvmpIJH38YyeccHoaYQCQCFz/FwOKsIgDcFGJ6AnFAG1aXxDBbpN8YBALDgZx0PP51fEFoD5lpK0EzNny2GVb+n51j6fKQThjg54OTn2GTzWtEI0B8ppCx+9GCWBPfjNAGtpQm84rLaOuPmLR/OpPuD0rqbCzttgntJfInIH3AQTk9x159K4a2KQTB7a3kt5iNyykbgD64x1+teh6TqV29pmcwMMBgZUw499wzyaANfQb63gvS+p2zAnKtc+WCM+hK5KD6163p1xD5LT6bqkRTPSb96g7BcjJH4148t+8atc2rXBlUAPEGBYZ9PU/XtWlo/ia1TUWXVLXUNOl3/8fcBBXPqQPr3oA9Y1O1iaNLyayjaVektsT5bfX2GT2yawde8OnUrQmzgjuNwGI5cKzKe4B5Hfium0BIIwl7FfvdxSfw+T69+Mc+/vWnf6FpnnPOulSW0zNzLbRgh89yqnJ/EUAeLp4blVWiSwiaNcgIX8tlI9CMg9OwrPvA8b+QY7tpAdoV9pfPbBU56fSvTfEpg024Rp7RbyPbsJLtAVHuvUf5xiuPu9agWUpb2Oo+SQC0byrcBUz1IZiaAObjERkIivRHcZ5SXC7lHbkD8TSXWo3TxSrPdaaY9u5UjbduP93Ocg4/CupuJtPvLSRZIHIHaWPI9gCRXJanbW0u6a0gVQgxtFqJNpPfbQBz7QwXFyYniMihc/eD8+x65pDohhlSay+wxuCOHcxkL7qw4NWbqydo82sW26jyN8aMgz7Z7896vQS3AiMGpxuCqndtjBP4AkfnzmgDI1S5unT7OL2CGaMhmMJbbjtnsalnn1uaz8qwlEyoPmMEqsD9V61pWeh21xOJ7MTKVIJ82ELjHptXpRrdusEIhkR4GcH94tuZdo/H/CgDCsLrULWVF1G2ldxyXbG4evfpW6niqSNShbXn56Q8KPwAIrItrPWZYn+y6iZkJ3KGnMZI7YBHWpLQ3MBjW5C3b8/M8q7foeeDQBFqepwXt2ftsviBIickyv/wDWziuo00eHHjcR3k0JBw26diTx7DmsW406J0WRY7FT18uNi7A/X/OKbaK1mzGN7aFhwu21BI+jGgDWnis7NjK9+s8YOAfLmbHsSadFeGFDLFFGoI/1k0u0bfUDk/nWDqU99cuoF5NMoOADKUA/4CuKkXR4rkhZba8uXxyLeMoBxzlicnPp0oA0J9QsLpiLTyLm9H/TRtoPuas2bwWqrLq2qPaMOPJhuH2qPTavWqU7WOnQiGJbqN1A/drDuK59eaW0iuPs5MaXNmo43M4hJz9WbOfpQAazfWZbzLeKbHAE8kP3vZd2fzqvo2qx+awh0wm4BILysuc/8BHAqY6bIk0U93K5hjO4uYvNOPZiAB9fzrYgbwtfXEjNZS31wzmQIZ5di55ICqcAeg6AcUAUjrUF3N5VxtkYHDLA28jnu3QdOBzXSQvbafGk4sLOHHzHKMznI5J5AFY7W0UE7S2NnBp0WR8wcqR7BF5PQ9RVHzZLphHaDUbjJ2szBYlPPdjhiKAOhk8cahdbbeaOaSNgFWGGQRq3oQSRx9Kku0vLueKW5tZIPLYOGMrSH2AGf1rEisWh5Wf7PO5LMtqfOmk9zxwa04BG0SfaG1qRJD5aobU7XwMhcgcnjrkCgCJIru4Ypb2l3aWS582SC2VZW9iWwR9TWg0l5ZWTvpdhJawyMPPvLyfjH+/0z7ZqJtOubq+hMMF1FMmeLgghcd9p4H1Oa3IfsdrJHLq11eahfKu7YkpZU/AYX8gDQBz9m8l8hM7yNKBy82FUD+8ATwPc8Vmahd2/l+Rp8NlcYOGdk3r17sMZH6V1ery2l7Ckdwd0K/OtrCSVJz3Hr+NcrrOpi2zBBCtssYzvY7to+gPFAHMXcsMtwGQQxqykNFHltki9QmMnaeuOceuMVlz3MAuQUs1PynaCxJYdwQO4pby9hkDItxc3DM+QFGwbvYDvRHpUIhBuriSTf8yxICTkdjno1AFFJzezNPKwEMIByVODzgDH16mlhljDMbW381yB+9kHQ56A9FpslkYg53FVkG0wnBZhkHBGMdR+dV/tLQgxRxKrEBXD9z69KANdbqGBWe5w0jrluh3EfwkDofeq66g0sbPFCgwOGIJJHoxNZNzOkX7ycLJcs+SSAF24PYDrnHNUbrUZ3/drJsh6BFOB/wDXoAlu7ooZAJMrknA/nx2rKaUlifm/Sld+hz8xyeev51GUOTwg9uaAObX5uwHbilxg47/Xv+VKB8wHOOuD3p3BGBjHWgBEJIySR6j/ACKtQsp6Ptx038D+fFVV5GMcZoQ7lUnucYB6UAdPaWcVztQ3kdvKxxsY8AfX1PtVmLTXtJAlykgLAjchHrXLxu6DaGOM5wa2dK1h7eQJKymJiCwkXcB/UfhQB0ttZSBAIJZJAwyqTLk4HUjmtSymvwskUF5FDNjmN2AI92wf0FJot3pVzJiBo43kIARTjp7dT9M1vXGkzzRhbiC1kiLZjmjiCsvH8QHb9aAMldVkhlcatHbjBG2eIEOOOCdvQn3Fd7oeuwTqV8pNSgGN2XBkT/Z4GT9OtcsNFult96TQSFUyXTLYz6LyQKigtDdGRZEWCVW+8WwCR6Z7/jxQB7TpWoaLaIWtb66sWyC1rdMXhPsPlzngcZGK7XSNZMDDdMrRvtBDycKT/d5OfoK+e7WO40+Nknub8xhmGAysGyOMZ610PhjxfcWGVY+fajgxzBC+0eyn5ee2KAPoqN7a9jbYySjGCRgkZ5wR2+hrnPEvh3R7hVWWOS3kblTbxZyeuThTj9K5y08QadqKwq1ujSZBUTrJvTP91hjHHoRXY2sojtlYarDBFjCKw4HvlzmgDy/U/BqXJZorqWc5yWM/lRyDsp3Y/HpmuY1TRW06VmEbWJDfIxbg8csCpII/WvoM2ayHzZ5bchv40jClhj+9nP5VlTaPdQWzo063QckBECxFh2HOdx+poA+fpE1C8i/0O/hum6MypuJwfuklhgfUH61g3mna/dqYi/zxqd0ZkTPPIGeua9j8R+HNQllMkOLWQMQImKklfwwP1FcfcW1y++G802dlB2iZoi2TjGcrnH4nFAHJQ6OXjjF07QXAQfKLoghh2wQeK0LYXx3pDdZUfeQq0rZPG3cOB259O1bEdpqYYfZ4IHQNtK3MO4KoH+7mqGppeoVDppayDkGJfLxjuMYxn6UAZraTfzzHdY3CxleZRKzJx2wCcH04qf7DKiP5WoaU7KQhXyvnJxwCGAwfY1LHJr1tAc6vCMISFmyOp4GfasqWeQXCi7CXs6ny1cLu2jvwBQBZu572OEC8v1T5fuJbrj/gJA6VlafB50jrFBEyNk5Ix9eT3rY05Lm7BWNYLdQ2MSR4BA4HDCtOXwvJcxZnu7D5OgGBx9R/KgDFVrazk5WOGTGd7xtjA/2s4z9KstrOoBNlrLJIrcB1lIUZ9WJNWX0aG1ARltJVPHDE57e/Sr9po0Ux8yLylY5Zii5yR9c0AY9jZ6wheZfsMbMc75NST88devarU0MwDyand/aFA+4twhA9Ru2nmuoh8P21su6e6dnfkbygIHsMDisi58O215J5cV7dOm4L5UUOSwPTBBoAqaM1nOzFdIW+hfAHn7pFwOo5CgY96l1T7KSFax063QAjEcyp+gbOPqa6iD4e3dzH5lxeTWMRXa0t2dzEDj+I+nrzW74a8B6WJSlpq63dwqgs1vEBGv4ggH+dAHmGn6HJeXRm011iz0CQyOQeh785/Gt+z8F373qx71afIbExDso458scDHruP0r3HRtCj02MgyCRj/EFK8e+Sas3mm2kqDfADg7sBmH44HWgDjND8GHT4w17fwu+c+Ulurce/OSa0ZpZcNFJeSPkbVUAIAo7YAx+tVdY0iVczwSz2kH3lhihG7HfOTt/EnNcbeatbQTIs5kt4SSSZ54yxPoBk80Aa+t6RpKRpDqFyygsWWNR87d+M8kj6EGuK1C8Dp5mn2N1CVYost22HBHYKPX0xVq+8RWCo0dvPLciUlHZdibR2BA6msTVdXeK3kkvbmaEONqtLIPwwgAx6c0AZP8AbEk9w0MkEoAGMRnykbHqc5/DpVtobJ4yJEkkI+byYV2IgP8AeyePxJz2rPj12/vSfstt8gXDyuMKv+AP41Hc65BaALJsYjr5bZAB7DPJH0xQBYYaRbZ3ssUJ+9HCMg+nOMbq5LU7+zmumFiHijHO58lnOepx3qTVdSi3FpFy7KQqlTx6H3Fc5LqpV2eJPnPAZxkgYwcelAF+8BtkLyTOhPReAx9zx0rDa7YM2xseo7mq1y7SbjJKXJ/vHJ/OojlnO1iccHAHBoAeXO5Dkhc9CeRSOzDt68Hv+tMjkdYmUHhmy2B0I9PzpshKl1Dqw9c9aAHKd8nQDIwR0/HrTSpJyADn1xn+dMZsg9z1x6UjMcnCZ/A0AYZHcjmjGFIPPGetO7egPvSkEZIHyZ6/5FACZ4znGKdkLkcd84XjrSFcAtjke2aCoLEZI7ZoAXqMHp0xT1IUknAz1OBTAp24P14peQN3GBQBYileMgxHBHQg4xW/ofiO+0yZWFzcNADyqzuv6Z5/GudXHbGB+NPGMfXJznoaAPW9P8baRfJGly09tMpx5vTH4itx9TzKGnEk64zvaNW3fpg/oK8MXdnnnA4/zitCx1S+spM21zJGDk4zx064oA92stV02QYjhmsyT8rBN0RPQk9h+GK0rHVrO3Vra+sPPtyuAqW/mxbQeyk5BzzjrXh+neKbu3ZCSemDsO0EfTkZPriu20nxRpE+x5L2S0uGHzRvJxkeuVwfzFAHrSazBZRoLbTrwRyEcRsURR/uspKn8fwrqdN8W6aNkk32xcx5RULBkUYyWQHbj6g15Xo2o6VcwCO21Al2zny5HwfU9CMdua6a0g06W0h+e/ClCUH2Ysh56kYX9aAPRIvG+kRM6QWF80eRtkSyZVYkcD1z74ArpNN1SK/jB2NHuH3ZMA/T614nea+1pxZjUI7wKAv2i2Ub8dWI3cfjUC+J9RguSbuIXsAQKI0VowcjOBzhcc5YnmgD3DUtE07UyBPGN6jHyHt7jp+lcjqvw+jgc3OkXckD9DGY1KHPUnjP5ce1Z+h+LtHmmto7vQFtQ4LedHhvLA7uR/ic131hrGkvGkVtdRIuAVV8oSD0+9g0AeU6lbapbSeVcElOTuCK2wAd9rDOfoKyJTJGzSySQthVIDIqkc9eWPNe4mHSrtWjC2km/ghduT+VUb/wxZ3UXlrhAcA5QHK+nagDxq9gvru3ZTc2RBPKvHv6c9xjArjLuG8+0eXLdypan5SYYCiZznGQMmvfJ/hxp7nMbJGQ2RtVgCM9CN365rTh8JQRx7B5AwdwcRZYfgaAPmqG4hMpggN3fTHllxK2Ofc/jXQxWuvmPNjpFssROSZUAIHcc173aeGLSIDzwZgeo2KmOc/w1pGCC2hIgsUO0/dwPz7mgDwzS/C2s3ZWa4sI1lZSCLVi3BORznFTyeDNfjuxKul30yqCSpuUUOe+SBn/AB9a9qtZmVsLb2kRIGVE3zbvQjb2q/lgmWABHJAyaAPJNN8Da7JErfYtF0/dyVmTz3XPUZ5/nXVx+FNSJRf7bktoUP8AqrZNquPQ4xgfStK7126R2jttH1CU8gTCH5c/7rMpxXPaj4r1uBnIsNgAH7qRBG3/AH0GYUAdXDoGnBFFxaw3LDvKu/8ARs1ZeWz0y32BEghXoqLtH4AV5re+OtbZjFCtpbNhvmA8zDfw9TXM6nq+p6jOovNZju0YjMMarFg9wDkAkf3SaAPVbnx3oVuWV7o+YCQqYwXPoM8Vg6749lMBXTRawbhnfPL84HqFwefbmvOb3UNNtY1RY3uQxK8SxFV9RhVySfrWHc+IIdIhdo9JaDcN2+R+CM9gOR9aAN7U9a8hWurx52jwWMtyxQMPQLjLc+uKyo7h9cY/Z7T7Rb4BEjDaoyOeSM8E+x964PUPENveXaS3zM6biWhVS2R23HoPyqve+NJvJMVqH29AZDgFT1GwYAoA7u+0uwslZ4pVjJ/dgQM7HPqBnGfrisGaz+yxLc3nylfl3XDA5PbIJz+ArhY9dv1kYC+liR1O7aw6bScc+vT8azZ7qadSZ5pHJ65fPNAHZXXiKBISJJprhsfLHGdigA465z+FcvfajNc3QcFozztwx6fXOaz95YE4zg8AnP600gHOCF980ASyTGXcWBbccknrTTgFSSGCnG09/wDOKiUO33SwHP0pQoCguSCRnBBP4UASJE8rO0cRYLywBwoycAZP41A43HrxweeOKH2ggkktkE+lBK4IBHA9ep9+aABiMgke2CcmmO/dSw49aDkfLjnoen8800jjBGfoQPwoAUsGRQd2QTn0xUYC46E0MOwOecGmkRkktJg+mDQBnsnyA4B9KCpyeD9etP6tz71JGASuQDzQBCV6gnIPrT9jHgZGDjFKCRgA4we1KOUXPr/WgBAnXA3EH60eWB06+g6CrCKGZQwBGO9QsAHbAxyKAGlcDpzntzUqADHykA8nrTVJLsCeKm6sc0ANIOeDtPfAxxTlxxggflTkVdvQflSRk+aOT1NACruXoR+FSb2I6Z6CoYidq8mnx/6v/gJoAswySQnfA0sbZBypwf061sWnizXLXzhDrN7hxg75i2R7A8D8KyLRVe8tldQymRRgjI5xmq90SLh8HHzHp9aAOs0zxx4gsYGSLUpHVjkmbDsD7Mef1rcj+KWpMJPt9la3Rbjd8wK/8CHP615wpPr61I/QUAek6f8AEULOJHthaxjG6OPL7/QDJ4Fb/wDwtCyaAeSGSQAcTBgCe4ypBH5145GAUHAqKQkHAJAxQB9K6D8RrZogn2zT1JQsRHMykexD9fpmtyP4mpcBbRNcsVlChlOSufTOP/QckV8qQsSEyT0qyfuKe/H86APsmw+IEUdsiSvpUXUfJcooB9QCe1TQfEWwhEX2tZJS/wByVANrD14YiviwKN68D739akeRxKVDsFAwBnigD7MuvibZQBpALeWIn5R5wRsfiaxrL4yaOZXE1lDaI3AzOmWPvtzXya5IJIJ+6KjhJaR9xzwOv4UAfYEvxK8Ls4uIzpwlOf3n2kK344GefSsS4+K2nRTEx6tCvXrM8qKfTjtXy8ANnQdB/M01DtBC8DA6UAfTU3xWs3/13iuBcnBWK2cHHtgZ/wAa47xN8StOcH7Pf3F85BDNteMZ9eT07YrxZyRkg4P/ANaoizNJyxOTk5PvQB6L/wAJ/bBG3aRAJWXG5Tzu7ck5rNk8cXju23T7T5vlGN4A/I1xkhPlMcnOaVADDGT1yP50AbN94p1W5aPzLsxBckeQPLPPbI5rKuZ3nYvNJI7jjLsWYd+/NRyfKWK8Z9KgHIOeev8AOgCbecqQwJ6DjFN5UYJPGRj0pYgDNIpA246dqjYnKc+tADhICM5+b1p1uFMsQeQxoScuE3lcAnoDzyMfrVZ2bzJBuOPTPtU/8X40AS3MqOIkiiKRxJsGB8z8nLMR1Jz9AAAOnMJ2g/MPqMVPGoMSkgE471X/AOWifUUAO2sxOCMc8E4zim8AA/5xT5ABggAHB6Uzv+BoAQ+xx7YpOMkH7vcmlXkDP96klJDPgkfNigAZVLLkYTuQORzSzIElkWFy8QJw+0hiueCR2oeR0lfY7LnzEODjK/MMfTFNIBkYEZGKAIXIDe2eeef1pu0npuFOkAXcV4PtTJGZZGCkgZ6A0Af/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound of a hepatic hemangioma shows a homogenous, hyperechoic lesion with an etched border.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2499=[""].join("\n");
var outline_f2_28_2499=null;
var title_f2_28_2500="Croup in infants and children";
var content_f2_28_2500=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Croup in infants and children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/28/2500/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/28/2500/contributors\" id=\"au6230\">",
"       Charles R Woods, MD, MS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/28/2500/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/28/2500/contributors\" id=\"se4413\">",
"       Sheldon L Kaplan, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/28/2500/contributors\" id=\"se5114\">",
"       Ellen M Friedman, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/28/2500/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/28/2500/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/28/2500?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CROUP OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The term croup is used to describe a variety of respiratory illnesses in children. It mostly occurs in infants and young children between six months and three years of age, and is rarely seen in children older than six years. It is most commonly seen in the fall and early winter months. It is slightly more common in boys compared to girls.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CROUP CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The most common cause of croup is a viral infection (such as parainfluenza or influenza) that leads to swelling of the larynx (voice box) and trachea (windpipe). However, infection with these viruses is common and most children with these infections do not develop croup.",
"    </p>",
"    <p>",
"     The viruses infect the nose and throat initially, and then spread along the upper respiratory tract (back of the throat) to the larynx and trachea (windpipe) (",
"     <a class=\"graphic graphic_figure graphicRef56535 \" href=\"UTD.htm?28/23/29044\">",
"      figure 1",
"     </a>",
"     ). As the infection progresses, the top part of the trachea becomes swollen, which narrows the space available for air to enter the lungs. This leads to the symptoms of croup. (See",
"     <a class=\"local\" href=\"#H3\">",
"      'Croup symptoms'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Bacterial infection of the same areas can occur during the viral infection, but this does not happen very often. Bacterial coinfection is usually more severe and requires a different treatment than a viral infection.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      CROUP SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The primary symptoms of croup are a &ldquo;barking cough&rdquo; and hoarseness. Croup is usually mild and lasts less than one week, although it is possible for symptoms to become severe and life threatening. Symptoms are usually worse at night. The more severe cases are due to difficulty breathing caused by swelling in the upper part of the windpipe. Symptoms usually start gradually, beginning with nasal irritation, congestion, and runny nose. Difficulty breathing can develop and become worse during the 12 to 48 hours after congestion and barking cough begin.",
"    </p>",
"    <p>",
"     Most children develop a fever, which may range from mild (100.4&ordm;F or 38&ordm;C) to very high (104&ordm;F or 40.5&ordm;C). The fever itself does not cause them harm (see",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"      \"Patient information: Fever in children (The Basics)\"",
"     </a>",
"     ). The information in the Table describes how to take a child's temperature (",
"     <a class=\"graphic graphic_table graphicRef57109 \" href=\"UTD.htm?7/6/7277\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Other symptoms such as rash, eye redness (called conjunctivitis), and swollen lymph nodes may develop, depending upon the virus causing the illness. Dehydration can occur if the child is not able to drink enough fluids.",
"    </p>",
"    <p>",
"     As the upper airway narrows, high-pitched, noisy breathing (called stridor) develops and the child may breathe faster; the child may become restless or anxious (agitated) as breathing becomes more difficult. Agitation can increase the narrowing, which leads to even more difficulty breathing and further agitation. The effort required to breathe faster and harder is tiring, and the child may become exhausted and unable to breathe on his or her own in severe cases.",
"    </p>",
"    <p>",
"     Low oxygen levels (called hypoxia) and blue-tinged skin (called cyanosis) can develop as airflow to the lungs is restricted. Cyanosis may first be noticed in the fingers and toenails; ear lobes; tip of the nose, lips, tongue; and inside of the cheek.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Contagiousness",
"     </span>",
"     &nbsp;&mdash;&nbsp;Croup is caused by viruses that can be spread easily through coughing, sneezing, and respiratory secretions (mucus and droplets from coughing or sneezing). Children with croup should be considered contagious for three days after the illness begins or until the fever is gone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Severity of croup",
"     </span>",
"     &nbsp;&mdash;&nbsp;Croup can be very mild or very severe, depending on how difficult it is for the infant or child to pull air into the lungs. The size (diameter) of the windpipe (which is normally smaller in infants) and degree of narrowing due to swelling are important determinants of severity. Croup may become more severe when a child becomes agitated or upset.",
"    </p>",
"    <p>",
"     A child with moderate to severe croup may have to struggle to breathe in ways that can be frightening for both the child and parent (or other caregivers).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Mild croup",
"     </span>",
"     &nbsp;&mdash;&nbsp;A child with mild croup generally is alert and without blue-tinged skin or retractions (sucking in of the skin around the ribs and the top of the sternum) (",
"     <a class=\"graphic graphic_figure graphicRef59786 \" href=\"UTD.htm?26/31/27121\">",
"      figure 2",
"     </a>",
"     ). There may be a barking cough. Stridor (high-pitched, noisy breathing) is not present at rest but may be present as the child coughs or cries. A child with mild croup can develop more severe symptoms intermittently throughout the course of the illness, especially during the evening hours.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Moderate croup",
"     </span>",
"     &nbsp;&mdash;&nbsp;A child with moderate croup may have stridor (high-pitched, noisy breathing) and retractions (sucking in of the skin around the ribs and the top of the sternum) at rest, may be slightly disoriented or agitated, and may have moderate difficulty breathing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Severe croup",
"     </span>",
"     &nbsp;&mdash;&nbsp;A child with severe croup has stridor and retractions at rest. Retractions are a sign of severe croup. These include inward movement (sucking in) of the sternum (breast bone) or skin between the ribs as the child struggles to take a breath. The child may appear anxious, agitated, or fatigued. Cyanosis (blue-tinged skin) is common, initially only when the child is moving or crying, but progressively worsening so that it is present even when the child is resting.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      CROUP DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Croup is usually diagnosed based upon the child's symptoms and signs, including a barking cough and stridor, especially if these findings occur during the fall and winter months. X-ray and laboratory testing are rarely needed.",
"    </p>",
"    <p>",
"     The healthcare provider who examines your child must determine if your child is likely to worsen and require care in an emergent care setting.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      CROUP TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of croup depends upon the severity of symptoms and the risk of rapid worsening; children with mild symptoms who have no risk factors for severe croup generally are treated at home, while a child with moderate to severe symptoms or who is at risk for rapid worsening should be treated in an emergency department.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Mild croup",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most children with croup have mild symptoms and can be successfully treated at home. This includes using mist from a humidifier or sitting with the child in a bathroom (not in the shower) filled with steam generated by running hot water from the shower. A parent should stay with the child during mist treatment; a favorite book or lullaby may help to decrease the child's anxiety and prevent crying, which can worsen stridor.",
"    </p>",
"    <p>",
"     Hot steam humidifiers should be avoided because of the risk of burns. If the child's stridor does not improve during the mist treatment, the parent should contact their child's healthcare provider.",
"    </p>",
"    <p>",
"     Other suggestions for home treatment of mild croup include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Allow the child to breathe cool air during the night by opening a window or door.",
"      </li>",
"      <li>",
"       Fever can be treated with an over-the-counter medication such as acetaminophen or ibuprofen. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=see_link\">",
"        \"Patient information: Fever in children (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Coughing can be treated with warm, clear fluids to loosen mucus on the vocal chords. Warm water, apple juice, or lemonade is safe for children older than four months. Frozen juice popsicles also can be given.",
"      </li>",
"      <li>",
"       Smoking in the home should be avoided; smoke can worsen a child's cough.",
"      </li>",
"      <li>",
"       Keep the child's head elevated. An infant can be placed in a car seat. A child may be propped up in bed with an extra pillow. Pillows should not be used with infants younger than 12 months of age.",
"      </li>",
"      <li>",
"       Parents may sleep in the same room with their child during an episode of croup so that they will be immediately available if the child begins to have difficulty breathing.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Emergent care",
"     </span>",
"     &nbsp;&mdash;&nbsp;Parents should seek immediate medical attention if, at any time, a child develops features of worsening or severe croup. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'When to seek help'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;A child with mild croup who is seen in a healthcare provider's office or the emergency department may be given mist treatment in addition to a single dose of a glucocorticoid medication. The most frequently used glucocorticoid is dexamethasone, which can be given as an oral syrup or as an intravenous (IV) or intramuscular (IM) injection (depending upon which treatment is easiest for the child).",
"    </p>",
"    <p>",
"     Dexamethasone provides long-lasting and effective treatment for mild croup, as well as for moderate and severe croup. It works to decrease swelling of the larynx, usually within six hours of the first dose. For a child with mild croup, dexamethasone can reduce the need for a repeat visit to the emergency department or provider's office and can improve the child's ability to sleep (by easing the work of breathing).",
"    </p>",
"    <p>",
"     Budesonide is another glucocorticoid medication that is sometimes used. It is administered by inhalation. Other oral glucocorticoids may be prescribed as well.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Moderate to severe croup",
"     </span>",
"     &nbsp;&mdash;&nbsp;Moderate to severe croup should be evaluated in an emergency department or clinic capable of handling urgent respiratory illnesses. Severe croup is a life-threatening illness and treatment should not be delayed for any reason.",
"    </p>",
"    <p>",
"     The treatment used depends upon the type and severity of signs and symptoms, but may include one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Humidified air or oxygen (if oxygen is necessary).",
"      </li>",
"      <li>",
"       Intravenous fluids may be needed if the child is dehydrated as a result of fever or rapid breathing, both of which increase the body's loss of fluids. Difficulty breathing can discourage a child from drinking, which can increase the risk of dehydration.",
"      </li>",
"      <li>",
"       Monitoring of oxygen levels, breathing and heart rate, skin color (normal versus blue-tinged), and level of alertness are used to measure the child's status and response to treatment. A child who fails to improve or who improves slowly may need further treatment.",
"      </li>",
"      <li>",
"       Placement of a breathing tube in the throat is rarely needed for children with severe croup; less than 1 percent of children seen in the emergency room require intubation.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Dexamethasone",
"     </span>",
"     &nbsp;&mdash;&nbsp;Dexamethasone is the most frequently used medication for the treatment of all types of croup; it is a glucocorticoid that provides long-lasting and effective treatment. It works by decreasing swelling of the larynx, usually within six hours of the first dose. It can reduce the need for a repeat visit to the emergency department or provider's office, decrease the time spent in the emergency department, and decrease the dose of other medications (eg, epinephrine).",
"    </p>",
"    <p>",
"     It can be given as an oral syrup or as an intravenous (IV) or intramuscular (IM) injection (depending upon which treatment is easiest for the child). Most children only require one dose, and serious side effects are rare.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Epinephrine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Epinephrine, commonly referred to as \"adrenaline\", is given by nebulizer (an inhaled mist) to children with moderate to severe croup. It also reduces swelling in the airway and begins to work faster than dexamethasone. It works for a short time period (two hours or less), and may be given every 15 to 20 minutes for severe symptoms. Retreatment may be needed after two hours if symptoms return after an initial response. When such \"rebound\" symptoms occur, it is usually within two to four hours after the treatment.",
"    </p>",
"    <p>",
"     Side effects of epinephrine include rapid heartbeat. Serious side effects are rare. Children who are given epinephrine must be monitored for three to four hours after the last dose to ensure that symptoms of airway blockage do not return.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Other therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other therapies, such as antibiotics, cough medicines, decongestants, and sedatives, are not routinely recommended for children with croup. Antibiotics do not treat viruses, which cause most cases of croup. Cough medicines and decongestants have not been proven to be helpful, and sedatives can mask symptoms of low blood oxygen and difficulty breathing.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      CROUP COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Complications of croup are uncommon. Symptoms of croup resolve in most children within two days, but can persist up to one week. Fewer than 5 percent of children with croup require hospitalization.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      CROUP PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Unfortunately, there is no way to prevent croup. There are no vaccines against most of the viruses that can cause croup.",
"    </p>",
"    <p>",
"     Simple hygiene measures can help to prevent infection with the viruses that can lead to croup. These measures include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Frequent hand washing with soap and water. Hands should ideally be wet with water and plain or antimicrobial soap, and rubbed together for 15 to 30 seconds. Special attention should be paid to the fingernails, between the fingers, and the wrists. Hands should be rinsed thoroughly and dried with a single-use towel.",
"      </li>",
"      <li>",
"       Use of alcohol-based hand rubs. These are a good alternative for disinfecting hands if a sink is not available. Hand rubs should be spread over the entire surface of hands, fingers, and wrists until dry, and may be used several times. Hand rubs are available as a liquid or wipe in small, portable sizes that are easy to carry in a pocket or handbag. When a sink is available, visibly soiled hands should be washed with soap and water.",
"      </li>",
"      <li>",
"       Avoid close contact with other adults and children with upper respiratory infection when possible. This may be difficult, especially when in public, but parents can try to limit direct contact. In addition, infants or children who are sick should not be sent to day care or school as this can potentially cause others to become ill.",
"      </li>",
"      <li>",
"       Yearly vaccination for the influenza virus is recommended for individuals older than six months. Flu vaccines are usually given in the fall and winter months. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"        \"Patient information: Influenza prevention (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     If, at any time, a child develops features of worsening or severe croup, the parent should seek",
"     <strong>",
"      immediate",
"     </strong>",
"     medical attention. This includes:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Difficulty breathing",
"      </li>",
"      <li>",
"       Pale or blue-tinged skin",
"      </li>",
"      <li>",
"       Severe coughing spells",
"      </li>",
"      <li>",
"       Drooling or difficulty swallowing",
"      </li>",
"      <li>",
"       Inability to speak or cry due to difficulty taking a breath",
"      </li>",
"      <li>",
"       A whistling sound with breathing, or noisy-high pitched breathing while sitting or resting",
"      </li>",
"      <li>",
"       Sucking in of the skin around the ribs and top of the sternum with breathing",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Parents should not attempt to drive their child to the hospital if the child is severely agitated, has blue-tinged skin, is struggling to breathe, or is excessively drowsy (lethargic); emergency medical services should be called, available in most areas of the United States by dialing 911.",
"    </p>",
"    <p>",
"     A parent should call their child's healthcare provider if:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A fever (temperature higher than 100.4&ordm;F or 38&ordm;C) lasts more than three days.",
"      </li>",
"      <li>",
"       Symptoms of mild croup last longer than seven days.",
"      </li>",
"      <li>",
"       There are questions or concerns about the child's condition.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Croup is a respiratory illness usually caused by a virus. As the illness progresses, the trachea becomes swollen, which narrows the space available for air to enter the lungs.",
"      </li>",
"      <li>",
"       The viruses that cause croup can be spread easily through coughing, sneezing, and respiratory secretions (mucus, droplets from coughing or sneezing). Children with croup should be considered contagious for three days after the illness begins, or until the fever is gone.",
"      </li>",
"      <li>",
"       Croup is usually mild, although it is possible for symptoms to become severe and life-threatening. Symptoms usually start gradually, beginning with nasal irritation, congestion, and a runny nose, which may worsen after 12 to 48 hours to include difficulty breathing, a \"barking cough\", and hoarseness. Symptoms of croup usually resolve within two days, but can persist up to one week (with gradual improvement during this time).",
"      </li>",
"      <li>",
"       If, at any time, a child develops features of worsening or severe croup, the parent should seek immediate medical attention. Features of severe croup include:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Difficulty breathing",
"      </li>",
"      <li>",
"       Pale or blue-tinged skin, especially in the lips, fingers, toes, or earlobes",
"      </li>",
"      <li>",
"       Severe coughing spells",
"      </li>",
"      <li>",
"       Drooling or difficulty swallowing",
"      </li>",
"      <li>",
"       Inability to speak or cry due to difficulty taking a breath",
"      </li>",
"      <li>",
"       A whistling sound with breathing or noisy-high pitched breathing while sitting or resting",
"      </li>",
"      <li>",
"       Sucking in of skin around the ribs with breathing",
"       <br/>",
"       <br/>",
"       Parents should not attempt to drive their child to the hospital if the child is severely agitated, cyanotic, struggling to breathe, or excessively drowsy (lethargic); emergency medical services should be called, available in most areas of the United States by dialing 911.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mild croup can usually be treated at home. Home treatment includes using mist from a humidifier or by sitting with the child in a bathroom filled with steam generated by running hot water from the shower. Hot steam humidifiers should be avoided because of the risk of burns.",
"      </li>",
"      <li>",
"       Moderate to severe croup should be evaluated in an emergency department or clinic capable of handling urgent respiratory illnesses. Severe croup is a life-threatening illness and treatment should not be delayed for any reason.",
"      </li>",
"      <li>",
"       Other therapies, such as antibiotics, cough medicines, decongestants, and sedatives, are not recommended for children with croup. Antibiotics do not treat viruses, which cause most cases of croup.",
"      </li>",
"      <li>",
"       Smoking in the home should be avoided. Parents may sleep in the same room with their child during an episode of croup so that they will be immediately available if the child begins to have difficulty breathing.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804512553\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H248132418\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/63/32754?source=see_link\">",
"      Patient information: Croup (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/7/13427?source=see_link\">",
"      Patient information: Cough in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H248132426\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=see_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17561?source=see_link\">",
"      Approach to chronic cough in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31144?source=see_link\">",
"      Approach to the management of croup",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21464?source=see_link\">",
"      Assessment of stridor in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28088?source=see_link\">",
"      Causes of chronic cough in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43529?source=see_link\">",
"      Clinical features, evaluation, and diagnosis of croup",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10201?source=see_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44505?source=see_link\">",
"      Etiology and management of hoarseness in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/11/31928?source=see_link\">",
"      Pharmacologic and supportive interventions for croup",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/MEDLINEPLUS/ency/article/000959.htm\">",
"      www.nlm.nih.gov/MEDLINEPLUS/ency/article/000959.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.healthychildren.org/english/health-issues/conditions/chest-lungs/pages/croup.aspx\">",
"      www.healthychildren.org/English/health-issues/conditions/chest-lungs/pages/Croup.aspx",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/28/2500/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/28/2500?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Alberta Clinical Practice Guidelines Guideline Working Group. Guidelines to the diagnosis and management of croup. www.topalbertadoctors.org/download/252/croup_guideline.pdf (Accessed on March 20, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2500/abstract/2\">",
"      Russell KF, Liang Y, O'Gorman K, et al. Glucocorticoids for croup. Cochrane Database Syst Rev 2011; :CD001955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2500/abstract/3\">",
"      Cherry JD. State of the evidence for standard-of-care treatments for croup: are we where we need to be? Pediatr Infect Dis J 2005; 24:S198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2500/abstract/4\">",
"      Vernacchio L, Mitchell AA. Oral dexamethasone for mild croup. N Engl J Med 2004; 351:2768.",
"     </a>",
"    </li>",
"    <li>",
"     Schmitt BD. Croup. In: Instructions for Pediatric Patients, 2nd ed, Saunders, Philadelphia 1999. p.70.",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_28_2500=[""].join("\n");
var outline_f2_28_2500=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CROUP OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CROUP CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           CROUP SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           CROUP DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           CROUP TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           CROUP COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           CROUP PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/23/29044\" title=\"figure 1\">",
"           Pediatric airway anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/31/27121\" title=\"figure 2\">",
"           Severe breathing trouble PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?7/6/7277\" title=\"table 1\">",
"           Measuring temperature PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_28_2501="Nonoliguric versus oliguric acute tubular necrosis";
var content_f2_28_2501=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonoliguric versus oliguric acute tubular necrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/28/2501/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/28/2501/contributors\">",
"     Orfeas Liangos, MD, FASN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/28/2501/contributors\">",
"     Bertrand L Jaber, MD, MS, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/28/2501/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/28/2501/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/28/2501/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/28/2501/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/28/2501/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glomerular filtration rate (GFR) may fall to very low levels in acute tubular necrosis (ATN). This change, however, is not necessarily associated with a parallel reduction in urine output, which can vary from oliguric levels (less than 500",
"    <span class=\"nowrap\">",
"     mL/day)",
"    </span>",
"    to relatively normal values [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although oliguria is common in patients with ATN, anuria (urine output &lt;50",
"    <span class=\"nowrap\">",
"     mL/day)",
"    </span>",
"    is rare. Anuria is most often seen in two conditions: shock and complete bilateral urinary tract obstruction. Other less common causes are the hemolytic-uremic syndrome, renal cortical necrosis, bilateral renal arterial obstruction, and crescentic or rapidly progressive glomerulonephritis, particularly anti-GBM antibody disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF URINE OUTPUT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The difference in urine output between oliguric and nonoliguric ATN may be due to one of two factors: nonoliguric patients may have a higher GFR than those with oliguria; or they may have the same filtration rate but reabsorb less in the tubules. If, for example, the GFR falls to 7",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    (equal to 5",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    the urine output may still be relatively normal at 1 to 2",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    if only 5 to 6 L is reabsorbed.",
"   </p>",
"   <p>",
"    Studies in animal models have shown that there is less morphologic and functional damage in nonoliguric as compared to oliguric acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/3\">",
"     3",
"    </a>",
"    ]. There is also evidence in humans suggesting that the absence of oliguria in ATN generally reflects less severe disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report noted a direct and close correlation between the urine flow rate and the residual GFR in patients with three to six days of acute renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/4\">",
"       4",
"      </a>",
"      ]. Oliguric patients generally had a GFR (measured by creatinine and inulin clearance) of less than 5",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      whereas it was 10 to 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      in patients with a urine volume of 50 to 100",
"      <span class=\"nowrap\">",
"       mL/h.",
"      </span>",
"     </li>",
"     <li>",
"      These observations are compatible with another study which found that nonoliguric patients had a lower peak plasma creatinine concentration (6 versus 9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 528 versus 792",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      than oliguric patients and a lower incidence of requiring dialysis during the acute phase of the illness (28 versus 84 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were noted in a randomized trial evaluating the efficacy of synthetic atrial natriuretic peptide (ANP) in critically ill patients with ATN [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/5\">",
"       5",
"      </a>",
"      ]. The probability of dialysis-free survival at 21 days was much higher in the patients with nonoliguric ATN (54 versus 18 percent).",
"     </li>",
"     <li>",
"      A single-center retrospective analysis of 879 consecutive patients with ATN evaluated the association of urine volume in the 24 hours preceding nephrology consultation with mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/6\">",
"       6",
"      </a>",
"      ]. Patients were divided into the following five groups based on urine volume: anuria (less than 50 mL, group one), oliguria (50 to 400 mL, group two), and three levels of non-oliguria (400 to 1000 mL, group three; 1000 to 2000 mL, group four; and greater than 2000 mL, group five). After adjusting for multiple variables including the presence of uremic symptoms or serum urea &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      mechanical ventilation and use of vasoactive drugs, declining urine output was associated with a consecutive increase in the risk for in-hospital death with odds ratios of 0.3, 0.5, 1.0 (reference variable), 1.8, and 2.0, for groups one to five, respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=see_link&amp;anchor=H14#H14\">",
"       \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Atrial natriuretic peptide'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, nonoliguric ATN is not necessarily associated with a better prognosis in all settings. In an observational study of patients with ATN who required dialysis, a higher urine volume was independently associated with increased time from admission to start of dialysis and with higher in-hospital mortality (odds ratio 3.8, 95% CI 1.1-12.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible explanation is that the anticipation of recovery of kidney function in patients with nonoliguric ATN (or inducement of urine output in oliguric patients) might delay proper initiation of dialysis. To address the issue of earlier identification of patients with nonoliguric ATN who might require dialytic support, a prospective study examined urinary biomarkers in 73 patients with nonoliguric ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/8\">",
"     8",
"    </a>",
"    ]. Higher levels of urinary cystatin C and alpha1-microglobulin predicted subsequent requirement for dialysis. The clinical utility of these observations is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OLIGURIA AND FLUID BALANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of a positive fluid balance as an independent predictor of mortality was demonstrated in several prospective, multicenter observational studies from Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/9\">",
"     9",
"    </a>",
"    ], North America [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/10\">",
"     10",
"    </a>",
"    ] and",
"    <span class=\"nowrap\">",
"     Australia/New",
"    </span>",
"    Zealand [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/11\">",
"     11",
"    </a>",
"    ], as well as in a secondary analysis derived from the Fluid and Catheter Treatment Trial (FACTT), a prospective randomized trial of conservative versus liberal fluid administration strategies in acute lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/12\">",
"     12",
"    </a>",
"    ]. In the first study of 3147 critically ill patients, of whom 1120 suffered from ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/9\">",
"     9",
"    </a>",
"    ], oliguric patients had a mean (SD) positive fluid balance of 0.62 (1.33) liters compared with only 0.27 (1.23) liters in nonoliguric patients. In the second analysis of 618 patients with ATN, fluid overload defined as a more than 10 percent increase in body weight was associated with an adjusted odds ratio (OR) for death of 2.07 (95% CI 1.27&ndash;3.37) within 60 days of enrollment. The third observational study, which evaluated the 1453 patients enrolled in the Randomized Evaluation of Normal versus Augmented Level Renal Replacement Therapy Study (RENAL), the mean daily fluid balance among survivors was -234",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    compared with +560",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    among nonsurvivors. A negative mean daily fluid balance was independently associated with a decreased risk of death at 90 days (OR 0.318; 95% CI 0.24-0.43). Finally, the study using data from FACTT showed that in the 306 patients who suffered ATN from a total of 1000 enrolled, a positive fluid balance was associated with an increased adjusted 60-day mortality (OR 1.61 per",
"    <span class=\"nowrap\">",
"     L/d;",
"    </span>",
"    95% CI 1.29-2.00). These data underscore the critical interplay between oliguria, fluid balance and their effects on outcomes in critically ill patients with ATN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ROLE OF DIURETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical issue that often arises is the possible improvement in renal prognosis by increasing the urine output in oliguric patients with a loop diuretic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    . A multinational survey of nephrologists and critical care specialists on the use of diuretics for acute renal failure confirmed widespread use, primarily of intermittent bolus doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The most common indications were pulmonary edema (86 percent) and rhabdomyolysis (56 percent), followed by major surgery (56 percent), cardiogenic shock (56 percent) and sepsis (50 percent). The majority of participants did not believe that diuretics could reduce mortality (74 percent) or need for dialysis (51 percent) or enhance renal recovery (68 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/13\">",
"     13",
"    </a>",
"    ]. Experimental and anecdotal human evidence suggests that these agents may be beneficial in early oliguric acute renal failure (first 24 hours) by protecting against cellular injury and by washing out obstructing intratubular casts. Two small randomized single-center trials found no difference between intraoperative treatment with mannitol versus placebo during cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=see_link\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, using high doses of a loop diuretic to increase the urine output after three to four days of",
"    <strong>",
"     established",
"    </strong>",
"    oliguric ATN does not shorten the duration of renal failure, decrease the requirement for dialysis, or improve survival when compared to untreated patients who remain oliguric [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. This was best demonstrated in a trial in which 388 patients with established ATN requiring dialysis were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    (66 of 166 patients with oliguria) or placebo (79 of 164 with oliguria) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/17\">",
"     17",
"    </a>",
"    ]. Furosemide was administered at a dose of 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day intravenously (maximum of 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    which was given over four to six hours) or 35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally (maximum of 2.5",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"   </p>",
"   <p>",
"    No differences were observed between the two groups in terms of patient survival, renal recovery rates, number of dialysis sessions required, and time on dialysis. However, the use of a diuretic was associated with a significantly reduced time to a 2 L per day diuresis (5.7 versus 7.8 days) as well as an increased incidence of obtaining such a diuresis (57 versus 33 percent).",
"   </p>",
"   <p>",
"    A lack of benefit from diuretics was also observed in a large cohort study of 552 critically ill patients with acute renal failure; patients treated with diuretics in an effort to induce or maintain urine output had a higher risk of death or nonrecovery of kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/20\">",
"     20",
"    </a>",
"    ]. Attempting to induce urine output with diuretics in patients with oliguric ATN may have been associated with a worse prognosis possibly by delaying initiation of dialysis.",
"   </p>",
"   <p>",
"    A meta analysis (eleven controlled trials with a total of 962 patients) that tested the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    in the prevention or treatment of acute renal failure also found no difference in hospital mortality, requirement of renal replacement therapy, or number of required intermittent dialysis sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, high-dose diuretic therapy can lead to permanent hearing loss in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At later stages of ATN, ischemic injury is already complete, and damaged nephrons are nonfunctioning. In this setting, the increase in urine output may be due to decreased tubular reabsorption in the remaining functioning nephrons, not to the recruitment of previously nonfunctioning nephrons. This diuresis may result from the suppression of membrane transporter mRNA. As an example, in rats in which the renal pedicle was clamped for 30 minutes, mRNA levels of the Na-H exchanger and the Na-K-ATPase pump were decreased by 75 and 88 percent, respectively, 12 hours after unclamping [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, diuretics should",
"    <strong>",
"     not",
"    </strong>",
"    be used as a possible therapy of established ATN. They can be given for a short length of time for volume control, but such use should not postpone the initiation of dialysis (if required) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2501/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=see_link&amp;anchor=H9#H9\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decrease in glomerular filtration rate (GFR) that occurs in acute tubular necrosis (ATN) is not always associated with a reduction in urine output. Urine output can vary from oliguric levels (less than 500",
"      <span class=\"nowrap\">",
"       mL/day)",
"      </span>",
"      to relatively normal values. Anuria (urine output &lt;50",
"      <span class=\"nowrap\">",
"       mL/day)",
"      </span>",
"      is relatively rare, however. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The difference in urine output between oliguric and nonoliguric ATN may be due to variations in GFR or in the rate of tubular reabsorption. Animal and human studies suggest that less severe injury is present in nonoliguric compared with oliguric subjects. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Determinants of urine output'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of diuretics to increase urine output in patients with established oliguric ATN does not shorten the duration of renal failure, decrease the requirement for dialysis, or improve survival. Among patients with oliguria and established ATN, diuretics should not be used as a possible therapy of ATN. Diuretics may be given for a short length of time for volume control, but such use should not postpone the initiation of dialysis (if required). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Role of diuretics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/1\">",
"      Anderson RJ, Linas SL, Berns AS, et al. Nonoliguric acute renal failure. N Engl J Med 1977; 296:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/2\">",
"      Dixon BS, Anderson RJ. Nonoliguric acute renal failure. Am J Kidney Dis 1985; 6:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/3\">",
"      Honda N, Hishida A. Pathophysiology of experimental nonoliguric acute renal failure. Kidney Int 1993; 43:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/4\">",
"      Rahman SN, Conger JD. Glomerular and tubular factors in urine flow rates of acute renal failure patients. Am J Kidney Dis 1994; 23:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/5\">",
"      Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997; 336:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/6\">",
"      Avila MO, Zanetta DM, Abdulkader RC, et al. Urine volume in acute kidney injury: how much is enough? Ren Fail 2009; 31:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/7\">",
"      Liangos O, Rao M, Balakrishnan VS, et al. Relationship of urine output to dialysis initiation and mortality in acute renal failure. Nephron Clin Pract 2005; 99:c56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/8\">",
"      Herget-Rosenthal S, Poppen D, H&uuml;sing J, et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004; 50:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/9\">",
"      Payen D, de Pont AC, Sakr Y, et al. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008; 12:R74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/10\">",
"      Bouchard J, Soroko SB, Chertow GM, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009; 76:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/11\">",
"      RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, et al. An observational study fluid balance and patient outcomes in the Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy trial. Crit Care Med 2012; 40:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/12\">",
"      Grams ME, Estrella MM, Coresh J, et al. Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol 2011; 6:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/13\">",
"      Bagshaw SM, Delaney A, Jones D, et al. Diuretics in the management of acute kidney injury: a multinational survey. Contrib Nephrol 2007; 156:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/14\">",
"      Bagshaw SM, Bellomo R, Kellum JA. Oliguria, volume overload, and loop diuretics. Crit Care Med 2008; 36:S172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/15\">",
"      Smith MN, Best D, Sheppard SV, Smith DC. The effect of mannitol on renal function after cardiopulmonary bypass in patients with established renal dysfunction. Anaesthesia 2008; 63:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/16\">",
"      Yallop KG, Sheppard SV, Smith DC. The effect of mannitol on renal function following cardio-pulmonary bypass in patients with normal pre-operative creatinine. Anaesthesia 2008; 63:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/17\">",
"      Cantarovich F, Rangoonwala B, Lorenz H, et al. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis 2004; 44:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/18\">",
"      Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure: a controlled trial. Clin Nephrol 1981; 15:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/19\">",
"      van der Voort PH, Boerma EC, Koopmans M, et al. Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial. Crit Care Med 2009; 37:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/20\">",
"      Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/21\">",
"      Ho KM, Power BM. Benefits and risks of furosemide in acute kidney injury. Anaesthesia 2010; 65:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/22\">",
"      Wang Z, Rabb H, Haq M, et al. A possible molecular basis of natriuresis during ischemic-reperfusion injury in the kidney. J Am Soc Nephrol 1998; 9:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2501/abstract/23\">",
"      Lameire N, Vanholder R, Van Biesen W. Loop diuretics for patients with acute renal failure: helpful or harmful? JAMA 2002; 288:2599.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7215 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2501=[""].join("\n");
var outline_f2_28_2501=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETERMINANTS OF URINE OUTPUT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OLIGURIA AND FLUID BALANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ROLE OF DIURETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_28_2502="Tolterodine: Pediatric drug information";
var content_f2_28_2502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tolterodine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14646?source=see_link\">",
"    see \"Tolterodine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/25/41364?source=see_link\">",
"    see \"Tolterodine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Detrol&reg;;",
"     </li>",
"     <li>",
"      Detrol&reg; LA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F230066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Detrol&reg;;",
"     </li>",
"     <li>",
"      Detrol&reg; LA;",
"     </li>",
"     <li>",
"      Unidet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1039769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1039803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14646?source=see_link\">",
"      see \"Tolterodine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: Adults: Treatment of overactive bladder:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release tablet: 2 mg twice daily; the dose may be lowered to 1 mg twice daily based on individual response and tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosing adjustment in patients concurrently taking CYP3A4 inhibitors: 1 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release capsule: 4 mg once daily; dose may be lowered to 2 mg once daily based on individual response and tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosing adjustment in patients concurrently taking CYP3A4 inhibitors: 2 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Use with caution (studies conducted in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet: 1 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release capsule: 2 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet: 1 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release capsule: 2 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as tartrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Detrol&reg; LA: 2 mg, 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as tartrate: 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Detrol&reg;: 1 mg, 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1039809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer without regard to food; do not break, crush, or chew extended release capsules.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1039790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1039770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F230107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tolterodine may be confused with fesoterodine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Detrol&reg; may be confused with Ditropan",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F230105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fatigue, headache, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dry skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dry mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision, dry eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Bronchitis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, angioedema, confusion, dementia aggravated, disorientation, hallucinations, memory impairment, palpitation, peripheral edema, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1039774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tolterodine or fesoterodine (both are metabolized to 5-hydroxymethyl tolterodine) or any component; urinary retention; gastric retention; uncontrolled narrow-angle glaucoma; myasthenia gravis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F5729459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with bladder flow obstruction; may increase the risk of urinary retention. Use with caution in patients with gastrointestinal obstructive disorders (ie, pyloric stenosis); may increase the risk of gastric retention. Use with caution in patients with controlled (treated) narrow-angle glaucoma, hepatic impairment (dosage adjustment is required), and renal impairment (dosage adjustment is required).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1039775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Cases of angioedema have been reported with oral tolterodine; some cases have occurred after a single dose. Discontinue immediately if develops. Has been associated with QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation at high (supratherapeutic) doses. The manufacturer recommends caution in patients with congenital prolonged QT or in patients receiving concurrent therapy with QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs (class IA or III antiarrhythmics). However, the extent of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation even at supratherapeutic dosages was &lt;15 msec. Individuals who are poor metabolizers via CYP2D6 or in the presence of inhibitors of CYP2D6 and CYP3A4 may be more likely to exhibit prolongation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Dosage adjustment is recommended in patients receiving CYP3A4 inhibitors; a lower dose of tolterodine is recommended. Also see QT prolongation in &ldquo;Concerns related to adverse effects&rdquo; above.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F230094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F230039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tolterodine. Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinBLAStine: May increase the serum concentration of Tolterodine. Management: Reduce tolterodine dose to 1 mg twice daily (regular release formulation) or 2 mg daily (extended release formulation) (adult doses) and monitor for increased levels/effects of tolterodine with initiation of vinblastine therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Tolterodine may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1039789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Food increases bioavailability (~53% increase) of tolterodine immediate release tablets, but does not affect the pharmacokinetics of tolterodine extended release capsules; adjustment of dose is not needed. As a CYP3A4 inhibitor, grapefruit juice may increase the serum level and/or toxicity of tolterodine, but unlikely secondary to high oral bioavailability. The herbal medicine St John's wort (",
"     <i>",
"      Hypericum perforatum",
"     </i>",
"     ) appears to induce CYP3A enzymes and could decrease tolterodine levels/effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F230051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1039792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tolterodine is a competitive antagonist of muscarinic receptors. In animal models, tolterodine demonstrates selectivity for urinary bladder receptors over salivary receptors. Urinary bladder contraction is mediated by muscarinic receptors. Tolterodine increases residual urine volume and decreases detrusor muscle pressure.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1039794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Immediate release tablet: Rapid; &ge;77%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: I.V.: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 113 &plusmn; 27 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;96% (primarily bound to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic, primarily via CYP2D6 (some metabolites share activity) and CYP3A4 usually (minor pathway). In patients with a genetic deficiency of CYP2D6, metabolism via CYP3A4 predominates. Forms three active metabolites.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet: Extensive metabolizers: ~2 hours; poor metabolizers: ~10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release capsule: Extensive metabolizers: ~7 hours; poor metabolizers: ~18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release tablet: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release tablet: 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (77%); feces (17%); excreted primarily as metabolites (&lt;1% unchanged drug) of which the active 5-hydroxymethyl metabolite accounts for 5% to 14% (&lt;1% in poor metabolizers)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1039812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/25/41364?source=see_link\">",
"      see \"Tolterodine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause headache, dry mouth, dizziness, nervousness, or sleepiness; use caution when driving, climbing stairs, or engaging in tasks requiring alertness until response to drug is known; or abdominal discomfort, diarrhea, constipation, nausea, or vomiting; small frequent meals, increased exercise, adequate hydration may help. Report back pain, muscle spasms, alteration in gait, or numbness of extremities; unresolved or persistent constipation, diarrhea, or vomiting; or symptoms of upper respiratory infection or flu. Report immediately any chest pain or palpitations, difficulty urinating, or pain on urination.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13073 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2502=[""].join("\n");
var outline_f2_28_2502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230065\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230066\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1039769\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1039803\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230044\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230030\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1039809\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1039790\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1039770\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230107\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230105\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1039774\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5729459\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1039775\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230094\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230039\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1039789\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230041\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230051\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1039792\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1039794\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1039812\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13073\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13073|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14646?source=related_link\">",
"      Tolterodine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/25/41364?source=related_link\">",
"      Tolterodine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_28_2503="Spine MRI following contaminated epidural injection";
var content_f2_28_2503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Spine MRI of a patient who received a contaminated epidural injection of methylprednisolone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Sagittal T1 post-gadolinium image showing&nbsp;dural and leptomeningeal enhancement at L5/S1.",
"    <br>",
"     (B) Sagittal post-gadolinium image showing&nbsp;dural and leptomeningeal contrast enhancement.",
"     <br>",
"      (C and D) Axial post-gadolinium T1 images that&nbsp;correlate with&nbsp;images A and&nbsp;B, respectively, and show dural and nerve root enhancement (post-contrast).",
"      <div class=\"footnotes\">",
"       MRI: magnetic resonance imaging.",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Kerkering TM, Grifasi ML, Baffoe-Bonnie AW, et al. Early Clinical Observations in Prospectively Followed Patients With Fungal Meningitis Related to Contaminated Epidural Steroid Injections. Ann Intern Med 2012. Copyright &copy; 2012 American College of Physicians.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2503=[""].join("\n");
var outline_f2_28_2503=null;
var title_f2_28_2504="Erythrasma in axilla 2";
var content_f2_28_2504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59529%7EDERM%2F51713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59529%7EDERM%2F51713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 40-year-old diabetic male presented with red-brown patches in the axillae that resolved with erythromycin therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Jayakar Thomas, MD, PhD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrasma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clinical image of red-brown plaques of erythrasma in the groin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. John L. Aeling.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2504=[""].join("\n");
var outline_f2_28_2504=null;
var title_f2_28_2505="Anaplastic thyroid cancer 2";
var content_f2_28_2505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F88832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F88832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Anaplastic thyroid cancer: Findings on histology (pleomorphism, mitosis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anaplastic thyroid cancer demonstrating pleomorphism, mitosis (arrowhead), and neutrophilic infiltration (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ronald A Ghossein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2505=[""].join("\n");
var outline_f2_28_2505=null;
var title_f2_28_2506="Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies";
var content_f2_28_2506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/28/2506/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/28/2506/contributors\">",
"     Jeffrey A Sosman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/28/2506/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/28/2506/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/28/2506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/28/2506/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/28/2506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H177442132\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the incidence of malignant melanoma is increasing, most cases are diagnosed at an early stage. In that setting, surgical excision is curative in most cases, and patients at high-risk of developing metastatic disease may benefit from adjuvant therapy with interferon alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with disseminated disease is a difficult problem. Approaches that have been shown to provide clinically important benefit for appropriately selected patients with disseminated melanoma include immunotherapy with high-dose interleukin-2 (IL-2), immunotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    (a monoclonal antibody targeting CTLA-4), and inhibition of the MAP kinase pathway with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    in patients whose tumors contain a V600 mutation in the BRAF gene. There are no randomized trials that compare targeted therapy with immunotherapy and there are no data on the appropriate sequencing of these therapies for patients with a V600 BRAF mutation.",
"   </p>",
"   <p>",
"    This topic reviews the use of the monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    , which targets CTLA-4, as well as other immune checkpoint inhibitors, in the treatment of advanced melanoma. An overview of the management of advanced melanoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=see_link\">",
"     \"Overview of the management of advanced melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175770042\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of cellular immunity begins when T cells recognize peptide fragments of intracellular proteins that are expressed on the surface of antigen presenting cells (APCs) bound to specific mixed histocompatibility complex (MHC) molecules. This interaction requires the presence of a costimulatory molecule (B7). This activation results in upregulation of cytotoxic T-lymphocyte antigen 4 (CTLA-4). The CTLA-4 receptor on T lymphocytes is a negative regulator of T cell activation that outcompetes CD28 for binding to B7 on antigen presenting cells. CTLA-4 thereby serves as a physiologic &ldquo;brake&rdquo; on the activated immune system.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     Ipilimumab",
"    </a>",
"    is a monoclonal antibody to CTLA-4 that can prevent this feedback inhibition, resulting in an immune response against the tumor. In addition, preventing this feedback inhibition of the immune response can cause a breaking of tolerance to other host tissues that leads to potentially severe or life threatening autoimmune adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262059967\">",
"    <span class=\"h1\">",
"     IMMUNE RESPONSE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    and other immune checkpoint inhibitors requires an understanding of the different patterns of response seen with this class of agents. The patterns of response to treatment with these immunotherapy agents differ from those with molecularly targeted agents or cytotoxic chemotherapy in several important respects [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients may have a transient worsening of disease, manifested either by progression of known lesions or the appearance of new lesions, before disease stabilizes or tumor regresses. Therefore caution should be taken in abandoning therapy early. In general these delayed responses are not observed in patients with rapidly progressive, symptomatic disease.",
"     </li>",
"     <li>",
"      Responses can take appreciably longer to become apparent compared with cytotoxic therapy. Continued disease regression is frequently observed well after completion of the initial induction period.",
"     </li>",
"     <li>",
"      Some patients who do not meet criteria for objective response can have prolonged periods of stable disease that are clinically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immune-related response criteria have been proposed to deal with the altered patterns of response seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    and potentially other immunotherapies (",
"    <a class=\"graphic graphic_table graphicRef52907 \" href=\"UTD.htm?29/56/30604\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune-related complete response: Complete resolution of all measureable and nonmeasurable lesions, with no new lesions. Complete response must be confirmed by a second, consecutive assessment at least four weeks later.",
"     </li>",
"     <li>",
"      Immune-related partial response: A decrease in the total tumor burden of 50 percent or more compared to baseline, which must be confirmed by a second, consecutive assessment at least four weeks later. This category allows for the inclusion of progression of some lesions or the appearance of new lesions as long as the total tumor burden meets the response criterion.",
"     </li>",
"     <li>",
"      Immune-related stable disease: Not meeting the criteria for either a partial or complete response or for progressive disease.",
"     </li>",
"     <li>",
"      Immune-related progressive disease: An increase in tumor burden of 25 percent or more relative to the minimum recorded tumor burden. This must be confirmed by a second, consecutive assessment no less than four weeks after the initial documentation of an increase in tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of these immune-related response criteria (",
"    <a class=\"graphic graphic_table graphicRef52907 \" href=\"UTD.htm?29/56/30604\">",
"     table 1",
"    </a>",
"    ) are important because the application of traditional RECIST criteria (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"UTD.htm?41/48/42764\">",
"     table 2",
"    </a>",
"    ) in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    may lead to premature discontinuation of treatment in a patient who will eventually respond to treatment or have prolonged disease stabilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175769012\">",
"    <span class=\"h1\">",
"     IPILIMUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     Ipilimumab",
"    </a>",
"    is a monoclonal antibody directed against CTLA-4. Its presumed mechanism of action is to break down tolerance to tumor-associated antigens in the melanoma. This mechanism of action can also result in autoimmune reactions against self antigens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262059990\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two large phase III trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    significantly prolonged survival in patients with advanced melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H327750091\">",
"    <span class=\"h3\">",
"     Previously treated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a placebo-controlled phase III trial, 676 patients were randomly assigned in a 3:1:1 ratio to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    plus a glycoprotein 100 (gp100) vaccine, ipilimumab alone, or gp100 alone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/3\">",
"     3",
"    </a>",
"    ]. All patients were HLA-A*0201 positive and had unresectable metastatic melanoma. All patients had received prior systemic treatment for advanced disease with either cytotoxic chemotherapy or IL-2.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     Ipilimumab",
"    </a>",
"    (3",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vaccine were given every three weeks for four doses. Patients with confirmed partial or complete response or stable disease for three months or more after completion of the 12 week induction period were allowed to receive reinduction with their original treatment if they subsequently had disease progression. The primary endpoint of the trial was overall survival.",
"   </p>",
"   <p>",
"    Key results of this trial included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall survival was significantly increased in patients given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      (ipilimumab plus gp100 versus gp100, median 10.0 versus 6.4 months, HR for death 0.68; ipilimumab alone versus gp100 alone 10.1 versus 6.4 months, HR 0.66). Overall survival rates for the ipilimumab plus gp100, ipilimumab alone, and gp100 alone were 44, 46, and 25 percent at 12 months and 22, 24, and 14 percent at 24 months, respectively.",
"     </li>",
"     <li>",
"      Subset analyses found no evidence that the survival benefit was restricted to any particular subsets. Benefits were independent of sex, age (&le;65 or &gt;65 years), stage at presentation (M0, M1a, and M1b versus M1c), baseline LDH (normal versus elevated), or prior use of interleukin-2 (",
"      <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"       table 3A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The objective response rate was significantly improved in both groups of patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      compared to gp100 alone (5.7 and 10.9 versus 1.5 percent, respectively). When objective partial or complete responses were observed, these were maintained for at least two years in 4 of 23 (17 percent) patients treated with ipilimumab plus gp100, 9 of 15 (60 percent) with ipilimumab alone and 0 of 2 with gp100 vaccine only. Responses to ipilimumab, either alone or in combination with gp100, continued to improve more than 24 weeks after initiation of therapy; five patients with stable disease eventually achieved a partial response without additional therapy, and four patients with a partial response went on to achieve a complete response.",
"     </li>",
"     <li>",
"      Among 31 patients who initially received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      either alone or with gp100 and then underwent reinduction therapy with ipilimumab, six (21 percent) had an objective response to retreatment, and 15 (48 percent) had stable disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The phase III trial limited enrollment to patients who were HLA-A*0201 positive because of the use of the gp100 vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/3\">",
"     3",
"    </a>",
"    ]. Retrospective analysis of 453 previously treated patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    in four phase II trials compared patients who were HLA-A*0201 positive with those who were HLA-A*0201 negative [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/4\">",
"     4",
"    </a>",
"    ]. In this analysis, ipilimumab had similar activity regardless of HLA type.",
"   </p>",
"   <p>",
"    Patients who were treated with high-dose IL-2 may receive substantial benefit from treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    ; the clinical response or duration of progression-free survival following IL-2 does not accurately predict the response to subsequent ipilimumab treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/5\">",
"     5",
"    </a>",
"    ]. In a retrospective analysis of 208 patients who had been treated with high-dose IL-2, there were 48 patients who subsequently were treated with single agent ipilimumab. The median overall survival was 12 months, with sustained remission beyond two years in some cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H327750098\">",
"    <span class=\"h3\">",
"     Previously untreated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a second phase III trial, 502 patients with metastatic melanoma were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    or to placebo plus dacarbazine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/6\">",
"     6",
"    </a>",
"    ]. Approximately one-fourth of patients had received prior adjuvant therapy, but those previously treated for metastatic disease were not eligible. Patients with brain metastases, ocular melanoma, mucosal melanoma, or autoimmune disease were excluded.",
"   </p>",
"   <p>",
"    All patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    (850",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    intravenously) every three weeks for eight cycles in the absence of disease progression or significant toxicity. Patients were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    at a dose of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or placebo on weeks 1, 4, 7, and 10. At week 24, patients with stable disease or an objective response were eligible for maintenance therapy with ipilimumab at 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or placebo given every twelve weeks.",
"   </p>",
"   <p>",
"    Major results of this trial include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall survival, the primary endpoint of the trial, was significantly increased in patients assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      compared with placebo plus dacarbazine (median 11.2 versus 9.1 months). Survival rates at one, two, and three years consistently favored treatment with ipilimumab (47 versus 36, 29 versus 18, and 21 versus 12 percent, respectively).",
"     </li>",
"     <li>",
"      The rate of disease control (objective response plus stable disease) did not differ significantly between the two groups (33 versus 30 percent), nor did the best overall response rate (15 versus 10 percent).",
"     </li>",
"     <li>",
"      The overall incidence of grade 3 or 4 toxicity was significantly higher with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      compared with dacarbazine alone (56 versus 28 percent). Overall, grade 3 or 4 immune-mediated adverse reactions were significantly more common with the ipilimumab combination (38 versus 4 percent).",
"     </li>",
"     <li>",
"      Hepatic toxicity was significantly more common with the combination than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      alone (overall incidence of transaminase elevation 29 to 33 versus 6 percent). Furthermore, the incidence of hepatic toxicity was much higher compared with that observed in the phase III trial when",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      was given without dacarbazine or in prior phase II trials in which ipilimumab administered at this dose and schedule. The increase in hepatic toxicity may be due to its combination with dacarbazine, which is also known to be hepatotoxic.",
"     </li>",
"     <li>",
"      The incidence of other immune related toxicities (colitis, rash, hypophysitis) was less than that seen in prior studies with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      alone, perhaps suggesting that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      may have blunted these toxicities",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the higher incidence of hepatotoxicity may have pre-empted or altered the immune toxicity profile. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether this blunting of immune toxicity by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    might have also blunted the antitumor effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    is a matter of speculation. However, the overall pattern of toxicity and efficacy on this trial do not support the addition of dacarbazine to ipilimumab nor the use of ipilimumab at the 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose compared with the approved 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19256013\">",
"    <span class=\"h3\">",
"     Long-term duration of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although only a minority of patients achieve a complete response, such responses appear to be durable and of prolonged duration in most cases. As an example, in the composite experience from the National Institutes of Health, 177 patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    in three studies between 2002 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/7\">",
"     7",
"    </a>",
"    ]. Nearly 9 percent of these patients experienced a complete response, and all but one of these were ongoing at 54 to 99 months. The responses could be very delayed in developing, in some cases even after 30 months. The complete responses were most frequent in those who received interleukin-2 with the ipilimumab.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1294345621\">",
"    <span class=\"h3\">",
"     Dose and schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     Ipilimumab",
"    </a>",
"    has been studied at different doses and schedules. The approved dose of ipilimumab is 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    by intravenous infusion given every three weeks for four doses based upon the results of the phase III trial in previously treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/3\">",
"     3",
"    </a>",
"    ]. Ongoing phase III trials for which results are not yet available have used ipilimumab at a dose of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    by intravenous infusion given every three weeks for four doses with maintenance ipilimumab at 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    provided every 12 weeks. (See",
"    <a class=\"local\" href=\"#H262059990\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Three dose levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    were compared in a double-blind phase II trial, in which 217 patients with advanced melanoma were randomly assigned to one of three dose levels: 0.3",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    3.0",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients were treated every three weeks for four cycles, with provision for maintenance treatment every 12 weeks in patients with an objective response or stable disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The objective response rate (complete plus partial response) increased progressively with dose (0, 4.2, and 11.1 percent in the 0.3, 3, and 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      groups, p = 0.002 for trend).",
"     </li>",
"     <li>",
"      Overall survival improved progressively with dose (median 8.6, 8.7, and 11.4 months; one-year survival rate 39.6, 39.3, and 48.6 percent; and two-year survival rate 18.4, 24.2, and 29.8 percent, respectively), but these differences were not statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was an increase in the frequency of adverse events at increasing dose levels:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serious adverse events (35, 49, and 53 percent, at 0.3, 3.0, and 10",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      respectively).",
"     </li>",
"     <li>",
"      Immune-related adverse events (26, 56, and 70 percent, respectively) and serious (grade 3 to 4) immune-related adverse events (0, 7, and 25 percent, respectively).",
"     </li>",
"     <li>",
"      Adverse events leading to drug discontinuation (13, 10, and 27 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 3 and 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    doses have been compared in a phase III trial which completed accrual in 2010 (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01515189?term=NCT01515189&amp;rank=1\">",
"     NCT01515189",
"    </a>",
"    ). The primary endpoint of the trial is overall survival; results are pending.",
"   </p>",
"   <p>",
"    In some protocols, patients with an objective tumor response or stable disease after the induction period could receive an additional dose every 12 weeks as &ldquo;maintenance therapy&rdquo; as tolerated until disease progression. In other trials, including the initial phase III [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/3\">",
"     3",
"    </a>",
"    ], patients did not receive routine maintenance therapy; however, those exhibiting disease progression after having disease response or stable disease following the induction period were allowed to undergo &ldquo;reinduction&rdquo; according to the same schedule if they subsequently progressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175769719\">",
"    <span class=\"h3\">",
"     Brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with untreated brain metastases were excluded from the initial phase III trial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/3\">",
"     3",
"    </a>",
"    ]. Preliminary results from phase II studies indicate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    has activity in patients with brain metastases and that its safety profile in those patients is similar to that in patients without brain metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=see_link&amp;anchor=H13565191#H13565191\">",
"     \"Management of brain metastases in melanoma\", section on 'Immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262060305\">",
"    <span class=\"h3\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EORTC melanoma group is conducting a phase III trial in patients with high-risk stage III disease (EORTC 18071,",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT00636168&amp;Search=Search\">",
"     NCT00636168",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/9\">",
"     9",
"    </a>",
"    ]. In this trial, patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    (dose 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every three weeks for four cycles then every 12 weeks for a total of three years treatment) or to placebo following complete resection to determine whether such treatment can prevent disease recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/10\">",
"     10",
"    </a>",
"    ]. The trial has completed accrual and results are pending.",
"   </p>",
"   <p>",
"    In addition, a cooperative group trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    at two dose levels to standard high dose interferon alpha in patients with resected stage IIIB, IIIC or IV disease is currently recruiting patients (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01274338?term=NCT01274338&amp;rank=1\">",
"     NCT01274338",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trials will be required to ascertain the role and optimal sequence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    relative to molecularly targeted therapies in patients with tumors possessing characteristic mutations in BRAF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"     \"Molecularly targeted therapy for metastatic melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177442771\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of immune-mediated adverse events have been observed. The most common serious manifestations include enterocolitis, hepatitis, dermatitis, and endocrinopathies. (See",
"    <a class=\"local\" href=\"#H175770042\">",
"     'Rationale'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the phase III trial that demonstrated an increase in survival, immune-related adverse events occurred in approximately 60 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    ; these typically did not occur until several weeks into therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/3\">",
"     3",
"    </a>",
"    ]. Overall, severe or life-threatening (grade 3 or 4) toxicity was seen in 10 to 15 percent of ipilimumab-treated patients, compared to 3 percent in those receiving only gp100. The phase III trial used a dose of 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of ipilimumab every three weeks. A somewhat higher incidence of side effects was observed with a dose of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every three weeks in the randomized phase II trial that assessed the effects of dose on activity and toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1294345621\">",
"     'Dose and schedule'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H600390555\">",
"    <span class=\"h3\">",
"     Treatment of immune-mediated toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase II and phase III trials have shown that prompt medical attention and early administration of corticosteroids are essential for the management of immune-related adverse events and to prevent their progression to more serious toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/3,8,11,12\">",
"     3,8,11,12",
"    </a>",
"    ]. In the United States, the Food and Drug Administration (FDA) has created a Risk Elimination and Management System (REMS) to provide additional information to both healthcare providers and patients, which is available on the internet [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment requires interruption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    and the use of corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/15\">",
"     15",
"    </a>",
"    ]. Treatment is based upon the severity of the observed toxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with grade 2 (moderate) immune-mediated toxicities, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      should be withheld and should not be resumed until symptoms or toxicity is grade 1 or less. Corticosteroids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      or equivalent) should be started if symptoms do not resolve within a week.",
"     </li>",
"     <li>",
"      For patients with grade 3 or 4 (severe or life-threatening) immune-mediated toxicities, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      should be permanently discontinued. High doses of corticosteroids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      or equivalent) should be given. When symptoms subside to grade 1 or less, steroids can be gradually tapered over at least one month.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177442793\">",
"    <span class=\"h3\">",
"     Enterocolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colitis are among the most common, and potentially most serious, complications of anti-CTLA4 treatment. In the phase III trial, diarrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colitis was reported in 31 percent of cases, of which 6 percent were serious or life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/3\">",
"     3",
"    </a>",
"    ]. Although the clinical presentation is similar to that with inflammatory bowel disease, the distribution of lesions and histopathology are not characteristic of Crohn&rsquo;s disease or ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of colitis can develop rapidly and become life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Bowel perforation, sepsis, and death have been reported as complications of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/17,20,21\">",
"     17,20,21",
"    </a>",
"    ]. In the phase III trial, the median time to development of moderate or severe enterocolitis after initiating ipilimumab therapy was six to seven weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meticulous attention to gastrointestinal symptoms is required to prevent progression to more serious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients should be monitored for symptoms of enterocolitis (diarrhea, abdominal pain, mucus or blood in the stool) and appropriate treatment initiated promptly. (See",
"    <a class=\"local\" href=\"#H600390555\">",
"     'Treatment of immune-mediated toxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild (grade 1) symptoms (less than four stools per day over baseline) can be managed symptomatically.",
"     </li>",
"     <li>",
"      Colonoscopy is indicated if grade 2 symptoms (increase of four to six stools per day over baseline) or greater occur. Treatment should be initiated if colitis is observed.",
"     </li>",
"     <li>",
"      For patients with severe or life-threatening enterocolitis (grade 3 or 4, increase of seven or more stools per day over baseline or other complications), treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      should be permanently discontinued. High doses of corticosteroids should be given. For those who do not respond to high-dose steroid therapy within one week, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      should be considered. In some cases refractory to infliximab,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      may be needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     Budesonide",
"    </a>",
"    , an orally administered corticosteroid that is used to treat inflammatory bowel disease, was proposed as a potential way to prevent the immune-related colitis in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    . However, this approach was not beneficial in a randomized phase II trial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Upper gastrointestinal tract involvement has also been reported, including involvement of the esophagus, duodenum, and ileum [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262060483\">",
"    <span class=\"h3\">",
"     Hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune-mediated hepatitis has been seen in 2 to 9 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/3,8,11\">",
"     3,8,11",
"    </a>",
"    ]. At least one death due to liver failure has been reported; this was attributed to a delay in the initiation of steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/11\">",
"     11",
"    </a>",
"    ]. The reported incidence of hepatoxicity exceeds 30 percent when ipilimumab is combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    , and the combined used of these agents should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatic function (transaminase and bilirubin) should be monitored prior to each dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade 2 hepatic toxicity: AST or ALT &gt;2.5 times the upper limit of normal (ULN) but &le;5 times the UNL, or total bilirubin &gt;1.5 times the ULN but &le;3 times the ULN.",
"     </li>",
"     <li>",
"      Grade 3 or greater hepatic toxicity: AST or ALT &gt;5 times the ULN, or total bilirubin &gt;3 times the ULN.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Corticosteroids are the initial treatment for grade 3 or higher hepatic toxicity.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    may be useful in patients with persistent severe hepatic toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H600390555\">",
"     'Treatment of immune-mediated toxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H600390149\">",
"    <span class=\"h3\">",
"     Dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatologic side effects are common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    therapy and can be manifested by pruritus, rash, vitiligo, and alopecia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/23\">",
"     23",
"    </a>",
"    ]. In the phase III trial, the incidence of dermatologic adverse events in patients treated with ipilimumab alone was 40 percent; of these, 2.5 percent were more severe (Stevens-Johnson syndrome, toxic epidermal necrolysis, full thickness dermal ulceration) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]. The median time to onset of moderate or severe dermatologic toxicity was three weeks.",
"   </p>",
"   <p>",
"    Mild to moderate dermatitis (rash, pruritus) can be managed symptomatically. More severe manifestations require discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    and management with corticosteroids. (See",
"    <a class=\"local\" href=\"#H600390555\">",
"     'Treatment of immune-mediated toxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177442801\">",
"    <span class=\"h3\">",
"     Endocrinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of autoimmune endocrine side effects have been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/24\">",
"     24",
"    </a>",
"    ]. Although these are less common than diarrhea and colitis, they have the potential to be serious or fatal.",
"   </p>",
"   <p>",
"    Hypophysitis and hypopituitarism are uncommon side effects of anti-CTLA-4 immunotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/25\">",
"     25",
"    </a>",
"    ]. In the phase III trial, nine patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    (1.8 percent) had severe or life-threatening hypopituitarism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]. Several of these patients also had other endocrine side effects (hypothyroidism, adrenal insufficiency, or hypogonadism). An additional 12 patients (2.3 percent) had moderate endocrinopathies requiring hormone replacement therapy or other medical intervention. The median time to onset of endocrine symptoms was 11 weeks, but in some cases symptoms did not appear until after completion of the initial four courses of therapy.",
"   </p>",
"   <p>",
"    Patients should be monitored for clinical signs or symptoms associated with pituitary, thyroid, or adrenal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/15\">",
"     15",
"    </a>",
"    ]. These may be nonspecific, and can include fatigue, headache, mental status changes, abdominal pain, change in bowel habits, or hypotension. Thyroid function and clinical chemistries should be monitored prior to each dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    and as indicated by clinical signs or symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=see_link\">",
"     \"Clinical manifestations of hypopituitarism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the endocrine manifestations of hypophysitis (eg, adrenal insufficiency, hypothyroidism, hypogonadism), swelling of the pituitary can sometimes be detected on imaging studies and may result in neurologic symptoms including headache or visual abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/23,26\">",
"     23,26",
"    </a>",
"    ]. Swelling of the pituitary must be distinguished from brain metastasis.",
"   </p>",
"   <p>",
"    Primary thyroid disease can be manifested by hyperthyroidism in association with Graves disease or as hypothyroidism secondary to a destructive thyroiditis. Hypothyroidism may also be secondary to hypophysitis, panhypopituitarism, and decreased production of TSH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of endocrinopathies includes hormone replacement therapy as needed, corticosteroids, and cessation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    based upon the severity of the complication. (See",
"    <a class=\"local\" href=\"#H600390555\">",
"     'Treatment of immune-mediated toxicity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=see_link\">",
"     \"Treatment of hypopituitarism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177442817\">",
"    <span class=\"h3\">",
"     Other immune-mediated adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports or large series have identified a number of other immune-related adverse events that affect various organ systems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ocular symptoms associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      include conjunctivitis, uveitis and scleritis, and Graves ophthalmopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/18,27,28\">",
"       18,27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neurologic complications include Guillain Barre syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/3,29\">",
"       3,29",
"      </a>",
"      ], inflammatory myopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/30\">",
"       30",
"      </a>",
"      ], aseptic meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/31\">",
"       31",
"      </a>",
"      ], temporal arteritis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/11\">",
"       11",
"      </a>",
"      ], inflammatory enteric neuropathy causing constipation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/32\">",
"       32",
"      </a>",
"      ], and posterior reversible encephalopathy syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autoimmune pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hematologic manifestations that have been reported include red cell aplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/35\">",
"       35",
"      </a>",
"      ], pancytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/36\">",
"       36",
"      </a>",
"      ], and autoimmune neutropenia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sarcoidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic vasculitis, including kidney disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/11,40\">",
"       11,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acquired hemophilia A due to the presence of a factor VIII inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link&amp;anchor=H2#H2\">",
"       \"Acquired inhibitors of coagulation\", section on 'Factor VIII inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When rare immune-mediated complications are identified, management should follow the general guidelines for treatment interruption and corticosteroid. (See",
"    <a class=\"local\" href=\"#H600390555\">",
"     'Treatment of immune-mediated toxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177442669\">",
"    <span class=\"h1\">",
"     OTHER ANTI-CTLA4 ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tremelimumab, another monoclonal antibody directed again CTLA-4, showed activity in phase I and II clinical studies in previously treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Based upon this, a phase III trial was conducted in which previously untreated patients were randomly assigned to either tremelimumab or chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/44\">",
"     44",
"    </a>",
"    ]. Although there was a prolongation in response duration among those treated with tremelimumab, the difference in overall survival was not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175770315\">",
"    <span class=\"h1\">",
"     PROGRAMMED DEATH 1 PROTEIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The programmed death 1 protein (PD-1) is another key immune checkpoint receptor expressed by activated T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. PD-1 binds to its ligands PD1-L1 (B7-H1) and PD1-L2 (B7-DC), which are expressed on tumor cells, thereby causing immunosuppression and preventing the immune system from rejecting the tumor.",
"   </p>",
"   <p>",
"    Monoclonal antibodies targeting both PD-1 and PD-L1 are being developed to interrupt this pathway and to augment the antitumor immune response; these have demonstrated significant clinical activity against several tumor types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175770342\">",
"    <span class=\"h2\">",
"     Anti-PD-1 monoclonal antibody",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196090715\">",
"    <span class=\"h3\">",
"     Nivolumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nivolumab (BMS-936558) is a humanized monoclonal antibody that targets the PD-1 protein. This monoclonal antibody was evaluated in a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study in 296 patients with a variety of heavily pretreated malignancies, including 104 patients with melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the entire study cohort, grade 3 or 4 treatment related adverse events were observed in 32 of the 296 patients (14 percent) enrolled in the study. A variety of autoimmune side effects were observed, although autoimmune toxicity appeared to be less frequent than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    . Autoimmune adverse events observed include pneumonitis, vitiligo, colitis, hepatitis, hypophysitis, and thyroiditis.",
"   </p>",
"   <p>",
"    There were 26 objective responses among the 94 evaluable patients with advanced melanoma (28 percent). In addition, there were six patients with stable disease for greater than 24 weeks; the overall progression-free survival rate at 24 weeks was 41 percent, when melanoma patients in all dose groups were considered. At the time of data cut-off, 10 patients remained in response for more than one year.",
"   </p>",
"   <p>",
"    Two phase III trials are being conducted to evaluate the role of nivolumab in patients with advanced melanoma. In one, patients who have progressed following anti-CTLA-4 therapy are being randomly assigned to nivolumab or chemotherapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT01721746&amp;Search=Search\">",
"     NCT01721746",
"    </a>",
"    ). In the other trial, previously untreated patients known to be BRAF wild type will be randomly assigned to nivolumab or dacarbazine (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01721772?term=NCT01721772&amp;rank=1\">",
"     NCT01721772",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196090722\">",
"    <span class=\"h3\">",
"     MK-3475",
"    </span>",
"    &nbsp;&mdash;&nbsp;MK-3475 is another anti-PD1 monoclonal antibody. Preliminary results from a phase I dose escalation study showed a response rate of approximately 50 percent in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    na&iuml;ve patients and approximately 40 percent in those who had previously received ipilimumab [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/47\">",
"     47",
"    </a>",
"    ]. A randomized phase II trial has been initiated in previously treated patients to compare MK-3475 with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    chemotherapy (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01704287?term=NCT01704287&amp;rank=1\">",
"     NCT01704287",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175770350\">",
"    <span class=\"h2\">",
"     Anti-PD1-L1 monoclonal antibody",
"    </span>",
"    &nbsp;&mdash;&nbsp;BMS-936559 is a monoclonal antibody that binds to PD1-L1, thus preventing its interaction with PD-1. BMS-936559 is being tested in a dose escalation phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study in pretreated patients with a variety of malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/46\">",
"     46",
"    </a>",
"    ]. The trial includes 207 patients, including 55 with melanoma. Overall, potentially immune-related adverse events were seen in 39 percent of patients.",
"   </p>",
"   <p>",
"    There were 9 objective responses among the 52 evaluable melanoma patients (17 percent). Five of these had an objective response lasting at least one year, and six additional cases had stable disease that was maintained for at least 24 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175769923\">",
"    <span class=\"h2\">",
"     Other immune regulatory checkpoints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal antibodies targeted against a number of other regulatory checkpoints are being evaluated in patients with advanced melanoma based upon our current understanding of the development of cellular immunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175770397\">",
"    <span class=\"h3\">",
"     4-1BB",
"    </span>",
"    &nbsp;&mdash;&nbsp;4-1BB (CD137) is a member of the tumor necrosis factor (TNF) family and acts as a costimulatory molecule that causes T cell proliferation. A humanized MAb, BMS-663513, targeted at CD137 acts as an agonist and can cause costimulation of CD8+ and CD4+ cells.",
"   </p>",
"   <p>",
"    In a preliminary report of the initial phase I study with this agent, three partial responses were observed among 54 patients with melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175770404\">",
"    <span class=\"h3\">",
"     OX40",
"    </span>",
"    &nbsp;&mdash;&nbsp;OX-40 is another tumor necrosis factor (TNF) receptor, which also acts as a costimulatory factor for T cells. A MAb targeting this receptor has begun phase I study [",
"    <a class=\"abstract\" href=\"UTD.htm?2/28/2506/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177442841\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CTLA-4 receptor on T lymphocytes is a negative regulator of T cell activation that blocks positive stimulatory effects to these cells mediated by other T cell receptors. The monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      binds to CTLA-4 and thus prevents this feedback inhibition. This mechanism of action results in an immune response directed against melanoma, as well as a variety of autoimmune side effects. (See",
"      <a class=\"local\" href=\"#H175770042\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a phase III clinical trial in previously treated patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every three weeks for four doses) significantly improved overall survival compared with a control vaccine. In a phase III trial in previously untreated patients, ipilimumab (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every three weeks for four doses) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      significantly increased overall survival compared with dacarbazine alone, but was associated with significant hepatotoxicity. (See",
"      <a class=\"local\" href=\"#H262059990\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients without a V600 BRAF mutation, we recommend immunotherapy (high dose IL-2 or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      ) rather than chemotherapy as the initial systemic therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Targeted therapy is not indicated in patients without a characteristic V600 mutation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=see_link&amp;anchor=H863137387#H863137387\">",
"       \"Overview of the management of advanced melanoma\", section on 'Choice and sequence of therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For good performance status patients who have access to appropriate specialized programs, we suggest high-dose IL-2 rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Ipilimumab is an alternative when IL-2 is not available or appropriate. Ipilimumab can be used sequentially after IL-2 in some patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link\">",
"       \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a poor performance status or untreated brain metastases who thus are not candidates for high dose IL-2, we recommend immunotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H327750098\">",
"       'Previously untreated patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a V600 BRAF mutation and a good performance status, we suggest immunotherapy rather than targeted therapy as the initial systemic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=see_link&amp;anchor=H863137387#H863137387\">",
"       \"Overview of the management of advanced melanoma\", section on 'Choice and sequence of therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have access to appropriate specialized programs, we suggest high-dose IL-2 rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Ipilimumab is an alternative when IL-2 is not available or appropriate. Ipilimumab can be used sequentially after IL-2 in some patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link\">",
"       \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a V600 BRAF mutation and a poor performance status, we suggest targeted therapy rather than immunotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Immunotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      is an alternative. Immunotherapy may also used for second line therapy in patients who progress while on targeted therapy. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"       \"Molecularly targeted therapy for metastatic melanoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=see_link\">",
"       \"Interleukin-2 and other immunotherapies for advanced melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The following factors should be considered when a patient is treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The optimal dosage of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      has not been definitively determined. The phase III trial in previously treated patients demonstrated prolonged survival using a dose of 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      repeated every three weeks for four cycles and this regimen was approved by the United States Food and Drug Administration (FDA). All subsequent and ongoing clinical trials use a dose of 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on the same schedule. (See",
"      <a class=\"local\" href=\"#H1294345621\">",
"       'Dose and schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      may have a transient worsening of disease (manifested either by progression of known lesions or the appearance of new lesions) before responses develop or the disease stabilizes. Therefore caution should be taken in abandoning therapy early. In general, clinical responses are not observed in patients who have rapidly progressive, symptomatic disease after the initiation of ipilimumab therapy. Specific immune-response related criteria have been developed for assessment of patients treated with immunotherapy (",
"      <a class=\"graphic graphic_table graphicRef52907 \" href=\"UTD.htm?29/56/30604\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H262059967\">",
"       'Immune response criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of maintenance therapy or retreatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      after the initial four cycles of therapy is uncertain. Maintenance therapy with ipilimumab is not indicated following the initial four cycles of treatment until further data on this approach are available. Reinduction therapy with ipilimumab may be an option for patients who initially respond and then subsequently progress. (See",
"      <a class=\"local\" href=\"#H1294345621\">",
"       'Dose and schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      did not appear to improve the efficacy of ipilimumab alone and was associated with a significant increased incidence of hepatotoxicity. Thus ipilimumab should not be given in combination with dacarbazine. (See",
"      <a class=\"local\" href=\"#H327750098\">",
"       'Previously untreated patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      causes a broad range of immune-related adverse events, which can be serious or fatal. Regular monitoring for these adverse events, prompt medical attention and early administration of corticosteroids are essential for the appropriate management of immune-related adverse events and to prevent their progression to more serious toxicity. (See",
"      <a class=\"local\" href=\"#H177442771\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For grade 2 (moderate) immune-mediated toxicities, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      should be withheld and should not be resumed until symptoms or toxicity is grade 1 or less. Corticosteroids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      0.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      or equivalent) should be started if symptoms do not resolve within a week.",
"     </li>",
"     <li>",
"      For patients with grade 3 or 4 (severe or life-threatening) immune-mediated toxicities, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      should be permanently discontinued. High doses of corticosteroids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or equivalent) should be given. When symptoms subside to grade 1 or less, steroids can be gradually tapered over at least one month.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phase III trials are currently assessing the role of adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      therapy in patients with resected high-risk stage III melanoma. Adjuvant immunotherapy with ipilimumab is not indicated outside the setting of a formal clinical trial. (See",
"      <a class=\"local\" href=\"#H262060305\">",
"       'Future directions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/1\">",
"      Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996; 14:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/2\">",
"      Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/3\">",
"      Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/4\">",
"      Wolchok JD, Weber JS, Hamid O, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010; 10:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/5\">",
"      Joseph RW, Eckel-Passow JE, Sharma R, et al. Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother 2012; 35:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/6\">",
"      Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/7\">",
"      Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/8\">",
"      Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155.",
"     </a>",
"    </li>",
"    <li>",
"     ClinicalTrials.gov database file://www.clinicaltrials.gov/.",
"    </li>",
"    <li>",
"     UN National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on September 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/11\">",
"      O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/12\">",
"      Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15:5591.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.yervoy.com/hcp/rems.aspx (Accessed on April 06, 2011).",
"    </li>",
"    <li>",
"     Yervoy (ipilimumab): Risk Evaluation and Mitigation Strategy (REMS): Severe Immune-Mediated Averse Reactions file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm249770.htm.",
"    </li>",
"    <li>",
"     FDA approved package insert file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/16\">",
"      Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/17\">",
"      Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na&iuml;ve patients with advanced melanoma. Invest New Drugs 2011; 29:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/18\">",
"      Thumar JR, Kluger HM. Ipilimumab: a promising immunotherapy for melanoma. Oncology (Williston Park) 2010; 24:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/19\">",
"      Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/20\">",
"      Phan GQ, Weber JS, Sondak VK. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol 2008; 15:3014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/21\">",
"      Smith FO, Goff SL, Klapper JA, et al. Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody. J Immunother 2007; 30:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/22\">",
"      Boasberg P, Hamid O, O'Day S. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol 2010; 37:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/23\">",
"      Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/24\">",
"      Corsello SM, Barnabei A, Marchetti P, et al. Endocrine Side Effects Induced by Immune Checkpoint Inhibitors. J Clin Endocrinol Metab 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/25\">",
"      Torino F, Barnabei A, De Vecchis L, et al. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 2012; 17:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/26\">",
"      Kaehler KC, Egberts F, Lorigan P, Hauschild A. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. Melanoma Res 2009; 19:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/27\">",
"      Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2011; 164:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/28\">",
"      Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 2011; 27:e87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/29\">",
"      Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barr&eacute; syndrome in a melanoma patient. Ann Oncol 2011; 22:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/30\">",
"      Neville MC. Introduction: milk lipid synthesis: chain length determination and secretory differentiation. J Mammary Gland Biol Neoplasia 2009; 14:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/31\">",
"      Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/32\">",
"      Bhatia S, Huber BR, Upton MP, Thompson JA. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 2009; 32:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/33\">",
"      Maur M, Tomasello C, Frassoldati A, et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012; 30:e76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/34\">",
"      Di Giacomo AM, Danielli R, Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009; 58:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/35\">",
"      Gordon IO, Wade T, Chin K, et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 2009; 58:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/36\">",
"      Di Giacomo AM, Danielli R, Calabr&ograve; L, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011; 60:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/37\">",
"      Akhtari M, Waller EK, Jaye DL, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 2009; 32:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/38\">",
"      Eckert A, Schoeffler A, Dalle S, et al. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 2009; 218:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/39\">",
"      Vogel WV, Guislain A, Kvistborg P, et al. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol 2012; 30:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/40\">",
"      Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/41\">",
"      Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011; 365:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/42\">",
"      Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009; 27:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/43\">",
"      Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010; 16:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/44\">",
"      Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/45\">",
"      Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/46\">",
"      Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455.",
"     </a>",
"    </li>",
"    <li>",
"     Hamid O. Preliminary report. 9th International Congress of the Society for Melanoma Research. 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/28/2506/abstract/48\">",
"      Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients with advanced cancer (abstract #3007). J Clin Oncol 2008.",
"     </a>",
"    </li>",
"    <li>",
"     Curti B, Weinberg A, Morris N, et al. A phase I trial of monoclonal antibody to OX40 in patients with advanced cancer (abstract). International Society for Biological Therapy of Cancer Annual Meeting, 2007.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15863 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-189.2.19.178-DF24B1B659-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2506=[""].join("\n");
var outline_f2_28_2506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H177442841\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H177442132\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175770042\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262059967\">",
"      IMMUNE RESPONSE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175769012\">",
"      IPILIMUMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H262059990\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H327750091\">",
"      - Previously treated patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H327750098\">",
"      - Previously untreated patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19256013\">",
"      - Long-term duration of response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1294345621\">",
"      - Dose and schedule",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175769719\">",
"      - Brain metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H262060305\">",
"      - Future directions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177442771\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H600390555\">",
"      - Treatment of immune-mediated toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177442793\">",
"      - Enterocolitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H262060483\">",
"      - Hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H600390149\">",
"      - Dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177442801\">",
"      - Endocrinopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177442817\">",
"      - Other immune-mediated adverse events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H177442669\">",
"      OTHER ANTI-CTLA4 ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175770315\">",
"      PROGRAMMED DEATH 1 PROTEIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175770342\">",
"      Anti-PD-1 monoclonal antibody",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H196090715\">",
"      - Nivolumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H196090722\">",
"      - MK-3475",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175770350\">",
"      Anti-PD1-L1 monoclonal antibody",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175769923\">",
"      Other immune regulatory checkpoints",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175770397\">",
"      - 4-1BB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175770404\">",
"      - OX40",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H177442841\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/15863\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15863|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/56/30604\" title=\"table 1\">",
"      Comparison between WHO criteria and the irRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/48/42764\" title=\"table 2\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8157\" title=\"table 3A\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/20/35149\" title=\"table 3B\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31348?source=related_link\">",
"      Clinical manifestations of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7625?source=related_link\">",
"      Interleukin-2 and other immunotherapies for advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39927?source=related_link\">",
"      Management of brain metastases in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=related_link\">",
"      Overview of the management of advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28006?source=related_link\">",
"      Treatment of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_28_2507="Six Ts of TBNA";
var content_f2_28_2507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Six essential \"T's\" of transbronchial needle aspiration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Tomographic (CT) evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type of needle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Technique",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tissue preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tissue interpretation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trained assistant",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Minai, OA, Dasgupta, A, Mehta, AC. Transbronchial needle aspiration of central and peripheral lesions. In: Bolliger, CT, Mathur, PN (Eds), Progress in Respiratory Research-Interventional Bronchoscopy. Karger, Basel, Switzerland, 1999.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2507=[""].join("\n");
var outline_f2_28_2507=null;
var title_f2_28_2508="Mgmt opioid constipation";
var content_f2_28_2508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common strategies for managing opioid-induced constipation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        1. Non-pharmacologic approaches for all patients, unless contraindicated by medical status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Increase fluid intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Increase dietary soluble fiber (avoid if severely debilitated or bowel obstruction is suspected)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Encourage mobility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ensure comfort and privacy for defecation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        2. Select a pharmacologic strategy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intermittent use of a rectal therapy, either a suppository or enema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intermittent use (every 2-3 days) of an osmotic laxative, such as magnesium hydroxide, magnesium citrate, or sodium phosphate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trial of a daily softening agent (sodium docusate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intermittent use (every 2-3 days) of a contact cathartic, such as senna or bisacodyl",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Daily use of a contact cathartic (with or without a concurrent softening agent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Daily use of lactulose (unless lactose-intolerant) or sorbitol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Daily use of polyethylene glycol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        3. Adjust dose and dosing schedule of selected therapy to optimize effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        4. Switch or combine conventional approaches if initial therapy is inadequate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        5. Consider methylnaltexone or trial of an alternative oral agent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2508=[""].join("\n");
var outline_f2_28_2508=null;
var title_f2_28_2509="Sulfasalazine and 5-ASA formulations";
var content_f2_28_2509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sulfasalazine and 5-aminosalicylic acid (5-ASA) formulations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade name",
"        <br/>",
"        (US or as noted)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Strength of commonly available oral preparations",
"        <br/>",
"        (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Oral 5-aminosalycylic acid (5-ASA) derivatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Sulfasalazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Non-enteric coated tablet (scored)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Azulfidine, Salazopyrin*",
"       </td>",
"       <td class=\"sublist_other\">",
"        500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Suspension",
"       </td>",
"       <td class=\"sublist_other\">",
"        Salazopyrin*",
"       </td>",
"       <td class=\"sublist_other\">",
"        250 per 5 mL*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Enteric-coated tablet (not scored)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Azulfidine EC, Salazopyrin EN-tabs*",
"       </td>",
"       <td class=\"sublist_other\">",
"        500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Mesalamine",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Delayed release enteric coated tablet",
"       </td>",
"       <td class=\"sublist_other\">",
"        Asacol",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , Asacol HD",
"       </td>",
"       <td class=\"sublist_other\">",
"        400",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , 800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Capsule containing delayed release tablet",
"       </td>",
"       <td class=\"sublist_other\">",
"        Delzicol",
"       </td>",
"       <td class=\"sublist_other\">",
"        400&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Delayed and extended release tablet, multimatrix",
"       </td>",
"       <td class=\"sublist_other\">",
"        Lialda, Mezavant*",
"       </td>",
"       <td class=\"sublist_other\">",
"        1200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Capsule containing delayed release enteric coated granules",
"       </td>",
"       <td class=\"sublist_other\">",
"        Apriso",
"       </td>",
"       <td class=\"sublist_other\">",
"        375",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Controlled release capsule",
"       </td>",
"       <td class=\"sublist_other\">",
"        Pentasa",
"       </td>",
"       <td class=\"sublist_other\">",
"        250, 500, 1000*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Enteric coated delayed release granules (packet, sachet)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Salofalk*, Pentasa Sachet*",
"       </td>",
"       <td class=\"sublist_other\">",
"        500, 1000, 1500, 2000 sachet*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Olsalazine capsule",
"       </td>",
"       <td>",
"        Dipentum",
"       </td>",
"       <td>",
"        250, 500*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Balsalazide capsule",
"       </td>",
"       <td>",
"        Colazal, Colazide*",
"       </td>",
"       <td>",
"        750",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     US: United States.",
"     <br>",
"      * Not available in US. Trade names shown are for products commonly available in areas other than US including Canada, United Kingdom, and Europe.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Mesalamine is US generic name. Mesalazine is an international generic (nonproprietary) name.",
"       <br>",
"        &Delta;&nbsp;Asacol 400 mg tablet is no&nbsp;longer marketed in US.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data courtesy of authors with additional data from: Ord&aacute;s I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 380:1606.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2509=[""].join("\n");
var outline_f2_28_2509=null;
var title_f2_28_2510="Antimicrob activity abx B";
var content_f2_28_2510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial activity of topical antibiotics used for external otitis: Part B",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Aminoglycosides",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Neomycin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Gentamicin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Tobramycin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Bacitracin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Chloramphenicol",
"       </td>",
"       <td class=\"subtitle2\">",
"        Gramicidin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Polymyxin B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Gram positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corynebacterium diphtheriae",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus aureus",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus epidermidis",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus sp",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus pneumoniae",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus pyogenes (group A beta-hemolytic)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Gram negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacteroides fragilis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Citrobacter sp",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterobacter aerogenes",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterobacter sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Escherichia coli",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Haemophilus influenzae",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Klebsiella pneumoniae",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Klebsiella sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Proteus sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pseudomonas aeruginosa",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bojrab DI, Bruderly T, Abdulrazzak Y, Otolaryngol Clin North Am 1996; 29:761.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2510=[""].join("\n");
var outline_f2_28_2510=null;
var title_f2_28_2511="Immunoassay technique";
var content_f2_28_2511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F52973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F52973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solid-phase enzyme-linked immunosorbent assay (ELISA)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 562px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Many variations of the solid phase immunoassay are possible. Depicted in the figure is a common antigen-binding immunoassay using a primary antibody (IgE in test serum) and secondary antibody (anti-IgE). The secondary antibody is labeled, either with a radioactive or fluorescent tag, or with an enzyme that can act on a substrate to generate a detectable product.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_28_2511=[""].join("\n");
var outline_f2_28_2511=null;
